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1.1 HISTORY AND EPIDEMIOLOGY OF CORNEAL TRANSPLANTATION
The first visually successful penetrating corneal transplantation in human was, as 
far as we know, performed exactly 100 years ago by Eduard Zirm.1 In a Moravian 
(Slovakia) hospital Zirm performed two penetrating keratoplasties (PKP) on a 
45-year old patient who had been bilaterally blinded by a lime injury. Two small 
fresh corneal grafts were derived from one enucleated eye of an 11-year old 
boy whose eye was injured by an intraocular foreign body. The corneal graft on 
the right eye of the patient failed. However, the left corneal transplant remained 
clear and a visual acuity of 6/36 was noted after one year.2 Great advances in 
surgical instrumentation and techniques and the introduction of antibiotics and 
corticosteroids over the second half of the last century, significantly improved 
the success rate for corneal transplantation. In fact corneal transplantation is 
at present the most widely practised form of clinical transplantation. In the UK 
2329 corneal transplantations were performed in 2003, in comparison with 
1697 renal transplantations.3 Approximately 46000 corneal transplantations are 
performed every year in the USA.4 Also in the Netherlands corneal transplanta-
tion is commonly performed with 642 transplantations in 2003, compared to 388 
renal transplantations.5 Although corneal transplantation is the most performed 
transplant, it is arguable whether it is the most successful in the long-term.
1.2 ANATOMY OF THE CORNEA AND THE REFRACTIVE SYSTEM
Anatomy
The total refractive power of the eye is about 58 diopters (D). The cornea provides 
80% of this refractive power and functions as a protective membrane. From 
anterior to posterior it has five layers: the epithelium, Bowman’s membrane, 
the stroma, Descemet’s membrane and the endothelium. The stroma accounts 
for 90% of the thickness of the cornea and consists of collagen fibers, precisely 
arranged thus as to preserve transparency, supported by scattered keratocytes. 
The maintenance of normal corneal hydratation, thickness and transparency is 
the responsibility of the endothelium.6
Endothelium
The corneal endothelium is a monolayer of cells derived from the neural 
crest during embryologic development. Human endothelial cell density is 
approximately 6000 cells/mm2 during the first month of life, but decreases 
to 3500 cells/mm2 by the age of 5 years.7,8 There is no evidence that human 
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endothelial cells divide under normal circumstances.9 During life, there is a 
gradual loss of cells at an average rate of 0.6% a year.10 Corneal transparency 
could be maintained with a density as low as 500 cells/mm2.11 Accelerated loss 
of cell density can be seen after intraocular operations.12 After an initial decline 
in cell density, a gradual loss of endothelial cells at an average rate of 2.5% per 
year is reported after extra capsular cataract extraction.12 After transplantation 
there is a rapid loss in cell number, initially due to surgical trauma and early 
postoperative inflammation.13 The average rate of postkeratoplasty endothelial 
cell decline is shown to be 7.8% during the first 3 to 5 years14 and 4.2% per 
year from 5 to 10 years.13 Increased cell loss can be observed during a rejec-
tion reaction.15 In some cases this results in transparency loss of the cornea 
and subsequent graft failure. Moreover, chronic endothelial cell loss can lead to 
decompensation of the graft (called slow endothelial decompensation). This is 
possibly the leading cause of graft failure after the first five postoperative years.13 
Thus, the long-term success of corneal transplantation depends on transplanting 
an adequate amount of functioning donor endothelium. Important reasons for 
not using donor corneas for transplantation are an endothelial cell count fallen 
below the arbitrary density of 2200-2300 cells/mm2, an irregular cell mosaic or 
an abnormal amount of cell loss during preservation.16,17
Progressive endothelial cell loss is also a long-term concern after phakic 
intraocular lens (IOL) implantation.18 Severe endothelial cell loss is seen in 
eyes with phakic angle supported IOLs.19,20 This could possibly lead to corneal 
decompensation in a substantial number of eyes. In the iris-claw phakic IOL 
the expected amount of endothelial cell loss is probably lower due to the firm 
iris fixation without contact with the angle.21 In highly myopic eyes corrected 
with an iris-claw lens, Menezo et al. reported an endothelial cell loss of 3.0% 
at 6 months, 5.5% at 1 year and 10.5% at 5 years.22 These percentages resemble 
those found after cataract extraction with IOL placement in the capsular bag.12 
In hyperopic eyes with phakic IOLs long-term endothelial cell loss might be a 
potential problem since a negative correlation was seen between endothelial 
cell loss, anterior chamber depth and thickness of the IOL.18,23 
Refractive system
Emmetropia is the optical condition in which parallel rays of light from a distance 
object are brought to focus on the retina by an eye with relaxed accommodation. 
In ametropia a disparity consists between the refractive power of the eye and the 
length of the eye. In myopia the optical power is too high for the axial length 
and in hyperopia the optical power is not enough.24 The formation of a clear 
image in an ametropic eye could be achieved artificially with help of a concave 
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lens in case of myopia and by a convex lens in case of hyperopia. A spectacle 
lens alters the size of the retinal image of a distant object, particularly in higher 
ametropia. Contact lenses are an alternative that reduces image magnification 
and minification. 
Astigmatism
Astigmatism is the optical condition in which the refracting power of the eye is 
not the same in all meridians. Parallel rays of light do not focus at a single point. 
In regular astigmatism the refractive power changes gradually form one merid-
ian to the next by uniform increments.25 Regular astigmatism can be corrected 
by a cylindrical lens. In irregular astigmatism, irregularities exist in the curvature 
of the meridian. In the terminology of astigmatism, ‘with-the-rule’ astigmatism 
refers to the condition in which the vertical meridian is the steepest. In ‘against-
the-rule’ astigmatism the horizontal meridian is the steepest. Conventionally, 
the astigmatic component of refraction is written as a cylinder and an axis. This 
format may characterize a single refraction but is not suited to statistical analy-
sis. Calculating average astigmatism or surgically induced astigmatism requires 
conversion of the polar coordinates (cylinder and axis) to a Cartesian coordinate 
system.26 The angles of astigmatism must be doubled so that 0 and 180 degrees 
are equivalent in order to apply conventional geometry and trigonometry. For 
conversion of a cylinder and axis to Cartesian coordinates, the following formula 
should be used:
   x = Cylinder * Cos (2 * axis)
   y = Cylinder * Sin (2 * axis)
Where x is the horizontal component and y is the vertical component. The 
cylinder magnitude is given in diopters. Once all data are converted standard 
descriptive statistic formulas can be applied. Cartesian coordinates can be 
converted back to standard polar notation for astigmatism according to the fol-
lowing formula:
   Cylinder = √(x2 + y2) 
   Angle = 0.5 * Arc tan (y/x),
   If x & y > 0 Axis = angle
   If x < 0  Axis = angle + 90
   If x > 0 & y < 0 Axis = angle + 180
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Refractive data must be adjusted for vertex distance before comparison to kera-
tometric data.
1.3 INDICATIONS FOR CORNEAL TRANSPLANTATION 
Improvement of vision is the usual indication for corneal transplantation. How-
ever, preservation of the globe, cosmetic appearance of the eye and reduction of 
pain due to corneal pathology are other indications dealing with different out-
come measurements. Depending on the geographic location, type of institution 
and time, indications for corneal transplantation vary.27-34 Leading indications 
for keratoplasty reported by published studies from Europe, North America, 
Australia and New Zealand are pseudophakic bullous keratopathy, keratoconus, 
regraft and Fuchs’ endothelial dystrophy. Other less common indications are 
keratitis, including herpetic keratitis, other corneal dystrophies and degenera-
tions, chemical burns and trauma.
1.4 CORNEAL GRAFT SURVIVAL
Corneal transplantation can be a successful procedure. A success rate in excess 
of 90% is reported in uncomplicated cases.35-38 Among the most common causes 
for transplant failure are irreversible rejection, late endothelial decompensation, 
ocular surface disease, glaucoma and astigmatism.37,39 In general topical cortico-
steroids are given after corneal transplantation as the sole rejection prophylaxis. 
The ability of the corneal graft to survive in the absence of systemic immunosup-
pression led to the proposition that the cornea is an immune privileged tissue at 
an immune privileged site.40
1.4.1 Immunology of corneal transplantation
Several mechanisms attribute to the corneal immune privilege, and still more 
explanations for this phenomenon derived from animal models of keratoplasty 
are to be expected. Known mechanisms for immune privilege in the normal 
cornea thus far are:
1) Lack of both afferent lymphatic and efferent blood vessels. There is a separa-
tion of ocular tissues and the intravascular space that is referred to as the 
blood-ocular barrier.41-44 The avascularity of the cornea contributes to a 
suppression of the afferent and efferent arm of the immune reflex arc, which 
could preclude transplant rejection.
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2) Lack of MHC-II+ antigen presenting cells (Langerhans cells) in the centre of 
the cornea.45-47 This feature is explained in more detail in section 1.4.2.2.
3) Anterior chamber associated immune deviation (ACAID) directed at for 
example graft antigens. Intracameral injection of alloantigens results in an 
altered form of immunity to that antigen. This is a tolerogenic form of im-
munity with a selective suppression of T cells mediating delayed type hyper-
sensitivity to antigens and suppression of complement fixing antibodies.48-50
4) Secretion of immunosuppressive molecules by corneal cells. These immu-
nosuppressive molecules such as IL-1 receptor antagonist and Fas-ligand 
(Fas-L) have the ability to inhibit complement activation and T cells. IL-1 is 
a potent proinflammatory cytokine, inducing chemotaxis and activation of 
antigen presenting cells (APC).51 Fas-L is expressed on the corneal epithelium 
and endothelium.52-54 It is proposed that Fas-L can interact with Fas+ immune 
effector cells (T cells) entering the eye during inflammation, inducing apop-
tosis of the immune effector cell without inflammatory damage.55,56 
5) The presence of immunosuppressive cytokines, derived from the aqueous 
humor, such as transforming growth factor-beta-2, tumor necrosis factor-
alfa, IL-10 and neuropeptides.57-60
1.4.2 Corneal graft rejection
Immune privilege is not absolute and can be lost due to certain circumstances. 
Immune rejection is an important and often the leading cause of corneal graft 
failure.61-65 
1.4.2.1 Clinical diagnosis of corneal graft rejection
The diagnosis of an immune mediated graft rejection is not always clear-cut. 
One of the earliest signs is conjunctival and episcleral vascular engorgement, 
thus a general inflammatory response.66 Corneal allograft rejection is considered 
when progressive clouding is seen in an until that time clear graft.63,67 Typically 
edema is limited to the graft and the eye was not previously inflamed. Other 
signs are keratic precipitates limited to the graft and mild aqueous flare. These 
keratic precipitates may progress to linear accumulations on the endothelium, 
called ‘Khodadoust rejection line’. This feature is considered a pathognomonic 
sign of rejection.63 Each layer of the cornea can manifest a rejection reaction.68 
An epithelial rejection is only observed in about 10% of all rejected grafts.63,68 
This epithelial rejection is seen as an elevated line starting in the periphery and 
progressing towards the centre of the graft. The rejection reaction of the stromal 
layer is characterized by subepithelial infiltrates, which are whitish infiltrates in 
the anterior stroma, randomly positioned in the graft.69 Each type of rejection 
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can occur concurrently with the others and separately. The endothelial rejection 
is the most common and has the worst prognosis since endothelial cells do not 
have the capacity to regenerate once affected. 
1.4.2.2 Mechanism of immunity underlying graft rejection
The mechanism of corneal graft rejection is still not completely understood. 
To initiate a rejection reaction (afferent arm of the immune reflex arc) antigens 
expressed by donor tissue must be presented to recipient T cells. Two distinct 
forms of antigen presentation are possible. In the direct pathway, donor-derived 
APCs migrate out of the transplant to the recipient’s lymphoid organs/tissue and 
stimulate directly recipient CD4+ Th cells. In the indirect pathway, recipient 
APCs phagocytose and express donor antigens and present them on their cell 
surface to naive recipient T cells.46,70,71 Via the indirect pathway major histocom-
patibility class I and II antigens as well as minor histocompatibility antigens can 
be presented to recipient T cells. Classically this indirect route is thought to play 
a more prominent role in late acute and chronic rejection. The indirect pathway 
is more likely to be the dominant afferent route for graft rejection in non-in-
flamed and unvascularised corneal grafts, since APCs (MHC- II+ dendritic cells) 
are absent in the normal cornea. The more effective direct pathway might play a 
relevant role in antigen presentation in vascularised or inflamed corneal grafts.72 
After T cell activation the efferent phase of the immune reflex arc starts. This is a 
destructive response. Fundamentally, two T cell mediated effector mechanisms 
can be observed in corneal graft rejection: a cytotoxic T cell (CTL) response and 
a delayed type hypersensitivity (DHT) response. The role of antibodies in corneal 
graft rejection is poorly understood and it appears that a B cell response plays no 
important role.46,48,73 CD4+ T cells are the main producers for DTH response and 
CD8+ T cells are considered classically as CTLs. Whether corneal graft rejection 
is mainly dominated by a CTL or DTH response is still not clear.74-76 Pathological 
examination of rejected corneal grafts has revealed a mixed cellular infiltrate 
compromised of both CD4+ and CD8+ T cells.77 Animal experimental studies 
indicate that corneal graft rejection occurs also in mice incapable of developing 
CTL responses.78 However, rejection of human transplanted corneas was found to 
be associated with a CTL response directed against donor HLA class I antigens.79 
Depletion of CD4+ T cells does result in a reduction of corneal graft rejection in 
animal models.80,81 CD4+ T cells can be further divided based on their function 
in Th1 cells and Th2 cells. A DTH response is a classic Th1 immune response, 
characterized by preferential production of the proinflammatory cytokine in-
terferon-gamma and IL-2. On the other hand there is evidence that some forms 
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of allograft rejection are Th2 mediated, since rejection is characterized by the 
presence of elevated Th2 cytokine expression in the inflammatory infiltrate.82 
1.4.2.3 Influence of HLA matching on rejection
HLA antigens play a prominent role in the presentation of foreign antigens to 
recipient T cells. The major histocompatibility complex (MHC), in human the 
human leukocyte antigen system (HLA), consists of two distinct classes encoded 
by genes located on the short arm of chromosome 6.83 HLA class I antigens 
(HLA-A, HLA-B and HLA-C) are cell surface molecules expressed on all nucle-
ated cells. The distribution of HLA class II antigens (HLA-DR, HLA-DP and HLA-
DQ) is quite different. Under normal circumstances HLA class II antigens are 
expressed on B-lymphocytes and on APCs like Langerhans cells in the cornea. 
HLA-DR and HLA-DQ are in strong linkage disequilibrium.84 The role of HLA-
DP as a transplantation antigen in corneal transplantation is quite obscure and 
not thoroughly investigated. HLA-A and HLA-B antigens have been identified 
on epithelium, stromal and endothelial corneal cells.85-87 HLA-C is expressed 
at only 10% of the level of HLA-A and HLA-B, and for that reason considered 
as a weak transplantation antigen.84 Expression of HLA-DR antigens carried on 
Langerhans cells has been demonstrated within corneal epithelium and stro-
mal layers.85,87 The central part of the cornea is normally devoid of Langerhans 
cells.85,88 However, migration and accumulation in the central part could be 
established by various factors, such as vascularisation and inflammation under 
the influence of interferron-gamma.89-91 Other cells that can function as APCs 
after migration to the cornea are monocytes and macrophages (called passenger 
leukocytes). Several studies have investigated the role of HLA-matching in cor-
neal graft rejection, but there has been little consensus. Studies have produced 
mixed results: some studies have suggested that HLA class I matching does not 
play an important role in corneal graft rejection,92 whereas others indicate that 
HLA class I matching results in a reduced risk of graft rejection and subsequently 
prolonged graft survival.93-95 Conclusions about HLA class II matching are even 
more controversial with a detrimental effect found by the Corneal Transplant 
Follow-up study96 and a beneficial effect found by others.94,97,98 In Table 1 a 
summary of published studies to matching for HLA-A and HLA-B antigens is 
presented92-97,99-101 and in Table 2 studies to matching for HLA class II antigens 
are summarized.92,94,96-98,102 Comparison of the results of divers studies is compli-
cated by different definitions of patients at high risk and various posttransplant 
treatment regimens. Results could further have been biased by the use of differ-
ent donor preservation methods and HLA typing protocols. 
18
C
ha
pt
er
 1
1.4.3 Donor corneal storage system
With Filatov,103 the use of cadaveric corneas for corneal transplantation instead 
of diseased eyes of living humans became more popular. This enhanced the 
supply of corneas for transplantation. A major difference between processing 
of donor corneas and other donor material is that the cornea does not need to 
be ‘fresh’ at transplantation. Recent advances in eye banking and corneal pres-
ervation now allow routine storage of the cornea for up to 5-6 weeks through 
the use of tissue-culture technique. In the Netherlands organ culture preserved 
donor corneas are used since 1982/3.17 The ability to store corneas provides 
an enormous advantage, as it allows both scheduling of transplant surgery and 
allocation and quality testing of the donor cornea before grafting. A further 
advantage of the use of organ culture storage might be an altered immunogenic-
ity of the donor cornea. This immunologic alteration is ascribed to the loss of 
‘passenger leukocytes’ and the relatively hypocellularity of the donor epithelium 
after organ culture.104,105 A depletion of HLA-DR bearing donor dendritic cells 
Table 1. A summary of published studies to matching for HLA-A and HLA-B antigens
First author, 
year 
No. of 
grafts
HLA 
typing 
Inclusion Event analysed Matching effect
Sanfilipo, 1986 97 serology high-risk rejection and 
immune failure
Beneficial effect for HLA-A and HLA-B 
matching
Ozdemir, 1986 40 serology high-risk graft failure Beneficial effect for HLA-A and HLA-B 
matching
Boisjoly, 1990 435 serology mixed, 
majority 
low-risk
rejection Beneficial effect for HLA-A and HLA-B 
matching, more pronounced in low-risk 
group
The CCTS, 
1992
419 serology high-risk rejection and 
immune failure
No effect of HLA-A or HLA-B matching
Hoffmann, 
1994
248 serology mixed rejection No significant effect of HLA-A matching, 
beneficial effect of HLA-B matching in 
both low and high-risk group 
Vail, 1997 602 not 
defined
mixed rejection Possible (not significantly) beneficial 
effect of HLA-A and HLA-B matching
Roy, 1997 693 not 
defined
mixed rejection No effect of HLA-A and HLA-B matching 
for high-risk group, beneficial effect of 
HLA-A and HLA-B matching for low-risk 
group 
Morita, 1998 80 DNA mixed rejection Beneficial effect for HLA-A matching for 
total group and high-risk group
Völker-Dieben, 
2000
1189 serology mixed rejection and 
immune failure
Beneficial effect for HLA-A and HLA–B 
matching
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is found after several days of organ culture preservation.85,106 This depletion of 
Langerhans cells or macrophages in donor corneas might improve graft survival 
and could be considered as a contribution to the immune privilege.107 HLA-A, 
HLA-B and HLA-C antigens are still present after organ culture preservation, 
though fewer.85 
1.4.4 HLA typing techniques
The HLA molecules are highly polymorphic. Within one individual the chance 
that the MHC genes on both chromosomes will encode the same allele is small; 
that is most individuals are heterozygote. It is also unlikely that two unrelated 
individuals would be identical at all loci. The observation of a higher percent-
age of homozygosity than expected should raises doubt. A common error with 
serological typing is failing to identify a second HLA-DR locus antigen, resulting 
in a higher percentage of homozygosity.108,109 In general serological typing for 
HLA class I is less prone to error and yields accurate broad typing results. The 
serological typing errors might partly be explained by the difficulty of typing 
peripheral blood samples from cadaver donors. A newer method of HLA typing 
is a technique using genomic DNA restriction fragment length polymorphism 
Table 2. A summary of studies to matching for HLA class II antigens
First author, 
year 
No. of 
grafts
HLA 
typing 
Preservation 
method
Inclusion Event 
analysed
Matching effect
Baggesen, 
1996
74 DNA Organ culture high-risk graft survival Beneficial effect for HLA-DR 
matching
The CCTS, 
1992
419 serology McCarry-
Kaufman/ KSOL 
culture medium
high-risk rejection 
and immune 
failure
No effect of HLA-DR matching
Munkhbat, 
1997
81 DNA Optisol 
preservation
mixed rejection Beneficial effect for HLA-DP 
matching in high risk group, 
no significant effect for HLA-
DR matching in either risk 
group
Vail, 1997 602 serology Moist chamber/ 
McCarry-
Kaufman/organ 
culture
mixed rejection Detrimental effect for HLA-DR 
matching
Völker-
Dieben, 2000
558 serology McCarry-
Kaufman/organ 
culture
mixed rejection 
and immune 
failure
Beneficial effect for HLA-DR 
matching on rejection and 
immune failure
Hoffmann, 
1994
248 serology Moist chamber mixed rejection Beneficial effect of HLA-DR 
matching in both low and high 
risk group
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(RFLP). Although RFLP typing yields good results for HLA-DR, this procedure 
is time consuming and cannot be prospectively used for typing of cadaver 
donors.110,111 Recently, PCR-based DNA typing systems have become available 
for HLA class I and II, which are rapid, more accurate than serological typing 
and can define single amino acid polymorphism.112,113 Accurate broad and split 
antigens for HLA class I and II can be defined by DNA typing systems. Using 
DNA typing techniques, approximately 25% of the HLA-DR antigens turned out 
to be erroneously typed by serological means.114,115
1.4.5 Other antigens influencing corneal graft rejection
Data derived from animal experimental studies indicate that incompatibility 
between donor and recipient for minor histocompatibility antigens play a role 
in graft rejection.116,117 There are problems, however, with relating data from 
animal models of keratoplasty to the human setting. Immunologic rejection of 
corneas in mice and rats is more aggressive than in humans. The ABO and H-Y 
antigens are the most well known human minor histocompatibility antigens. 
Data about the role of these minor antigens in human corneal transplantation 
are controversial and not conclusive with respect to ABO matching.95,118-120 Also 
a significant contribution of H-Y antigens to graft rejection in humans has so far 
not been shown.121
1.4.6 Predictors for corneal graft survival other than immune factors
Because rejection is a serious threat for graft failure, all risk factors for rejection 
are principally risk factors for graft failure. The state of the recipient cornea itself 
is an important factor that determines the success of the graft. This led to the 
proposition of high-risk recipients for corneal graft failure. In general high-risk 
recipients are identified by virtue of having deep stromal vascularisation or hav-
ing a history of previous graft rejection. Primary grafts have a significantly better 
long-term survival compared with regrafts.13,37,64,122 Vascularisation is an other 
important risk factor for graft survival.37,64,123-125 Other recipient factors possibly 
associated with an increased risk of graft failure are a history of pregnancy or 
blood transfusion,126 anterior synaechiae,39,127 glaucoma,36,39,65 dry eyes,69,128 
inflammation at the time of keratoplasty, especially in active herpetic infection65 
and aphakia.36,64,65,96 The indication for transplantation is highly related to the 
inflammatory condition of the eye and vascularisation of the recipient bed and 
subsequently to graft survival. Reported graft survival rates of different studies 
may vary with the inclusion of variable percentages of each indication. Overall 
10-year graft survival rates reported vary from 59 to 80%.13,64,129 Survival rates 
for the indication of keratoconus and Fuchs’ endothelial dystrophy are generally 
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good. For keratoconus survival rates of 92 to 95% are reported after 5 years to 
10 years.36-38 Reported graft survival rates for Fuchs’ endothelial dystrophy are 
61% at 4 years follow-up by Olsen et al.,130 89% at 8.4 years by Pineros et al.131 
and 81% and 90% at 10 years respectively by Ing et al.13,64 and Thompson et 
al..64 These high survival rates are in sharp contrast to the survival rates for herpes 
simplex keratitis, in particular after regrafting.65,120
1.5 POSTKERATOPLASTY COMPLICATIONS 
Several postoperative complications can influence graft survival or postoperative 
visual acuity. Some of these factors are discussed. 
Wound dehiscence
Erasmus Darwin wrote132 “Could not a small piece of cornea be excised with a 
trephine, the size of a small bristle or a large quill and would it not heal with a 
transparent scar?” 
It is a question whether the corneal wound after keratoplasty will ever be 
healed. Calkins et al. demonstrated that the strength of the graft-recipient 
interface is weak even 1 year after transplantation.133 Wound abnormalities in 
keratoplasty include incarceration of Bowman or Descemet membrane or ret-
rocorneal fibrous tissue sealing the wound.134,135 The imperative wound healing 
exposes the patient to a significant risk of wound dehiscence and even loss of 
the eye, since wound dehiscence can lead to a suprachoroidal haemorrhage or 
endophthalmitis.136-138 Furthermore, wound dehiscence creates an unpredictable 
and changing refractive error.136 Wound dehiscence appears not to be related to 
specific suture technique. Binder et al.139 reported a 5.7% incidence of spontane-
ous wound dehiscence after PKP using all kinds of suture techniques. However, 
the incidence of wound dehiscence is correlated with suture removal.139 Wound 
strength without sutures remains low indefinitely after PKP. To promote wound 
healing and to reduce the risk of wound dehiscence and astigmatism a modifica-
tion of the standard PKP could be used. In this technique a full thickness donor 
graft with a larger posterior diameter is used in conjunction with a peripheral 
lamellar wound configuration, resulting in a smaller anterior diameter of the 
graft.140 Although this technique is more time consuming than a standard PKP 
procedure, it may be a valuable alternative for posterior corneal pathology 
indications such as pseudophakic bullous keratopathy and Fuchs’ endothelial 
dystrophy. 
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Suture related problems
Several suture related complications can interfere with graft survival.141 Suture 
loosening increases the risk of rejection.142 Loose sutures also predispose to 
postoperative infection.69 Vascularisation might be encouraged by the presence 
of sutures, especially by interrupted sutures.143 On the other hand, sutures 
loosen especially in a vascularised recipient bed. For that reason continuous 
suturing in high-risk patients should be discouraged. Spontaneous suture ero-
sion through the epithelium is a significant risk for retained sutures.144 The risk 
for encountering suture related problems ends when all sutures are removed. 
However, suture removal is also a possible factor inducing graft rejection and as 
mentioned before wound dehiscence.141 
Astigmatism
A clear graft will not result in good vision if the optical properties of the cornea 
are inappropriate. The leading cause of poor vision in an otherwise clear corneal 
graft is astigmatism.65,145,146 Postoperative corneal astigmatism decreases with 
increasing graft size.147 However, larger grafts are shown to be associated with 
a higher risk of rejection.124,126,148 Malposition of donor and recipient cornea, 
irregularities in trephination and uneven suture tension are important causes of 
astigmatism after keratoplasty.149,150 Despite newer techniques and instruments, 
mean astigmatism after PKP ranges between 2.5 and 3.5 D with more than 40% 
of cases having an astigmatism greater than 3.0 D.131,151,152 Surgical techniques 
proposed to prevent or reduce astigmatism in corneal transplantation are numer-
ous. There is no common agreement about which suture technique is the best 
for astigmatism control. Adjustment of a continuous suture or selective removal 
of interrupted sutures are widely adopted techniques to reduce postoperative 
astigmatism.151-155 The effect of selective suture removal, however, is lost after all 
sutures are removed and the advantage is apparent only in the first years after 
transplantation.156 Furthermore, suture removal any time after transplantation 
can result in unpredictable and large changes in astigmatism.157-159 A non-biode-
gradable suture that can be left in place permanently without loosening could 
contribute to a better astigmatism control.
If optical correction of the astigmatism is required, the first option is spectacles, 
the second is contact lenses. If what can be achieved with optical devices is 
not acceptable for the patient, several surgical options are available to improve 
visual performance. Some of them will be discussed in the following sections.
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1.6 ALTERNATIVES TO PENETRATING KERATOPLASTY
Given the numerous side effects in corneal transplantation and restricted long-
term graft survival, other treatment modalities than PKP could be preferred in an 
attempt to delay or avoid PKP. The possible alternatives vary among the indica-
tion for transplantation. 
1.6.1 Posterior lamellar keratoplasty or deep lamellar endothelial keratoplasty
Posterior lamellar keratoplasty (PLK) and deep lamellar endothelial keratoplasty 
(DLEK) are basically two terms for the same procedure.160,161 This procedure can 
be used for the treatment of endothelial corneal pathologies, mainly pseudo-
phakic bullous keratopathy and Fuchs’ endothelial dystrophy. The philosophy 
is to selectively replace the diseased layer and to leave the healthy tissue intact. 
Advantages of PLK compared to PKP are less induced astigmatism and no need 
for sutures with associated problems. Although results of PLK are promising, this 
is still a procedure in development and long-term results remained to be seen.
1.6.2 Anterior lamellar keratoplasty
Indications for this procedure can be keratoconus or opacifications in the 
anterior to mid stroma of the cornea. Advantages of lamellar keratoplasty (LK) 
compared to PKP are preservation of the recipient endothelium, reduced risk 
for graft rejection, better wound stability and less need for corticosteroids.162 
Interface scarring and irregular astigmatism are the main problems limiting 
postoperative visual acuity in LK. Optical results are generally better with PKP 
than with LK. With a newer technique of deep lamellar keratoplasty (DLK) the 
limitations of conventional LK might be decreased.163 However, DLK is more 
difficult and carries the risk of Descemet’s membrane perforation.164
1.6.3 Non keratoplasty procedures
If the cornea is still transparent in an eye with keratoconus or marginal degen-
eration, other surgical options besides PKP or LK could be considered. These 
options are mainly aimed at the reduction of astigmatism in patients who are 
contact lens intolerant. Options such as photorefractive keratectomy (PRK) and 
laser in situ keratomileusis (LASIK) remain limited as keratoconus and marginal 
degeneration are considered as contraindications because of poor refractive sta-
bility and the risk of progressive ectasis.165,166 Epikeratoplasty could be regarded 
as an alternative to LK. The aim of this procedure is to flatten and stabilize the 
ectatic cornea.167 Optically PKP is found to be superior to epikeratoplasty.168 
Corneal wedge resection have been used in keratoconus and marginal degen-
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eration with variable results.169-172 Poor predictability and limited improvement 
in visual acuity with this procedure have precluded widespread use. 
1.6.3.1 Intracorneal rings
Previously intrastromal rings were used to correct low myopia. Recently, the 
use of these rings is evaluated in patients with keratoconus and early marginal 
degeneration.173-177 The goal of the treatment with intrastromal rings is to reshape 
the cornea: astigmatism might be reduced or irregular astigmatism might be 
changed towards more regular astigmatism. Two types of rings are available: 
Intacs corneal rings and Ferrara intracorneal ring segments (FICR). Differences 
between these rings are a more centrally placement and a triangular anterior 
shape of the FICR compared to a flat anterior shape of the Intacs. A summary of 
published studies on corneal rings for keratoconus is listed in Table 3. Although 
spherical equivalent error and astigmatism were significantly reduced in all 
studies after implantation of the ring segments, the predictability was moderate. 
Besides, stability of refraction and visual recovery after segment placement were 
not optimal with an ongoing decrease of refractive astigmatism during the first 
year, as shown by Colin et al..174 Unacceptable visual side effects such as glare 
and halo could occur. Extrusion of a segment with subsequent bacterial keratitis 
as reported by Kwitko175 is a serious complication. It is yet not known whether 
intracorneal rings accelerate the progression of corneal ectasia or stabilize the 
situation. Intacs might also be used for early pellucid marginal degeneration. Ky-
mionis et al.173 report on a successful case: best spectacle corrected visual acuity 
improved from 20/50 to 20/25 and refractive cylinder decreased from –8.50 D 
to –5.50 D. In advanced stages of the disease, however, it might be impossible to 
implant the segments, because of progressive thinning of the inferior cornea. For 
patients with keratoconus and marginal degeneration also combined surgical 
Table 3. Summary of studies correcting astigmatism with intrastromal ring segments in 
eyes with keratoconus
Author, year n rings Follow-up
(months)
Preop mean SE (D) Postop
mean SE (D)
Preop
mean Cyl (D)
Postop
mean Cyl (D)
Postop
mean BSCVA
Explantations or PKP 
during study (%)
Colin, 2001 10 intacs 12, all eyes NR NR 4 1.3±1.4 0.63 not included
Boxer Wachler, 2003 74 intacs mean 9 -3.89±5.16 -1.46±4.11 NR NR 0.63 5.4%
Siganos, 2002 26 FICR 6, all eyes -6.91±5.02 -1.11±2.56 4.42±2.23 2.20±1.02 0.60 7.7%
Kwitko, 2004 51 FICR mean 13 -6.08±5.01 -4.55±5.71 3.82±2.13 2.16±2.07 0.44 25.5%
SE, spherical equivalent; BSCVA, best spectacle corrected visual acuity; PKP, penetrating 
keratoplasty; NR, not reported; FIRC, Ferrara intracorneal ring (segments)
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procedures could be considered in cases with irregular astigmatism and a high 
degree of myopia: intrastromal rings plus a phakic IOL.
1.6.3.2 Phakic intraocular lenses
Toric iris-fixated phakic IOLs can be considered for the reduction of anisometro-
pia and astigmatism after penetrating keratoplasty.178,179 The use of phakic IOLs 
for the correction of myopia and astigmatism in patients with keratoconus and 
marginal degeneration is evaluated in this thesis (chapter 5 and 6).
1.7  REFRACTIVE SURGERY FOR AMETROPIA AND ASTIGMATISM IN EYES 
WITHOUT FURTHER PATHOLOGY
The primary goal of refractive surgery is to establish a permanent correction 
of the refractive error in order to make the patient contact lens or spectacle 
independent. Moreover, a superior quality of vision is critical, since patients 
for refractive surgery typically have no further ocular pathology. To compare 
refractive results of different studies it is essential that refractive data be reported 
in a consistent manner. The following elements are mandatory: safety, efficacy, 
predictability and stability.180 Safety can be expressed as percentage of eyes 
loosing one, two or more lines of best spectacle corrected visual acuity (BSCVA). 
The safety index is the ratio of mean postoperative BSCVA over mean preopera-
tive BSCVA. Efficacy can be described as percentage of eyes with uncorrected 
visual acuity (UCVA) of 20/20 or 20/40. This outcome measurement is less 
informative when amblyopic eyes are involved. Efficacy index is the ratio of 
the mean postoperative UCVA to the mean preoperative BSCVA and might be 
more informative. The accuracy of the refractive treatment is addressed by the 
predictability. Postoperative spherical equivalent (SE) could be given together 
Table 3. Summary of studies correcting astigmatism with intrastromal ring segments in 
eyes with keratoconus
Author, year n rings Follow-up
(months)
Preop mean SE (D) Postop
mean SE (D)
Preop
mean Cyl (D)
Postop
mean Cyl (D)
Postop
mean BSCVA
Explantations or PKP 
during study (%)
Colin, 2001 10 intacs 12, all eyes NR NR 4 1.3±1.4 0.63 not included
Boxer Wachler, 2003 74 intacs mean 9 -3.89±5.16 -1.46±4.11 NR NR 0.63 5.4%
Siganos, 2002 26 FICR 6, all eyes -6.91±5.02 -1.11±2.56 4.42±2.23 2.20±1.02 0.60 7.7%
Kwitko, 2004 51 FICR mean 13 -6.08±5.01 -4.55±5.71 3.82±2.13 2.16±2.07 0.44 25.5%
SE, spherical equivalent; BSCVA, best spectacle corrected visual acuity; PKP, penetrating 
keratoplasty; NR, not reported; FIRC, Ferrara intracorneal ring (segments)
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with percentage of eyes within 1.00 D and 0.50 D of attempted postoperative 
refraction. Spherical equivalent is not an appropriate measure of surgical suc-
cess in eyes with high astigmatism. Vector analysis should be used to calculate 
mean astigmatism and surgically induced astigmatism. The method for vector 
analysis of astigmatic data is given before. Stability should be given by showing 
SE refraction or change in astigmatism throughout the postoperative period.
Several surgical techniques for the correction of moderate to high ametropia 
combined with astigmatism are available. Indications for and advantages and 
disadvantages of different techniques are listed below.
PRK 
Photorefractive keratectomy (PRK) offers good results in low to moderate myo-
pia. To increase predictability of higher myopic corrections, multizone ablation 
techniques and scanning laser beams have been developed.181 Ablation depth 
could be reduced by the multizone technique. Hyperopic treatments require 
larger ablation diameters than myopic treatments. Hyperopic PRK appears to be 
relatively safe and effective for corrections up to +4.00 D.182-184 In the Nether-
lands, the advised upper treatment limit for myopia is –8.0 D.184 Higher myopic 
or hyperopic corrections, however, showed poor predictability (under and over 
corrections) and an increased risk of complications such as corneal haze and 
corneal irregularities.184-187 Loss of BSCVA may arise from these complications. 
As shown in Table 4, more than 10% of treated eyes lost two or more lines 
BSCVA.186-188 Another problem with correction of high myopia and hyperopia is 
regression.184,186,188 
LASIK
Laser in situ keratomileusis (LASIK) can treat a wide range of myopia. However, 
with increased amount of myopia, predictability, efficacy and stability decrease. 
Results are significantly worse in high myopia (> 7 D) compared to lower 
Table 4. Recent studies on moderate myopic and hyperopic astigmatism corrections with 
PRK
Author, year, Laser n Follow-up 
(months)
Preoperative mean SE or S 
& C (D)
% ± 0.50 D % ± 1.00 D Loss BSCVA 
≥ 2 lines
Hersh, 1998, Summit 68 6 SE -9.3 (range: -6.0 to -13.9) 29.4% 57.4% 11.8%
Nagy, 2002, Meditec 
Mel 70G
38 12 S: +3.56 and C: +2.64 42% 63.2% 15.8%
El-Agha, 2003, VISX S2 41 9 SE +3.06, C: +1.31 NR 80% 10.0%
SE, spherical equivalent; BSCVA, best spectacle corrected visual acuity; NR, not reported
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myopia.189-191 Furthermore, the correction that can be treated is limited by the 
amount of tissue, which has to be removed. A generally held minimum residual 
corneal bed thickness of 250µm remains a structural barrier to larger optical 
zones and thus higher corrections. A thinner residual corneal bed may lead to 
corneal ectasia, although the critical corneal thickness to avoid ectasia is not 
clear.192,193 In general a corneal thickness less than 500µm is a contraindica-
tion for LASIK.182 Although haze appears to be a minor problem after LASIK in 
comparison with PRK, other complications such as irregular corneal surface, 
decentration and induced astigmatism, can cause loss of BSCVA.186 After myopic 
LASIK the improvement in BSCVA appears to be less compared to after phakic 
IOL implantation. This phenomenon of gain in BSCVA is attributed to the image 
magnification inherent to correcting myopia closer to the eye’s nodal point.194 
The incidence of regression of more than 1 D after LASIK in eyes with moderate 
to high myopia has been shown to be almost 40%.195,196 It is difficult to compare 
different studies because of variations in the range of preoperative myopia and 
astigmatism, type of lasers and follow-up time. A summary of recently published 
studies on moderate to high myopic LASIK is presented in Table 5.186,189-191,197-200 
Results of LASIK for hyperopia and hyperopic astigmatism (Table 6) are generally 
worse compared to results for myopia. It is easier to flatten the central cornea 
Table 5. Recently published studies on the treatment of moderate myopia with LASIK
Author, year, Laser n Follow-up
(months)
Preoperative mean SE or S & 
C (D)
% ± 0.50 D % ± 1.00 D Loss BSCVA 
≥ 2 lines
Hersh, 1998, 
Summit
61 6 -9.23 (range: -6.0 to -14.4) 27.1% 40.7% 3.2%
Steinert, 1998, 
Summit
68 12 -9.2 (range: -6.0 to –12.0) 23% 54% 2%
Knorz, 2000, 
Keracor
89 3 S -7.83 (range: -6.1 to –12.0) &
C –1.06 (range: 0 to –3.5)
75% NR 5%
FDA, 2000, Nidek 322 6 >-7.0 43.4% 73.3% 3% a
FDA, 1999, Summit 6 >-7.0 61.3% b 83.9% b 3.3%
Sanders, 2003, 
VISX S2
559 6 -9.1 (range: -8.0 to –12.0) 53% 76% 2%
Reviglio, 2000, 
Lasersight 200
100 6 range: -6.0 to -25.0 68.4% 85.1% 0%
FDA, 1998, Kremer 248 6 >-7.0 42.3% 62.5% 6.4%
SE, spherical equivalent; BSCVA, best spectacle corrected visual acuity; NR, not reported
a result at 12 months; b including also low myopia group (<7.0 D)
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permanently for myopia than to steepen it centrally for hyperopia.184 LASIK has 
been shown to be very effective and predictable in lower hyperopia up to 3 
D.201 There is no general agreement about the upper limit of dioptric correction. 
However, above approximately 4 to 5 D, efficacy, predictability and stability 
falls off markedly.202-205 Significant regression has been reported in LASIK for 
hyperopia, being strongly associated with the magnitude of hyperopia.205 Goker 
et al.206 reported 42% of enhancements to achieve the reported results in Table 
6. Safety is another concern in LASIK for moderate hyperopia. Arbelaez and 
Knorz207 found considerable loss in BSCVA in a group with higher hyperopia. 
They advise against LASIK in these eyes.207 Decentration seems to be a particular 
risk with hyperopic LASIK. This problem is compounded by the typically small 
size of hyperopic eyes, the prerequisite for a large ablation zone and problems 
with fixation in possibly amblyopic eyes. Many hyperopic patients are not good 
candidates for hyperopic LASIK because of their morphologically different 
eyes.
Clear lens extraction/refractive lens exchange 
Posterior toric IOL implantation after clear lens extraction (CLE), also called 
refractive lens exchange, is another option to correct both ametropia as well 
as astigmatism.208 Clear lens extraction, however, will result in permanent and 
complete loss of accommodation in relatively young patients. Furthermore, 
CLE carries a risk for retinal detachment.209,210 Rotational stability might be a 
problem with toric IOLs in the capsular bag.208 With a toric plate haptic design 
lens rotational stability appears to be better, although axis misalignment of 10 
or more degrees was reported in 28% of cases.211 Probably the best candidates 
Table 6. Recently published studies on the treatment of moderate hyperopia or hyperopic 
astigmatism with LASIK
Author, year, Laser n Follow-up
(months)
Preoperative mean SE or S & 
C (D)
% ± 0.50 D % ± 1.00 D Loss BSCVA 
≥ 2 lines
Goker, 1998, Keracor 54 6 +6.5 (range: 4.25 to 8.0) 42.6% 81.5% 5.5%
Lian, 2002, Technolas 
117C
59 6 +3.12 (range: 1.0 to 5.75) 55.6% 81.5% 1.9%
Salz, 2002, 
LADARVision
143 6 S +3.65 (range: 1.0 to 6.0) & 
C-1.62
60.5% 88.7% 5.8%
Arbelaez, 1999, 
Keracor 117C
14 12 range: +3.10 to +5.00 NR 58% 14%
13 12 range: +5.10 to +9.50 NR 17% 15%
SE, spherical equivalent; BSCVA, best spectacle corrected visual acuity; NR, not reported
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for CLE are patients with high hyperopia, shallow anterior chambers and convex 
irises, who are neither good candidates for phakic IOL implantation nor for 
excimer laser correction.
1.7.1 Phakic intraocular lenses 
Implantation of phakic IOLs to correct high myopia started already in the 1950s, 
developed by Strampelli and Barraquer.212 The implantation of a phakic IOL 
might increase the risk of a retinal detachment, although this risk appears to be 
lower than after lens extraction.209,213 The expected incidence of a retinal detach-
ment in phakic myopic eyes (>-10 D) without previous surgery is estimated to be 
0.68% per year.214 It is not clear whether prophylaxis treatment with argon laser 
influences the risk of a retinal detachment.210
1.7.1.1 Angle supported anterior chamber intraocular lenses
Angle supported anterior chamber IOLs are dependent on the size of the ante-
rior chamber. A ‘white to white’ (horizontal corneal diameter) measurement is 
performed to determine the necessary size of this phakic IOL. Implantation of 
the haptics in the correct position at the angle and implantation of the correct 
lens size are essential to prevent complications.213 Pupil ovalisation is a frequent 
encountered complication related to an oversized lens.212,215 A small phakic IOL 
can rotate and decentrate, and produces complains of halo and glare. First gen-
eration angle-supported phakic IOLs were associated with high endothelial cell 
loss. This appears to be less in newer designs, which can be implanted through 
a small incision, although long-term results are not yet available. Despite the 
newer designs, pupil ovalisation remains a problem.212,215 To my best knowledge 
no studies have been published on a toric version of angle-supported IOLs thus 
far. A potential problem with toric angle-supported lenses is rotational stabil-
ity.216 
1.7.1.2 Posterior chamber phakic intraocular lenses
Two types of posterior chamber phakic intraocular lenses (PCPIOL) are com-
mercially available: the silicone phakic refractive lens (PRL)217 and the collamer 
implantable contact lens (ICL).218 Predictability and efficacy of the PCPIOLs have 
been shown to be very reasonable and superior to LASIK for myopia between –8 
and –12 D.199 Percentage of eyes within 1.00 and 0.50 D of attempted correction 
for high myopia as reported by two different studies is presented in Table 7.217,219 
Risks reported in PCPIOLs are cataractogenesis and pigment dispersion.220-224 
In hyperopic eyes there might be a significant higher risk of developing a pupil 
block glaucoma.225 However, the advantage of a PCPIOL in a hyperopic eye 
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might be a greater distance between the lens and the endothelial layer, com-
pared to an anterior chamber IOL. Although a toric version of the myopic ICL 
is available, published studies with the exception of one case report, describe 
only refractive results for the correction of moderate to high ametropia without 
astigmatism.224-227 Gimbel et al.228 report satisfactory results of the correction of 
high myopia and astigmatism in one eye with a toric ICL. A prospective study 
has started recently with the purpose to evaluate the safety and efficacy for the 
treatment of myopic astigmatism with a toric PCPIOL.229
1.7.2 The Artisan lens
In 1978 Professor Worst designed the iris-claw lens for the correction of apha-
kia. In 1980 a modification of this iris-claw lens was used in a phakic eye as 
an occlusive lens for treating acquired diplopia.230 Also years after implantation 
the cornea and crystalline lens of this eye remained clear.230 Worst and Fechner 
modified the existing iris-claw lens into a negative biconcave lens for the phakic 
eye, which was implanted for the first time in 1986 to correct high myopia.231,232 
In 1991 the optical part of the lens was altered into a convex-concave model 
with a larger optical zone of 5.0 mm to reduce photopic phenomena.233,234 In 
1998 the name of the lens was changed to the Artisan lens. Toric Artisan lenses 
for the correction of both ametropia and astigmatism are commercially available 
since 2000. The biomaterial of the toric Artisan lens consists of Perspex CQ-UV 
polymethylmethacrylate with ultraviolet filtration. Its overall diameter is 8.5 mm 
and the optical zone diameter is 5.0 mm. The toric Artisan lens is available in 
half diopter increments with a cylindrical power up to 7.5 D and a spherical 
power from –3.0 to –23.5 D for myopia and from +2.0 to +12.0 D for hyperopia. 
Two models of toric phakic Artisan lenses are available to allow the preferred 
approach and optimal implantation on the correct axis. In Model A, the axis 
runs through the claws at 0º and in Model B, at 90º. The necessary power of the 
lens can be calculated with the Van der Heijde formula.235 Required data for lens 
calculation are: subjective refraction, anterior chamber depth and keratometry. 
To achieve precise placement of the IOL in the correct cylinder axis, the encla-
vation sites should be marked prior to surgery. Exact enclavation of the lens is 
Table 7. Predictability of high myopic correction with PRL or ICL
PCPIOL type Preoperative myopia (D) % ± 0.50 D % ± 1.00 D
PRL ≥ -10.50 44% 79%
ICL > -10.00 56.9% 80%
PCPIOL, posterior chamber phakic intraocular lens; PRL, phakic refractive lens; ICL implantable 
collamer/contact lens
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paramount. Especially in higher degrees of astigmatism, minimal misalignment 
greatly reduces the corrective value of the lens. Approximately one third of the 
cylindrical correction is lost if the lens is rotated 10 degrees off axis, as illustrated 
in Figure 1. To be correct, marking must be done under binocular circumstances 
in a sitting position, without immobilization of the eye by anaesthetics. Different 
techniques could be used for marking the enclavation site: 1. Surface markers, 
which mark at the limbus or cornea, guided by a gravitation marker or by the 
reflex of the Javal keratometer, 2. Marking of the iris can be done by either 
YAG or Argon Laser,236 3. Natural reference points in the iris using a digital 
photograph or drawing could also guide to the axis of enclavation. 
It is not possible to implant the Artisan toric lens through a smaller than 5.2 
- 5.3 mm incision. Any induced astigmatism by the incision might influence 
accuracy of postoperative refraction. The clinical outcome of the toric Artisan 
lens for the correction of moderate to high myopia combined with astigmatism 
and for the correction of moderate to high hyperopia with astigmatism was 
investigated and results are described in chapter 7 and 8.
1.8 AIMS OF THE THESIS
Corneal transplantation can be a successful procedure. Despite a certain im-
mune privilege of the cornea, technological refinements in surgical procedures, 
organ culture storage of donor corneas and the use of corticosteroids after 
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Figure 1. Effect of lens rotation on postoperative cylinder correction.
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transplantation, allograft rejection is still a leading cause of graft failure. The risk 
of rejection is increased in patients having deep stromal corneal vascularisation 
or a history of previous graft rejection (so called high-risk patients). Disparity 
between donor and recipient at the HLA locus is the predominant basis for graft 
rejection in other organ transplantations. It might be expected that corneal graft 
survival in high-risk cases would increase after prospective HLA matching of 
donor and recipient. Nevertheless, allocation of donor corneas based on HLA 
matching has been a controversial topic for several years. Nowadays it is pos-
sible to determine HLA matches more accurate and precise. The objective of 
the studies described in chapter 2 and 3 was to assess the effect of HLA match-
ing on immune mediated graft rejection and failure using modern HLA typing 
techniques. Results of these studies might be of help in setting up guidelines for 
allocation of donor corneas. Besides by HLA matching, the outcome of corneal 
transplantations could be improved by preventing suture related problems and 
reducing astigmatism. The standard suture material used for corneal transplanta-
tions is Nylon (10.0 or 11.0). This material biodegrades and may loosen over 
time. This feature can be associated with high astigmatism, wound dehiscence, 
infiltrates, microbial keratitis and rejection. Mersilene is a non-absorbable su-
ture material. The study described in chapter 4 compares the use of Mersilene 
sutures with Nylon sutures, with regard to astigmatism control and suture related 
complications. 
Long-term graft survival is always worse compared to short-term graft survival. 
Restricting the necessarily graft survival time by delaying transplantation might 
be beneficial to a patient. If the primary indication for transplantation is high 
astigmatism in a contact lens intolerant patient, other treatment modalities than 
PKP could be considered, with the purpose of reducing astigmatism. Recently, 
a toric version of the Artisan iris-claw lens has become commercially available. 
In chapter 5 and 6 we report on the results of correcting high astigmatism due 
to corneal pathology (marginal degeneration and keratoconus) with the toric 
Artisan lens.
Refractive surgery is gaining widespread acceptance. Many of the refractive 
surgery procedures permanently and irreversibly alter corneal shape. LASIK and 
PRK have shown their limitations for high refractive errors in order to prevent iat-
rogenic corneal pathology requiring a subsequent transplantation. In the search 
for a reliable refractive solution for high ametropia, phakic IOLs have become 
increasingly popular. The toric Artisan lens is designed to achieve full correction 
of both high ametropia and astigmatism in one procedure. The purpose of the 
studies described in chapter 7 and 8 was to assess safety, efficacy and predict-
ability of toric Artisan lenses in the correction of high ametropia combined 
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with astigmatism with an emphasis on IOL axis misalignment and incisionally 
induced astigmatism in chapter 7. 
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ABSTRACT
Aim: To establish if coincidental HLA-A, HLA-B, and HLA-DR tissue matching is associated with a 
reduced likelihood of corneal graft rejection. 
Methods: Organ culture preserved random donor corneas were used for penetrating keratoplasty 
(PKP). Corneal tissue from all graft recipients and donors or blood samples from recipients after 
repeated transplantation were obtained in order to perform retrospective molecular HLA typing. A 
group of 21 recipients with a rejection episode (cases) after corneal transplantation was compared 
with a control group of non-rejectors (n = 43). 31 graft recipients were considered as high risk 
patients. The influence of HLA-A, HLA-B, and HLA-DR matching on rejection free graft survival time 
was analysed with Kaplan-Meier statistics and Cox regression. 
Results: A prolonged rejection free survival time was observed in graft recipients with one or two 
HLA-A matches (log rank test, p = 0.034). This effect was also observed in high risk graft recipients 
with one or two HLA-DR matches (log rank test, p = 0.030). 
Conclusions: Coincidental HLA-A and HLA-DR matches were observed and associated with a 
prolonged rejection free survival time in the total group and in the high risk group, respectively. 
These results support the beneficial effect of prospective HLA-A and HLA-DR typing upon corneal 
graft survival.
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INTRODUCTION
Corneal grafting is often a successful procedure.1 In contrast with transplantation 
of other solid organs, no systemic immunosuppressive agents are needed to 
prevent allograft rejection.2 In avascular corneas, graft survival results of 85-
95% were reported after 1 year of follow up.1,3 Nevertheless, immunological 
allograft rejection is reported to be the leading cause of corneal graft failure.3,4 
The incidence of immune mediated graft rejection and failure is increased in 
high risk patients, having corneal vascularisation or a history of graft rejection.5-8 
It might be expected that corneal graft survival in high risk cases would increase 
after prospective human leukocyte antigen (HLA) class I matching of donor and 
recipient,5,9-12 in accordance with HLA matching for increased graft survival of 
other solid organs.13,14 However, the role of HLA matching in reducing corneal 
graft failure could not be confirmed by all studies.3,15-18 A beneficial role of 
HLA-A and HLA-B matching can be explained by the finding that mismatched 
HLA class I antigens are immunogenic.19,20 HLA class I antigens are targets for 
rejection by CD8+ cytotoxic T lymphocytes.21 
Organ culture preservation of donor corneas was shown to contribute to a 
reduction in the amount of HLA class II bearing Langerhans cells,22-24 resulting 
in reduced antigenicity of the corneal graft.19,25 This may lead to a decreased 
incidence of rejection. HLA-DR (class II) matching in cornea transplantation 
showed beneficial effects26,27 and an adverse effect in another study.28 This con-
troversy may be explained partly by inadequacy of serological HLA-DR typing 
techniques.29
Although HLA matched corneal grafts were rarely used in patients at high 
risk of rejection at the University Medical Centre of Utrecht, Netherlands, a 
relatively high success rate of corneal transplants was observed over the last 
5 years.30 With the recent availability of DNA based typing techniques29,31,32 it 
is possible to perform HLA-A, HLA-B, and HLA-DR typing of recipients and 
donors retrospectively and accurately.33-36 The aim of this retrospective study was 
to examine whether differences exist with regard to molecular HLA-A, HLA-B, 
and HLA-DR matching and to rule out coincidental HLA matching between 
corneal graft recipients, with versus without immune mediated graft rejection. 
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PATIENTS AND METHODS
Patients
Between February 1995 and December 1997, 248 consecutive patients under-
went PKP with random corneal grafts at the University Medical Centre of Utrecht, 
Netherlands. Patient charts were revised for age, sex, use of systemic immune 
suppression, a history of glaucoma or herpes simplex keratitis (HSK), tear film 
insufficiency, number of previous grafts, indication for transplantation, degree 
of stromal vascularisation of the recipient cornea at the time of PKP, additional 
surgical procedures during PKP, any rejection episodes, and the final outcome 
of the corneal graft. In the category of patients with a history of glaucoma we 
included patients with ocular hypertension or primary open angle glaucoma 
(POAG) based on use of antiglaucoma medication, neuropathy with an excava-
tion of the optical nerve, defects in the visual field, a diagnosis of POAG or 
an intra-ocular pressure above 23 mm Hg. Furthermore, information about the 
donors and donor corneas was collected; age, sex, graft size, and storage time 
of organ culture preservation. High risk criteria for corneal allograft failure were 
defined according to the presence of two or more quadrants of deep stromal 
vascularisation and/or previous immunologically mediated allograft failure(s).8 
Out of the group of 248 patients a case (n = 21) and control group (n = 43) 
were selected. Cases were all transplant recipients undergoing a rejection epi-
sode, according to strict criteria described below (n = 23). Patients for whom it 
was not possible to differentiate between irreversible graft rejection and graft 
failure due to other causes were not included. Patients of whom no corneal 
tissue was available for DNA isolation (n = 2, one patient grafted for Fuchs’ 
dystrophy and the other for HSK) were excluded. The control group was formed 
out of a group of patients with at least one year of follow-up after PKP and no 
episodes of graft rejection. This group was matched for age and sex. Patients with 
graft failure because of other causes than rejection were not excluded as long as 
their cornea could be evaluated for rejection during the study period. Eight out 
of 43 grafts failed irreversibly due to other causes than graft rejection, two grafts 
failed as a consequence of intractable glaucoma and six because of presumed 
slow endothelial decompensation.
In the group of cases, 12 out of 21 (57%) could be considered as high risk and 
in the group of controls 19 out of 43 (44%). 
Patient, donor and graft characteristics of cases and controls are presented in 
Table 1. No significant differences were found between the two groups with 
respect to these characteristics. The indications for PKP are shown in Table 2.
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Diagnosis of rejection
The time between PKP and the first rejection episode, not necessarily ending in 
graft failure was used to analyse graft outcome. The diagnosis of immune medi-
ated allograft rejection was based on generally accepted criteria.37 All corneal 
grafts had to become clear after surgery and a diagnosis of rejection was not 
made for at least ten days after surgery. Rejection episodes were not diagnosed 
during a period of elevated ocular pressure. The presence of a ‘Khodadoust line’ 
was considered a pathognomonic sign of graft rejection. In the absence of a 
Khodadoust rejection line, graft rejection was diagnosed by the presence of cells 
in the anterior chamber, in combination with an increase in (partial) corneal 
thickness and/or keratic precipitates limited to the graft. For patients with a his-
tory of HSK, graft rejection, and recurrence of herpes simplex virus (HSV) infec-
tion needed to be differentiated. If no Khodadoust line was observed, additional 
tests were needed to diagnose HSV infection. Aqueous humour was obtained by 
paracentesis of the anterior chamber to determine intra-ocular antibody produc-
tion against HSV, expressed as the Goldmann-Witmer coefficient for HSV. Also, 
PCR analysis of HSV DNA was performed38 to exclude an active ocular herpes 
Table 1. Clinical characteristics of recipients and donors from the case and control group
Cases Controls
Number 21 43
Age (years): mean (range) 57.2 (29-79) 51.6 (11-83)
Male:female ratio 1.0:1.1 1.0:1.0
Use of systemic immune suppression 1 1
History of ocular hypertension or POAG 6 (28.6%) 9 (20.9%)
History of HSK 7 (33.3%) 14 (32.6%)
Tear film insufficiency 2 (9,5%) 3 (7.0%)
Number of previous grafts: 0 15 (71.4%) 35(81.4%)
1 4 (19.0%) 8 (18.6%)
>1 2 (9.5%) 0 (0%)
Vascularisation of recipient cornea 11 (52.4%) 15(34.9%)
Additional procedures: Cataract extraction 3 (14.3%) 9 (20.9%)
Synechiolysis 3 (14.3%) 4 (9.3%)
Iris reconstruction 1 (4.8%) 2 (4.7%)
Donor age (years): mean (range) 69.0 (20-89) 67.8 (16-86)
Donor sex; male:female ratio 1.7:1.0 1.9:1.0
Time in culture medium (days): mean (range) 15.8 (7-23) 15.9 (10-27)
Graft size (mm): mean (range) 7.5 (6.5-8.0) 7.5 (5.5-8.0)
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simplex infection. Herpes infected cases were excluded from analysis in this 
study. 
Methods
Donor procurement and medical procedures did not change during the study 
period. All donor corneas were obtained from Bio Implant Service and the 
Dutch Eye Bank, Amsterdam, Netherlands. The donor corneas were organ 
culture preserved as described by Pels et al.39 All donor corneas were stored 
in organ culture of Eagles minimum essential medium for at least seven days 
with a maximum of 27 days. PKP procedures were performed by one of three 
ophthalmic surgeons using similar surgical techniques. All patients were treated 
with a combination of prednisolone eye ointment (0.5%, at bedtime) and local 
dexamethasone/ gentamicin eye drops (0.1%, six times daily) after surgery, for 
4 weeks. At least 1-1.5 years after PKP, dexamethasone eye drops were applied 
and gradually tapered off. If PKP was combined with a cataract extraction or 
removal of an intra ocular lens, additional eye drops were given, containing 
a non steroid anti inflammatory drug (0.1%, four times daily) during the first 3 
months after surgery. Rejection reactions were treated with hourly application 
of prednisolone acetate 1% eye drops and three periocular injections with 0.1% 
dexamethasone, given every other day. Graft rejection has led to irreversible 
graft failure in nine out of 21 cases. 
DNA typing for HLA
Corneal tissue was used for retrospective DNA HLA typing. For this purpose, 
corneal tissue of the recipients and corneal rims of donor corneas were col-
lected at the time of surgery and stored frozen (at -80°C). After repeated trans-
plantation blood samples containing peripheral blood mononuclear cells were 
taken from recipients to obtain DNA. Corneal tissues and blood-derived cell 
Table 2. Indications for penetrating keratoplasty (PKP) of cases and controls
Indication for PKP Cases Controls
HSK 7 12
Allograft failure 6  8
Keratoconus - 11
Pseudophakic BKP 2  5
Corneal ulcers 4  3
Trauma 2  2
Fuchs’ dystrophy -  2
HSK, herpes simplex keratitis; BKP, bullous keratopathy
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suspensions were subjected to DNA extraction using the Qiagen DNA extrac-
tion kit (Boehringer, Mannheim, Germany) for blood and tissues, according to 
the manufacturer’s instructions. DNA solutions were stored at -80°C until further 
amplification. The diagnosis of rejection at the end of the follow-up was made 
before the HLA typing was known. HLA typing was done without knowledge of 
graft outcome. This molecular typing of HLA-A, HLA-B and HLA-DRB1 (all low 
resolution) was performed according to a reverse hybridisation line probe assay 
as described by the manufacturer of InnoLiPa (Innogenetics, Gent, Belgium).40
Typing data were available in all 64 donor/recipient pairs for HLA-DR. For 
HLA-A and HLA-B one and five pairs were not available respectively, owing 
to shortness of donor DNA (n = 2), technical problems with PCR (n = 1) and 
problems with analysing the Lipa test results for HLA-B (n = 3). Analysis was 
performed both on the broad HLA typing level (A1, A2, A3, A9, A10, A11, A19, 
A28, B5, B7, B8, B12, B13, B14, B15, B16, B17, B18, B21, B22, B27, B35, B37, 
B40, B41, B42, B53, B70, DR1, DR2, DR3, DR4, DR5, DR6, DR7, DR8, DR9, 
DR10) and split typing level (splits from A9, A10, A19, A28, B5, B12, B16, B17, 
B21, B22, B70, DR2, DR3, DR5, DR6). 
Analysis and statistics
Comparability of patient, donor and graft covariates between cases and controls 
were analysed using the χ2-test for categorical variables and the independent T 
test for continuous covariates. To analyse rejection free graft survival, cases and 
controls were subdivided into a group with and a group without matched HLA 
subtypes. The group with matches consisted of cases and controls with one or 
two matches of HLA-A, HLA-B or HLA-DR. Unadjusted survival probabilities 
for the total group as well as the high and low risk group were estimated using 
Kaplan-Meyer statistics and differences were assessed using the log rank test.41 
All tests were two sided and a p value of less than 0.05 was taken as statistically 
significant.
To assess the clinical relevance of matching we used Cox regression analysis 
estimating the odds ratios (OR) and 95% confidence intervals for the association 
between HLA matching per HLA locus and duration of rejection free graft sur-
vival, adjusting for confounding variables. Covariates were chosen for inclusion 
in the model if they were mildly correlated (p < 0.20) with rejection according 
to univariate analysis. Using this selection criterion, only vascularisation of the 
recipient cornea was included in the model (p = 0.12).
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RESULTS
The median follow up period of the control group (n = 43) was 2.6 years (range 
1 - 4 years). The median time until rejection of the case group (n = 21) was 9 
months (range 12 days to 1 year and 11 months). 
The maximum amount of matches based on split typing for a patient in this 
study was three, which was detected in six controls and one case. The distribu-
tion of HLA-A, HLA-B and HLA-DR split matches in cases and controls is shown 
in Table 3. Recalculation of split HLA DNA typing results into broad typing 
results did not yield significant differences between cases and controls with 
regard to HLA-A and HLA-B matching. However, an increased amount of broad 
HLA-DR matches was found compared to the amount of split HLA-DR matches 
in four cases. 
Corneal graft recipient-donor pairs with HLA-A matches had a longer rejec-
tion free graft survival compared with corneal grafts without HLA-A matches (log 
rank test, p = 0.034, Fig 1). We observed a trend towards a prolonged rejection 
free graft survival with increasing numbers of HLA-A matches. No difference 
was observed in rejection free graft survival time between cases and controls 
with respect to HLA-B matches (Fig 2) and HLA-DR matches (Fig 3). 
Analysing rejection free graft survival for the high risk (n = 31) and low risk 
(n = 33) group separately, a stronger association between longer rejection free 
graft survival and HLA-A matching in the low risk group was found (log rank 
test, p = 0.013). Graft survival was not significantly longer with respect to HLA-B 
matches in the high or low risk group (data not shown). Analysis of the HLA-A 
Table 3. Degree of HLA-A, HLA-B and HLA-DR matching of the case and control group
No. of split matches Cases Controls
0 16 (76%) 21 (50%)
HLA-A 1  4 (19%) 15 (36%)
2  1 (5%)  6 (14%)
0 14 (74%) 30 (75%)
HLA-B 1  5 (26%)  9 (22,5%)
2  0  1 (2,5%)
0 14 (67%) 25 (58%)
HLA-DR 1  6 (29%) 17 (40%)
2  1 (5%)  1 (2%)
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Figure 1. Kaplan Meyer curves indicating rejection free survival of corneal graft recipients 
with one or two matches at the HLA-A locus is significantly better than those with 0 HLA-
A matches (log rank test, p = 0.030, n = 63).
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Figure 2. Kaplan-Meyer curves indicating the presence of HLA-B matches did not improve 
rejection free survival of corneal graft recipients (log rank test, p = 0.50, n = 59).
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Figure 3. Kaplan-Meyer curves indicating the presence of HLA-DR matches did not 
improve rejection free survival of corneal graft recipients (log rank test, p = 0.92, n = 63).
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Figure 4. Kaplan-Meyer curves indicating HLA-DR matching in high-risk recipients showed 
a beneficial effect on the rejection free graft survival (log rank test, p = 0.030, n = 31).
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and HLA-B matches together showed no effect in the total group or in the high 
risk group. However, we observed a beneficial effect of matching for HLA-DR in 
the high risk group (log rank test, p = 0.030, Fig 4). 
According to Cox regression analysis, after adjustment for vascularisation of 
the recipient cornea, HLA-A matched transplants (one or two HLA-A matches) 
were almost three times less likely to reject than HLA-A unmatched transplants 
(Table 4). HLA-DR matched transplants were slightly, but not significantly, less 
likely to reject (Table 4). 
DISCUSSION
The results showed that the presence of HLA-A matches was associated with 
prolonged rejection free graft survival. When considering patients at high risk 
for rejection, a beneficial effect of HLA-DR matches was shown. These HLA 
matches were found retrospectively in corneal graft recipients who received 
random donor corneas at the time of PKP. 
Cases with and controls without an immune mediated graft rejection were 
analysed together according to their rejection free graft survival time. The first 
rejection episode, not necessarily leading to graft failure, was used as the end-
point of analysis. From an immunological point of view it is more appropriate 
to use rejection free graft survival time rather than time to immunological graft 
failure. Whether a rejection episode will lead to graft failure is dependent on 
treatment protocols of a rejection reaction used in different transplantation 
centres. Furthermore, each rejection episode accelerates the postoperative loss 
of endothelial cells, resulting in earlier graft failure.42,43 
A major advantage of HLA DNA typing, as used in this study, is that this method 
is less prone to errors than serological typing techniques.31,32 Discrepancy rates 
of 10 - 25% have been reported for serological HLA-DR typing in kidney trans-
Table 4. Odds ratios (OR) of corneal graft rejection
ORa (95% Confidence Interval)
HLA-A unmatched transplants
HLA-A matched transplants b
0.34 (0.13 – 0.95)
HLA-B unmatched transplants
HLA-B matched transplants c
1.07 (0.38 – 2.97)
HLA-DR unmatched transplants
HLA-DR matched transplants d
0.69 (0.27 – 1.70)
a Adjusted for vascularisation of the recipient cornea, b One or two matches for HLA-A, c One or 
two matches for HLA-B, d One or two matches for HLA-DR
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plantation.29 DNA can be derived from any organic tissue, including corneal 
tissue, which is easily obtained at PKP44 and nearly always available in contrast 
with blood samples necessary for serological typing. 
The diagnosis of an immune mediated graft rejection is not always clearcut. 
Rejection and recurrence of HSK can be impossible to distinguish clinically and 
may coexist.45 We excluded patients for whom it was not possible to differenti-
ate between graft rejection and HSK. 
Patient compliance is of great influence on graft survival.6 In our study topical 
steroids were given for at least one year in all patients. All patients with graft 
rejection within 1 year were still using topical steroids. These data, however, 
are based on patient records and a contribution of patient compliance to graft 
rejection could not be fully excluded.
HLA-A and HLA-B antigens have been identified on corneal epithelium, 
stromal cells, and corneal endothelial cells.19,46,47 The HLA class I antigens are 
targets for CD8+ cytotoxic T cells in the process of graft rejection.21 Theoreti-
cally, matching for HLA-A and HLA-B therefore would reduce the amount of 
target antigens, which could lead to a decreased incidence of rejection. An 
accumulating number of authors suggested that HLA-A and HLA-B matching 
was associated with improved outcome of corneal graft survival in high risk 
recipients.5,9-12,15,33,48,49 These data on HLA-A matching are in line with the results 
from our study. However, other studies, including the large Collaborative Cor-
neal Transplantation Study, failed to demonstrate a correlation of HLA matches 
and graft survival.16-18,50 A beneficial HLA-A matching effect was observed in all 
risk categories with a stronger association in low risk cases by Boisjoly et al.,11 
which is in accordance with our findings. In this study, HLA-B matches showed 
no significant effects on graft rejection. This might be due to the overall low 
number of matches observed in this study at the polymorphic HLA-B locus. In 
previous studies, matching of HLA-B showed a beneficial effect on corneal graft 
survival5,10,12 and an adverse effect in others.18,20 
Despite the fact that HLA-DR is considered to be important in renal trans-
plantation,29 the role of HLA-DR matching in corneal transplantation remains 
controversial.49,51 Significant beneficial effects of HLA-DR matching in high risk 
recipients were reported using RFLP typing techniques,26 but a historical control 
group was used. Japanese studies33,34,44 using DNA typing techniques reported 
a strong beneficial effect of HLA-DP matching and no effect of matching for 
HLA-DR. This may be explained by the overall low number of HLA-DR matches 
reported by this group, using donors and recipients from different ethnic back-
grounds. In our study, both donors and recipients originated mostly from the 
white population, and therefore from the same gene pool. This may add to the 
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explanation of the high number of coincidental HLA-A and HLA-DR matches 
we observed. In some studies, a beneficial influence of HLA-DR matching could 
not be found in low or high risk recipients,16,17,52 whereas in other studies an 
adverse effect was reported.28,51 However, in these studies serological typing 
techniques were used, which in general yield accurate broad but not split typing 
results. In our study HLA DNA typing included analysis of HLA split antigens. A 
beneficial effect of HLA-DR matching in high risk recipients was shown. After 
conversion of HLA-DR split to broad antigens (data not shown), a significant 
effect of matching could no longer be found, which is in line with the previously 
mentioned studies.
Expression of HLA-DR antigens carried on Langerhans cells has been dem-
onstrated within normal corneal epithelium and stromal layers.19,47 Migration 
and accumulation of Langerhans cells in the central part of the cornea, which 
is normally devoid of Langerhans cells19,24 can be established by vascularisation 
and inflammation.53 As a consequence of an increased number of Langerhans 
cells in the centre of the donor cornea, a rejection reaction may be provoked.54 
The beneficial effect of HLA-DR matching for high risk recipients as reported 
in our study might be explained by a higher number of Langerhans cells in the 
central area of the cornea after transplantation in this high risk group.
A drawback of this study is the overall low number of included patients. Owing 
to the random distribution of corneal grafts a relatively small amount of patients 
with more than one match at HLA-A, HLA-B or HLA-DR loci was included. As a 
consequence it was not possible to evaluate combinations of HLA-A and HLA-B 
matches or to evaluate the effect of HLA-DR in the absence of any HLA-A or 
HLA-B match. 
Although the case and control group are comparable with respect to the 
characteristics mentioned in Table 1, the indication for transplantation were not 
completely comparable, with Fuchs’ dystrophy (n = 2) and keratoconus (n = 11) 
being present only in the control group. One of the two excluded cases (no donor 
corneal tissue available) was transplanted for Fuchs’ dystrophy; if this patient had 
been included, the only remaining difference would have been the indication of 
keratoconus. Analysis of rejection free graft survival without considering these 
11 patients showed the same results for the high risk group (a longer rejection 
free graft survival for HLA-DR matched transplants). Furthermore, rejection free 
graft survival was longer for HLA-A matched transplants in the total group (n = 
52), despite the loss of power (p = 0.047).
We included controls with at least 1 year of follow-up. However, rejections 
are still observed after 1 year. Therefore, further studies with a longer follow up 
time will be needed to show a beneficial long-term outcome with matching. 
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Organ culture preservation of donor corneas, as used for all donor corneas in 
this study, allows time to allocate corneas based on HLA matching. Prospective 
DNA HLA typing and transportation of donor corneas over long distances to the 
most suitable recipient could give logistical problems if short term preservation 
techniques, such as McCarey-Kaufman medium, are used. The cost-benefit ratio 
of providing matched corneal grafts should be investigated in more detail. Espe-
cially in more heterogeneous populations where less coincidental HLA matches 
are expected, allocation of matched donor corneas could be more difficult but 
also more effective in preventing corneal graft rejection.
In conclusion, molecular typing of HLA-A, HLA-B and HLA-DRB1 is an 
accurate method and offers the possibility to perform HLA typing at any time 
postoperatively, using corneal derived DNA. Although all corneal graft recipients 
received random donor corneas, retrospectively a significantly higher number of 
HLA-A matches was found, in favour of recipients with longer rejection free graft 
survival. Furthermore, a beneficial effect of matching for HLA-DR was shown for 
high risk recipients. These results add to the evidence that prospective molecular 
HLA-A and HLA-DR typing has a beneficial effect upon graft survival.
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ABSTRACT
Purpose: To evaluate long-term follow-up of high-risk corneal transplants allocated after matching 
for broad HLA-A and HLA-B antigens and to establish whether matching for HLA-A and -B antigen 
“splits” would result in a reduced risk of immunologic graft failure.
Methods: A total of 303 high-risk corneal transplants was included. Class I antigen-matched donor 
corneas were obtained using broad HLA-A and -B antigen data and accepting 0 or 1 mismatch at 
each locus. Analysis of HLA antigens was performed also on the split typing level. The influence on 
immunologic graft failure for an increasing number of matched class I antigens based on split typing 
was analyzed with Kaplan–Meier statistics and Cox regression. Graft survival and indication for 
transplantation were investigated. 
Results: Rejection was the cause of 34% of all graft failures. A significantly higher immune failure 
free graft survival was found in a group with 0 or 1 HLA-A and -B mismatch based on split typing (log 
rank test, p = 0.002). A beneficial effect of matching for split antigens was shown with multivariate 
analysis (odds ratio, 0.41).
Conclusions: One third of graft failures in our high-risk population was caused by irreversible graft 
rejection. Allocation of donor corneas based on a 0 or 1 split antigen mismatch at both HLA-A and 
-B loci could contribute to a higher immune failure free graft survival and could result in a higher 
overall graft survival. 
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INTRODUCTION
Allograft rejection is reported to be the leading cause of corneal transplant fail-
ure.1,2 Patients having corneal vascularization are considered to be high risk of 
allograft rejection and failure as are individuals with a history of graft failure.3-6 
Current research has identified HLA-A and -B antigens on corneal epithelium, 
stromal cells and corneal endothelial cells.7-9 These HLA class I antigens have 
been shown to be targets for cytotoxic T cells in the process of graft rejection.10 
It might be expected that, as with other solid organ transplantation, HLA-A and 
-B matching would reduce the amount of target antigens, which could then 
lead to a decreased incidence of graft rejection. Although many studies have 
reported a beneficial effect of HLA-A and -B matching for corneal graft survival 
in high risk patients, no consensus about HLA class I matching has yet been 
reached.11 Theoretically, a decreasing amount of mismatched class I antigens 
would decrease the risk of allograft failure. However, allocating donor corneas 
based on a 0 class I mismatch will substantially increase waiting time and the 
cost of corneal transplantations. Consequently, it is essential to know whether 
an increasing amount of matches significantly reduces the incidence of graft 
failure. With the currently available techniques, it is possible to perform HLA-A 
and -B typing on “split” level (subtypes of broad specification). Allocation of 
donor corneas based on the so-called “split-typing” level have to be shown to 
be beneficial, as more logistical efforts should be made to use this type of al-
location. The current practice at the Eye Hospital Rotterdam is to use HLA-A and 
-B matched donor corneas based on a broad typing level for high-risk patients. 
This retrospective study was performed to evaluate the long-term graft survival 
of high-risk HLA-A and -B matched corneal grafts and to analyze whether al-
location on the split-typing level contributes in a decreased risk of immunologic 
graft failure. 
PATIENTS AND METHODS
Patients
Between January 1982 and January 1996, 2471 penetrating keratoplasties 
(PKPs) were performed at the Eye Hospital Rotterdam. HLA-A and -B matched 
donor corneas were obtained for patients considered to be at high-risk (n = 323, 
13.1%) due to either previous rejected transplants or deep stromal vasculariza-
tion in two or more corneal quadrants. Clinical records of all high-risk patients 
who received a matched corneal transplant were reviewed for age, gender, a 
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history of glaucoma or herpes simplex keratitis (HSK), number of previous grafts 
and previous matched grafts, current and primary indication for transplantation, 
and the final outcome of the corneal graft. All corneal grafts had to become clear 
after surgery, and a diagnosis of immunologic graft failure could not be made 
within a 14-day period after transplantation. The diagnosis of immunologic graft 
failure was made by one of the cornea surgeons of the Eye Hospital Rotterdam. 
Grafts were declared as immunologically failed if the following signs did not 
clear under treatment within 2 months: keratic precipitates limited to the graft 
and a Khodadoust rejection line and/or increase in (partial) corneal thickness 
due to edema in combination with a slight to moderate cellular response in the 
anterior chamber. Information about graft size and donor age was collected. We 
based our classification of 14 possible indications for corneal transplantation on 
the classification of the Kok-Van Alphen corneal study group. Possible indica-
tions were anterior and stromal dystrophies, congenital malformation, kerato-
conus, buphthalmus, scrophulosis (interstitial keratitis as part of lymphoglan-
dular tuberculosis), leucoma or ulcer, HSK, melting diseases, Fuch’s dystrophy, 
(pseudophakic) bullous keratopathy (PBK), trauma, chemical or thermal burns, 
allograft failure, and a category of “other” indications. For statistical purposes, 
only indications reported more than seven times were included in the analysis 
to evaluate this variable as a risk factor for immunologic graft failure. 
We excluded patients who were lost to follow-up within the first 2 postopera-
tive weeks (n = 15; two patients died within two weeks after transplantation 
and 13 patients were followed by ophthalmologists in other hospitals). Patients 
whose transplants never became clear after PKP (n = 5, four primary failures 
and one expulsive hemorrhage) were also excluded. A total of 303 high-risk and 
HLA-A and -B matched corneal transplants met the inclusion criteria and were 
included in this study.
Methods
HLA-A and HLA-B typing of donors and recipients was performed using the 
complement-dependent cytotoxicity assay at the Department of Immunohema-
tology and Blood Transfusion at the Leiden University Medical Center, accred-
ited by the European Federation for Immunogenetics.12 Analysis was performed 
both on the broad HLA typing level (A1, A2, A3, A9, A10, A11, A19, A28, A36, 
B5, B7, B8, B12, B13, B14, B15, B16, B18, B21, B22, B27, B35, B37, B40, 
B41, B42, B46, B47, B48, B53, B59, B67, B70 and B73) and split-typing level 
(splits from A9, A10, A19, A28, B5, B12, B15, B16, B17, B21, B22, B40 and 
B70). Donor corneas were allocated based on broad typing in which more than 
two mismatches were not accepted. All donor corneas were obtained from Bio 
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Implant Service (tissue branch of The Netherlands Transplant Foundation) and 
the Dutch Eye Bank, The Netherlands. Patients were followed by the cornea 
surgeons at the Eye Hospital Rotterdam in a regular pattern: 1 week, 4 weeks, 
8 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, 2 years, 2.5 
years, 3 years, and annually thereafter. All patients were treated with topical 
dexamethasone eyedrops (0.1%, six times daily) and chloramphenicol (0.5%, 
three times daily) for 2 months after transplantation. Dexamethasone eyedrops 
were gradually tapered off within a minimum of 1 year after transplantation. 
Donor procurement and medical procedures did not change throughout the 
duration of the study.
Statistics
Subgroups of patients were made based on the number of HLA-A and -B mis-
matches at split-typing level. The good match group was formed by patients 
with no or one mismatch (n = 216). The moderate match group was formed by 
patients with two or more mismatches (n = 87). Comparability of patient, donor, 
and graft covariates between the subgroups were analyzed using the χ2 test and 
the independent t test. 
Event-free survival (EFS) and overall survival (OS) were calculated using Kap-
lan-Meier statistics, and data of the subgroups were compared with the logrank 
test. EFS is defined as transplantation to immunologic graft failure. Patients with 
graft failure because of causes other than rejection were censored at the time 
of their graft failure. OS is defined from transplantation until graft failure from 
any cause. Patients who did not experience (immunologic) graft failure were 
censored at the time of their last follow-up. Odds ratio (OR) and 95% confi-
dence interval (CI) and adjusted survival probabilities for the different subgroups 
were estimated with the Cox proportional hazards model. Variables moderately 
correlated with graft failure according to univariate analyses (p < 0.20) were 
included in the model.
RESULTS
The median follow-up period for the 303 high-risk corneal transplants was 4.2 
years. Eighty-seven percent of corneal grafts survived 1 year after transplanta-
tion, 71% survived 3 years and 59% survived 5 years. During the entire follow-
up period 56.5% of all corneal grafts remained functional and clear. Immune 
rejection was the cause of 34.1% of all graft failures (45 grafts). Other causes of 
failure were slow endothelial decompensation (27 grafts), vascularized corneal 
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ulcer or perforation in 19 grafts, of which seven were a consequence of herpetic 
keratitis, corneal edema secondary to glaucoma (seven grafts), PBK (five grafts), 
phtisis bulbi (four grafts), and sequelae of trauma (two grafts). 
Patient, donor, and graft characteristics of the total study population and sub-
groups are presented in Table 1. A history of HSK was the only variable with a 
significant difference between the two subgroups (p = 0.02). A history of HSK, 
Table 1. Patient, donor, and graft characteristics of the total study population and 
subgroups based on split matching
Subgroup based on split matching
Study Group Good match group Moderate match group
Number 303 216 87
Age (yr), mean (range) 55.8 (6.2 – 86.9) 56.5 (6.6 – 84.6) 54.0 (6.2 – 86.9)
Male: female ratio 1.0: 0.67 1.0: 0.76 1.0: 0.45
History of glaukoma (%) 18.2% 17.9% 18.7%
History of HSK (%) 95 (31,4%) 59 (27.3%) 36 (41.4%)
No. of previous matched transplants 
(mean)
1.16 1.13 1.21
No. of previous transplants (mean) 2.28 2.28 2.25
Graft size (mm), mean 7.62 7.62 7.63
HSK, herpes simplex keratitis
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Figure 1. Indications for the primary transplantation.
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however, was not correlated with immune failure in univariate analysis. Percent-
ages of the primary indications for transplantation in these patients undergoning 
high-risk corneal transplantation because of repeated corneal transplantation or 
stromal vascularization are presented in Figure 1. 
We investigated the relationship of HLA mismatching and immunologic graft 
failure for split typing. Considering long-term graft survival, a significantly longer 
immune failure-free graft survival was found in the good match group (log-rank 
test, p = 0.002, Fig. 2). Comparing groups with either zero, one, two, three or four 
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Patients in FU
(0 or 1 mismatch)
216 179 130 87 47
Cum events   6  15 22 23
Cum failures  24  52 70 78
Cum LTFU  12  25 37
Patients in FU
(≥2 mismatches)
 87  68  46 28 15
Cum events  8  16 19 20
Cum failures 13  28 37 40
Cum LTFU  4  10 12
Figure 2. Kaplan-Meier curves indicate a longer immune failure-free graft survival for 
corneal transplants of the good match group with zero or one mismatch based on split 
typing (log-rank test, p = 0.002).
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immune failure was seen (log-rank test, p=0.001, Fig 3). Besides matching, other 
factors could have influenced immunologic graft failure. To correct for these 
possible confounding variables, we performed a multivariate analysis adjusting 
for variables moderately correlated with immune failure. Only the variables of 
“indication for transplantation” and “number of previous grafts in the same eye” 
were correlated (p = 0.03 and 0.001, respectively). After multivariate analyses 
with Cox regression methods, we noted that a significant beneficial effect of 
fewer split antigen mismatches could still be found (OR = 0.41, with 95% CI 
0.23-0.73). 
The effects of HLA-A and HLA-B split mismatches on immune failure-free graft 
survival were analyzed individually. According to this analysis using Cox regres-
sion, zero mismatches at either one of these loci was significantly associated 
with a longer immune failure-free graft survival. The benefits of HLA-A were 
more pronounced (p = 0.008 for HLA-A and p = 0.025 for HLA-B).
To evaluate the impact of class I mismatches based on split typing on overall 
graft survival, we performed Kaplan-Meier statistics and multivariate Cox regres-
sion with graft failure as the event. As expected, having zero or one mismatch 
was less correlated with overall graft failure than with immune failure; neverthe-
less, a significant beneficial effect of fewer split antigen mismatches could still 
be found (log-rank test, p = 0.04, Fig 4, OR = 0.66, with 95% CI 0.45-0.96).
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Figure 3. Kaplan-Meier curves indicate a tendency for more mismatches associated with 
more immune failure (log-rank test, p = 0.001).
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DISCUSSION
The results of this study show the advantages of matching HLA-A and HLA-B 
antigens using split typing for high-risk corneal transplantations. Grafts with 
up to one mismatch on a split typing level had a significantly longer immune 
failure-free survival compared with grafts with two or more mismatches.
Many studies suggest that HLA-A and HLA-B matching is associated with an 
improved outcome of corneal graft survival in high-risk corneal transplanta-
tions.3,13-20 Other studies, such as the large Collaborative Corneal Transplanta-
tion Study (CCTS), failed to demonstrate a correlation of HLA matches and graft 
survival.11 Most reports do not describe whether broad antigens or antigen splits 
were used in the mismatch calculation. Current practice, when using matched 
donor corneas, allocates donor corneas based on broad typing.21 Consequently, 
it is most likely that the majority of studies describes the influence of HLA broad 
matches on corneal graft survival. In this investigation, however, we analyzed 
the influence of HLA matching on immunologic graft failure on a split-typing 
level, showing a valuable effect when split antigens were used in the mismatch 
calculation. Analogous to this finding, a previous study showed that HLA-DR 
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Figure 4. Kaplan-Meier curves indicate a longer overall survival for corneal transplants of 
the good match group with zero or one mismatch based on split typing (log-rank test, p = 
0.04).
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matching was beneficial for high-risk corneal transplantations only when split 
antigen typing results were used.22
Studies differ in their definition of high-risk, thus making it difficult to compare 
graft survival rates. In our study, patients were considered to be at high risk 
of corneal transplantation failure if they had deep stromal vascularization in 
two or more quadrants or if they had a previous corneal graft failure due to 
rejection in the same eye. The CCTS included high-risk patients according to 
equal criteria, making it comparable with our own investigation. The overall 
failure rate reported by this group, using an intensive postoperative topical im-
munosuppressive regimen was 35% at 3 years postoperatively. These findings 
are comparable with our result of 39% graft failure at 3 years. Our survival rates 
compare favorably with other studies, despite the inclusion of all risk categories 
in these studies.23 
One third of graft failures in our study were due to an irreversible rejection 
reaction. Previous investigations reported similar results, showing that allograft 
rejection is still the leading cause of corneal graft failure.23,24 Overall graft survival 
depends also on the presence of nonimmunologic factors causing graft failure, 
such as improvement of surgical techniques,25,26 training of corneal surgeons,27 
and the use of newer topical or systemic immunosuppresive medication.28-30 
Attributing the cause of graft failure to rejection-related reasons or other nonre-
jection-related reasons can be difficult. In particular, rejection and recurrence of 
HSK can be impossible to distinguish clinically, more so during our investigation 
as this differentiation had to be made retrospectively. Even if graft failure due to 
any cause was taken as an event in the survival analysis, a beneficial result for 
the good match group based on split typing was shown. 
Although this study was performed retrospectively, we were not aware of 
the number of HLA matches at the time of diagnosing the final graft outcome 
because these data were kept in a separate data file. The good and moderate 
match subgroups were comparable with respect to most characteristics. How-
ever, a higher percentage of patients with a history of HSK were included in the 
moderate match group. Analysis of immune failure-free graft survival without 
considering all HSK patients showed equal results. 
In conclusion, one third of all graft failures of our investigated high-risk cor-
neal transplantations were due to an irreversible graft rejection. This number 
could possibly be lowered by allocating donor corneas based on split antigen 
matching since fewer HLA-A and HLA-B mismatches on the split antigen level 
contribute to a higher immune failure-free graft survival and to a higher overall 
graft survival.
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ABSTRACT
Purpose: Evaluation of corneal astigmatism and suture related complications for transplants sutured 
with Nylon and transplants sutured with Mersilene in primary corneal transplants for Fuchs’ endo-
thelial dystrophy. 
Methods: Retrospective observational and comparative study between transplants sutured with 
either Nylon 10/0 or 11/0 (n = 108) or Mersilene 11/0 (n = 58). Hundred and sixty-six eyes of 140 
patients who received a primary penetrating keratoplasty for Fuchs’ endothelial dystrophy between 
1995 and 2001 at the Rotterdam Eye Hospital, Netherlands were included.
Results: Overall transplant survival did not differ between groups (log rank test, p = 0.24). A sig-
nificant lower astigmatism was seen in transplants sutured with Nylon during the first two years 
after transplantation (p = 0.03). Transplants sutured with Mersilene had a significantly higher risk of 
surgical intervention to correct astigmatism or wound dehiscence after transplantation (Hazard Ratio 
2.83 with 95% Confidence Interval 1.34-6.01). Time to first infiltrate, metaplasia or cheesewiring 
was significantly less in the Mersilene group (p < 0.01). There was a tendency towards a higher risk 
of complications associated with loose or broken sutures in the Nylon group (Hazard Ratio 2.00 
with 95% Confidence Interval 0.57-6.98), which was more pronounced after two years.
Conclusion: Mersilene sutures are less accurate in the early postoperative period compared to Nylon 
sutures with regard to astigmatism and risk of developing complications. In long-term follow-up, the 
long lasting tensile strength of polyester may lead to fewer complications associated with loose or 
broken sutures for transplants sutured with Mersilene. These favorable long-term effects of Mersilene 
sutures may outweigh its short-term disadvantage in patients with Fuchs’ endothelial dystrophy.
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INTRODUCTION
The most established treatment for Fuchs’ endothelial dystrophy is penetrating 
keratoplasty.1 Graft survival for Fuchs’ dystrophy is good, with long-term graft 
survival rates of 89%.2,3 One of the major complications impairing visual acuity 
after successful penetrating keratoplasty is high astigmatism.2 Many factors can 
influence postoperative astigmatism, such as malpositioning of donor and recipi-
ent corneas, trephination irregularities, uneven tension on sutures and suturing 
technique. Selective removal of individual interrupted sutures has been proven 
to be effective in the reduction of astigmatism after penetrating keratoplasty.4-7 
When acceptable astigmatism is achieved, the remaining sutures are generally 
left in place. However, the commonly used suture material of Nylon biode-
grades over time and can weaken or loosen. Loose sutures are associated with 
complications such as (sterile) infiltrates, microbial keratitis, endophthalmitis 
and allograft rejection.8-10 Furthermore, wound dehiscence and large changes in 
astigmatism can occur after suture removal or suture degradation.11-13 It would 
be attractive to use a suture material which can be left in place permanently 
without loosing tensile strength. Patients with Fuchs’ endothelial dystrophy are 
at elevated risk of wound dehiscence after penetrating keratoplasty.8 Wound 
dehiscence has been related to age, preoperative corneal edema, use of Nylon 
sutures (by not inducing inflammation) and the use of postoperative corticoste-
roids.8,14,15 Consequently, Fuchs’ patients may benefit from a non-absorbable su-
ture. A non-absorbable suture material which is sometimes used is Mersilene, a 
polyester monofilament which is neither hydrolyzed nor degraded by ultraviolet 
light.16 Theoretically, Mersilene is more suitable than biodegradable sutures to 
control long-term postoperative astigmatism and to prevent wound dehiscence 
as it can be left in place permanently.
In this study, we compare mid-term stability of the corneal surface and suture 
related complications in primary corneal transplants for Fuchs’ endothelial 
dystrophy sutured with either Nylon or Mersilene filaments.
MATERIALS AND METHODS
A retrospective and observational study was done on 166 consecutive pen-
etrating keratoplasties performed at the Rotterdam Eye Hospital, Netherlands 
between 1995 and 2001. Only primary not HLA-matched transplants performed 
in patients with Fuchs’ endothelial dystrophy were included. Transplants were 
sutured with either Nylon or Mersilene sutures. Transplants in which combina-
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tions of both materials were used and patients who did not receive follow-up 
examinations at the Rotterdam Eye Hospital were excluded. Preoperative, in-
traoperative and postoperative data were collected retrospectively from patient 
charts and from the national follow-up program on keratoplasties. Preoperative 
data included patient age, gender, involved eye, history of glaucoma, previ-
ous eye operations, best corrected visual acuity (BCVA) and preexistence of 
systemic disease such as diabetes mellitus or collagenous disease. The diameter 
of the donor graft was systematically 0.50 mm larger than that of the recipi-
ent. Trephination of the donor button was done from the endothelial side by 
means of a disposable punch (Medical Workshop, Groningen, the Netherlands). 
Trephination of the recipient cornea was done by a Hesburg Barron suction 
trephine. All penetrating keratoplasties were performed by corneal surgeons at 
the Rotterdam Eye Hospital. Suturing techniques depended on the preference 
of the surgeon: one running suture (Nylon 11-0 or Mersilene 11-0), 16 inter-
rupted sutures (Nylon 10-0 or Mersilene 11-0) or a combination of 8 interrupted 
sutures with one running suture. Intraoperative keratoscopy was used to adjust 
suture tension whereafter, all knots were buried in the recipient cornea. Patients 
received subconjunctival antibiotics and Dexamethasone phosphate at the end 
of the procedure. All patients were treated with a fixed combination of topical 
Dexamethosone eye drops (0.1%, six times daily) and Chloramphenicol (0.5%, 
three times daily) for at least two weeks after transplantation. Dexamethason 
eye drops were gradually tapered off to one drop daily within one year after 
transplantation. Additional procedures performed (such as cataract extraction 
with intraocular lens implantation or intraocular lens exchange), intraoperative 
complications, suture material, suturing technique and graft size were noted. 
Postoperatively, transplant survival, rejection episodes, intra ocular pressure 
(IOP), suture related procedures and suture related complications such as neovas-
cularization, infiltration, loose or broken sutures, epithelial defects, metaplasia, 
filaments, wound dehiscence and cheesewiring were noted. Transplant survival 
was defined as the time that a transplant was functionally clear. Neovasculariza-
tion was defined as deep vascular growth in the donor at one or more suture 
sites. Infiltration was defined as deep infiltrates at the suture site. Postoperatively, 
patients were followed by the cornea surgeons in a regular pattern at 1 week, 
4 weeks, 8 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, 2 
years and annually thereafter. BCVA and keratometry were noted at 3 months, 6 
months, and yearly thereafter. Astigmatism was measured with a calibrated Javal 
keratometer. Interrupted sutures were removed selectively to reduce astigmatism 
one by one in cases with more than four diopters of astigmatism. Except for 
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broken sutures, which were removed immediately at time of presentation. There 
was no set protocol for final suture removal.
Statistics
Subgroups of transplants were based on suture type. The Nylon subgroup con-
sisted of 108 transplants of 95 patients and the Mersilene subgroup consisted of 
58 transplants of 53 patients. Eight patients received a transplant sutured with 
Nylon in one eye and Mersilene in the other eye. Comparability of preoperative 
characteristics between suture type groups were analyzed using the χ2 test for 
categorical variables and the Students t test for continuous covariates. 
Eyes with astigmatism equal to or greater than 4.00 D were considered highly 
astigmatic. Postoperative keratometric astigmatism (diopters) in the first two 
years as it differed between the two suture materials, was adjusted for possible 
confounding factors and was analyzed with mixed model ANOVA using SAS 
software 8.2. Before analysis, keratometric astigmatism was converted from the 
polar values (cylinder and axis) to Cartesian coordinates (X and Y), according to 
Holladay.17 Possible confounding variables included in the model were suturing 
technique, age and patients having two eyes operated. The covariance structure 
of the repeated measurements was assumed to be random with the variance 
components between patients and within patients (between both eyes, between 
follow-up times and residual error). The modification of the suture material-ef-
fect on astigmatism through time was also tested. The mean absolute change 
in astigmatism between the different follow-up times was analyzed with vector 
analysis and also compared between the two groups with mixed-model ANOVA. 
The dependent variable in this model was the Ln-transformed vectorial change 
in keratometric astigmatism between two follow-up times. As independent 
variables along with Nylon or Mersilene sutures, left or right eye, suture tech-
nique and age were included. No structure was imposed on the (co)variance of 
repeated measurements. 
Overall graft survival was calculated using Kaplan Meier statistics and data for 
the subgroups were compared with the log rank test. 
Only the first transplant of a patient was included for complication analysis. 
If one patient had a transplant sutured with Nylon and another with Mersilene, 
both transplants were included. Each suture related complication was scored as 
a different event. If a complication occurred more than once, only the first was 
scored as an event. Transplants, which were not complicated by an event were 
censored at the time of last follow-up. Event-free survivals for each complication 
were estimated with the Cox proportional hazards model. Possible confounding 
factors such as suturing technique and age were included in the model to es-
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timate adjusted survival probabilities. Besides an individual evaluation of each 
complication, the more serious complications such as endophthalmitis, neovas-
cularization, infiltration and wound dehiscence were categorized in one group 
and the effect of suture type on this category was also evaluated. Complications 
related to loose or broken sutures were also categorized in one group for the 
evaluation of suture effect on this category. All broken or loose sutures leading 
to corneal infiltration, endophthalmitis, wound dehiscence, rejection reaction 
(reversible and irreversible) or progression of astigmatism of 3 or more diopters 
were considered as events in the category of complications related to loose or 
broken sutures. 
Some complications can occur more than once without interfering with 
transplant survival. For this reason, the yearly complication rate for certain com-
plications was also calculated using Poisson regression analysis. All transplants 
were included in this analysis. A general linear model was used with maximal 2 
repeated measurements (left or right eye) per patient. Empirical standard errors 
of the estimated coefficients (denoting the natural logarithm of the complication 
rate ratio) were estimated using the GEE method.18 A level of significance of p = 
0.05 was used.
RESULTS
Preoperative patient data did not reveal significant differences between the 
Mersilene or Nylon suture groups (Table 1). However, there was a significant dif-
ference among groups in distribution of suturing technique (p < 0.01, Table 2). 
Penetrating keratoplasty was combined with cataract extraction and intraocular 
lens implantation in 66 eyes (61%) of the Nylon suture group in 29 eyes (50%) 
of the Mersilene suture group. The overall low intraoperative complication rate 
did not differ between suture groups (p = 0.85). The most encountered intraop-
erative complication, capsular rupture with or without vitreous loss, occurred in 
9 eyes (8.3%) of the Nylon group and in 4 eyes (6.9%) of the Mersilene group. 
The average follow-up between the two groups was significantly different, 4.13 
± 1.54 (SD) years for the Nylon group (median 4.04 years) and 3.15 ± 1.88 years 
for the Mersilene group (median 2.55 years). Overall transplant survival was not 
significantly different between the two groups (log rank test, p = 0.24, Figure 
1). Thirty-three (21.6%) of 153 eyes without a history of glaucoma developed 
an IOP more than 21 mmHg during the first postoperative year. In most cases, 
this IOP rise was related to the use of topical corticosteroids. Response to IOP 
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lowering medication was good in all cases. Suture material was not found to be 
related to IOP rise.
Table 1. Preoperative patient data
Mersilene (n = 53) Nylon (n = 95) p-values
Gender 64% Female 66% Female 0.80
Age (mean, yrs) 72.8 70.5 0.10
Pseudophakia 39% 27% 0.15
History of glaucoma  7%  8% 0.74
Diabetes Mellitus  9% 10% 0.82
Collagenous disease  7%  9% 0.61
Table 2. Distribution of suturing techniques
Mersilene (58 eyes) Nylon (108 eyes)
Interrupted sutures 18 (31.0%) 12 (11.1%)
Running suture  4 (6.9%)  1 (0.9%)
Combination of one running suture with
interrupted sutures 
36 (62.1%) 95 (88.0%)
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Figure 1. Overall transplant survival for suture type, log rank test, p = 0.24. 
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Visual acuity and astigmatism
Mean preoperative BCVA was 0.24 ± 0.14 in both groups. Further pre and 
postoperative values are summarized in Table 3. No significant difference in 
BCVA was seen among the groups at all follow-up periods. The keratometric 
cylinders are presented graphically in Figure 2. High astigmatism (≥ 4 D) did not 
occur more frequently in either group at any follow-up period. A mean 0.88 ± 
0.41 D lower astigmatism was seen in the Nylon group the first two years after 
transplantation (mixed model ANOVA, p = 0.03). At three years follow-up a 
slightly lower astigmatism was observed in the Mersilene group. There was no 
significant difference between groups in astigmatic change between follow-up 
periods (Table 4).
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Figure 2. Mean keratometric cylinder at follow-up periods for suture type.
Table 3. Average and standard deviation of pre and postoperative visual acuity and
postoperative astigmatism
Preoperative 3 months 6 months 1 year 2 years 3 years
Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon
(n = 58) (n = 108) (n = 56) (n = 107) (n = 56) (n = 106) (n = 52) (n = 104) (n = 36) (n = 100) (n = 25) (n = 86)
BCVA 0.24 ± 0.14 0.24 ± 0.17 0.31 ± 0.21 0.32 ± 0.18 0.42 ± 0.24 0.46 ± 0.23 0.52 ± 0.27 0.57 ± 0.25 0.58 ± 0.27 0.58 ± 0.24 0.54 ± 0.28 0.56 ± 0.26
Flat k-readings - - 40.9 ± 3.7 42.0 ± 2.8 42.2 ± 3.0 42.8 ± 3.2 43.0 ± 3.7 43.5 ± 3.2 42.8 ± 3.5 44.0 ± 2.8 42.9 ± 3.7 44.2 ± 2.7
k-cylinders - - 5.63 ± 3.15 5.17 ± 2.92 5.24 ± 3.22 4.38 ± 2.60 4.39 ± 2.83 3.67 ± 3.15 4.67 ± 2.89 3.84 ± 2.96 4.27 ± 2.63 4.44 ± 3.09
% ≥ 4 D 
astigmatism
- - 63.0% 50.5% 52.7% 44.7% 41.2% 28.9% 34.9% 34.4% 43.5% 41.9%
BCVA, best corrected visual acuity; n = number of eyes
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Suture adjustment
Significantly more eyes in the Mersilene group required surgical changing of 
suture tension by the addition or the replacement of sutures due to corneal 
astigmatism, according to multivariate analysis with Cox regression methods 
(Hazard Ratio (HR) = 2.83 with 95%Confidence Interval (CI) 1.34-6.01). The 
frequency of suture adjustment by selective suture removal in the steep axis 
was not significantly different between groups (Cox analysis, HR = 0.84, with 
95% CI 0.52-1.37). All transplants with single running Mersilene sutures (n = 
4) needed surgical correction shortly after transplantation. The running sutures 
were too loose in two cases, plus cheesewiring caused loosening of the sutures 
in one eye and the transplant was too flat in another. 
Suture-related complications
Time to first infiltrate, metaplasia or cheesewiring was significantly shorter in the 
Mersilene group (Cox regression analysis, p < 0.01). 
Table 4. Comparison of absolute cylindric change according to vector analysis at different 
follow-up periods between the Mersilene and Nylon groups
Follow-up period Mersilene Nylon Adjusted effect of Mersilene relatively to Nylon*
mean astigmatism (D) mean astigmatism (D) Exponent β 95% Confidence 
Interval
p -value
3 to 6 months 4.3 3.2 1.22 0.98-1.53 0.08
6 months to
1 year
3.7 3.4 1.05 0.81-1.37 0.71
1 to 2 years 4.4 3.9 1.30 0.98- 1.72 0.07
2 to 3 years 3.0 4.6 0.80 0.54-1.19 0.27
*Adjusted for the possible inclusion of two transplants per patient, suture technique and age
Table 3. Average and standard deviation of pre and postoperative visual acuity and
postoperative astigmatism
Preoperative 3 months 6 months 1 year 2 years 3 years
Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon Mersilene Nylon
(n = 58) (n = 108) (n = 56) (n = 107) (n = 56) (n = 106) (n = 52) (n = 104) (n = 36) (n = 100) (n = 25) (n = 86)
BCVA 0.24 ± 0.14 0.24 ± 0.17 0.31 ± 0.21 0.32 ± 0.18 0.42 ± 0.24 0.46 ± 0.23 0.52 ± 0.27 0.57 ± 0.25 0.58 ± 0.27 0.58 ± 0.24 0.54 ± 0.28 0.56 ± 0.26
Flat k-readings - - 40.9 ± 3.7 42.0 ± 2.8 42.2 ± 3.0 42.8 ± 3.2 43.0 ± 3.7 43.5 ± 3.2 42.8 ± 3.5 44.0 ± 2.8 42.9 ± 3.7 44.2 ± 2.7
k-cylinders - - 5.63 ± 3.15 5.17 ± 2.92 5.24 ± 3.22 4.38 ± 2.60 4.39 ± 2.83 3.67 ± 3.15 4.67 ± 2.89 3.84 ± 2.96 4.27 ± 2.63 4.44 ± 3.09
% ≥ 4 D 
astigmatism
- - 63.0% 50.5% 52.7% 44.7% 41.2% 28.9% 34.9% 34.4% 43.5% 41.9%
BCVA, best corrected visual acuity; n = number of eyes
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The risk of developing a complication, regardless of type, was three times 
higher for the Mersilene group (HR = 3.24, with 95% CI 2.10-4.99). The risk of 
developing neovascularization, loose or broken sutures, epithelial defects, fila-
ments or wound dehiscence, was not significantly different for the two groups 
(according to individual evaluation of each complication by Cox regression 
analysis).
Among the group of more serious complications (endophthalmitis, neovascu-
larization, infiltration and wound dehiscence) there was no significant difference 
between suture groups (HR for Mersilene sutures was 1.82 with 95% CI 0.86-
3.84). Endophthalmitis was seen in three eyes with Nylon sutures, from which 
two were related to a broken suture. The other case was caused by a bacterial 
keratitis. None of the eyes in the Mersilene group developed endophthalmitis. 
There was a tendency towards a lower risk of complications associated with loose 
or broken sutures in the Mersilene group (HR = 0.50 with 95% CI 0.14-1.74). 
This was especially pronounced after two years (Figure 3). No complications 
due to broken or loose sutures appeared in the Mersilene group after one year. 
Some eyes experienced loose or broken sutures and infiltrates more than 
once. The yearly complication rate for loose or broken sutures, however, did not 
differ between the Mersilene group relatively to the Nylon group (Rate ratio (RR) 
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Figure 3. Cumulative probability of developing complications associated with broken or 
loose sutures (HR=0.50 with 95% CI 0.14-1.74).
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= 1.12 with 95% CI 0.70-1.79). The yearly rate for infiltrates was significantly 
higher for the Mersilene group (RR = 4.64 with 95% CI 1.29-16.680).
DISCUSSION
A significantly lower astigmatism was observed during the first two years after 
transplantation in transplants sutured with Nylon compared to transplants su-
tured with Mersilene. The risk of developing complications such as infiltrate, 
metaplasia and cheesewiring was higher in the Mersilene group. Our clinical 
impression, that transplants sutured with Nylon are prone to develop serious 
complications, such as endophthalmitis, was confirmed. Using Mersilene 
sutures, however, did not reduce the risk of developing serious complications 
during mid-term follow-up. There are, however, some indications that this might 
not be the same in late-term control since after two years there were fewer 
complications associated with loose or broken sutures in the Mersilene group.
This study provides a longer follow-up and a higher number of patients 
compared to other studies evaluating the effect of Mersilene sutures in corneal 
transplantation.19-26 Previous studies evaluating Mersilene sutures in corneal 
transplants were conducted on eyes with a variety of pathologies. We felt that, 
to properly be able to compare the effect of Mersilene versus Nylon sutures, a 
more homogeneous group of patients was required. For this reason, in this study 
only primary transplants for Fuchs’ endothelial dystrophy were included. This 
is the only study comparing transplants sutured with either Mersilene or Nylon 
filaments, in which no combination technique of interrupted Nylon sutures with 
a running Mersilene or Nylon suture is used. To our opinion this is the most 
appropriate method to evaluate whether complications are associated with 
Mersilene or Nylon. 
A drawback of this study was that eyes were not randomized to either the 
Nylon or Mersilene suture group. The decision for suture type was merely based 
on the current preference of the surgeon; however, all surgeons were equally 
represented in both suture material groups. After encountering a complica-
tion with the use of Nylon sutures, a surgeon could be expected to change 
his preference to Mersilene sutures and vice versa. However, no preoperative 
patient factors were observed to influence this decision. Further, average length 
of follow-up was different in both groups. To correct for this, we used survival 
statistics, which adjust for follow-up time, to evaluate the risk of developing 
complications. Transplants are excluded from further analysis with survival 
statistics after an event has occurred. However, certain events can occur more 
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than once without interfering with transplant survival. To obviate this problem 
the yearly complication rate of complications that occurred more than once 
in one transplant was calculated. Results of this analysis, however, resembled 
those of the Cox regression analysis. A possible bias to the study results was 
the use of conventional keratometry to quantify astigmatism. This measures the 
astigmatism at a diameter of 3 mm from the center of the cornea. In case of ir-
regular astigmatism, these measurements can be difficult and less useful.27 Also, 
these measurements are not objective. Another weakness of this study was an 
unequal distribution in suturing techniques between the Nylon and Mersilene 
group, with relatively more interrupted sutures in the Mersilene group and more 
combined interrupted and running sutures in the Nylon group. Although there 
is no general agreement regarding which suture technique is the best to reduce 
astigmatism, it is obvious that suturing technique might play a role in postkera-
toplastic astigmatism.4,28,29 All statistical analyses were therefore adjusted for this 
variable. 
Controversy consists about the use of Mersilene sutures in penetrating kerato-
plasty. Several studies conclude that Mersilene can be used effectively in corneal 
transplantation,21-26 although these studies are non-comparative, evaluating the 
use of Mersilene sutures alone or in combination with Nylon sutures. A study by 
Ramselaar et al.,26 comparing interrupted Nylon sutures combined with either a 
running Mersilene suture or a running Nylon suture, concluded that Mersilene 
appeared to be suitable for penetrating keratoplasty. In contrast to the aforemen-
tioned studies, Bertram et al.20 concluded that Mersilene was inappropriate for 
use in penetrating keratoplasty because of its high incidence of complications. 
Our results are partly in concordance with those of the study of Bertram et al., 
with a higher risk of complications in the Mersilene group, as we noted a higher 
risk of metaplasia among these patients. This was also described by Frueh et 
al..23 Furthermore, we confirmed the higher risk of cheesewiring among eyes 
in the Mersilene group.20 As shown by others, suture removal after penetrating 
keratoplasty is not always an uneventful procedure. Removal of Nylon sutures 
even more than one year postoperatively can cause an unpredictable change in 
astigmatism, or even wound dehiscence, followed by choroidal hemorrhage.11-
13,30 This was confirmed in the 61 eyes (56.5%) of our Nylon suture group, where 
either the running Nylon suture or all Nylon sutures (in 21 eyes) were removed 
at the end of follow-up. Wound dehiscence or an increase in astigmatism of 
more than 3 diopters occurred in 13 (21.3%) of the 61 eyes, whereby another 
2 eyes (3.3%) even developed an expulsive choroidal haemorrhage after suture 
removal. 
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The slightly lower astigmatism in the Mersilene group after 3 years follow-up 
may be explained by the increase in astigmatism after suture removal in the 
Nylon group in this period. In the early postoperative period, however, more 
surgical corrections for astigmatism and wound dehiscence were necessary in 
the Mersilene group. This may have been due to the inelasticity of Mersilene 
and the difficulties to handle Mersilene during surgery, resulting in too tight 
or too loose sutures. Transplants sutured with single running Mersilene sutures 
needed surgical intervention in all four cases. Handling sutures is more criti-
cal in a running suture technique than in an interrupted suture technique. Too 
tight sutures may cause postoperative cutting of the recipient and donor cornea, 
with subsequent complications due to loose sutures. Nylon sutures are easier 
to control during surgery and cause fewer problems in the early postoperative 
period. After 2 years, however, in contrast to Mersilene, Nylon sutures start to 
degrade allowing for spontaneous breakage. This was illustrated in our finding 
that no complications due to broken or loose sutures appeared in the Mersilene 
group after more than one year, in sharp contrast to the Nylon group. It would 
be interesting to compare complications and astigmatism between both groups 
after all Nylon sutures are removed. Eventually, a significantly beneficial effect 
for Mersilene sutures could then possibly emerge. 
Our study indicates that Mersilene sutures will certainly not solve all problems 
of postkeratoplastic astigmatism and suture-related complications. Considering 
that all transplants sutured with a single running Mersilene suture needed surgi-
cal correction shortly after transplantation, the use of only a Mersilene running 
suture should be discouraged. Also concerning the risk of developing complica-
tions, Mersilene sutures are shown to be less suitable in the first two postoperative 
years. Nylon sutures appear to be preferable to Mersilene sutures with regard 
to the control of astigmatism and complications during the first two years after 
transplantation. However, a tendency for a beneficial effect of Mersilene sutures 
regarding complications due to loose or broken sutures is observed after two 
years. Longer follow-up after which all Nylon sutures are removed or hydrolyzed 
is required to assess a possible beneficial effect of Mersilene sutures in penetrat-
ing keratoplasty. In the meantime, other techniques such as “mushroom shaped” 
keratoplasty31 and posterior lamellar keratoplasty are being developed.32 These 
techniques might help in solving the problem of wound dehiscence, (other) 
suture-related complications and postoperative astigmatism.
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 CHAPTER 5
IMPLANTATION OF A TORIC PHAKIC INTRAOCULAR 
LENS TO CORRECT HIGH CORNEAL ASTIGMATISM IN 
A PATIENT WITH BILATERAL MARGINAL CORNEAL 
DEGENERATION
M.C. Bartels
G. van Rij
G.P.M. Luyten
J Cataract Refract Surg 2004; 30: 499-502
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ABSTRACT
We present a patient with marginal corneal degeneration and corneal astigmatism of more than 
10.0 diopters (D). A toric phakic intraocular lens (IOL) of 7.0 D cylindrical power was implanted 
in both eyes to correct the high astigmatism. An uncorrected visual acuity of 20/40 was achieved 
in both eyes, and the best corrected visual acuity improved by 4 Snellen lines to 20/20 in both 
eyes. Refraction and visual acuity remained stable at 1.5 years postoperatively. Implantation of a 
toric phakic IOL can be an option to correct high corneal astigmatism even when the full corneal 
astigmatism can not be treated.
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INTRODUCTION
Peripheral marginal degeneration of the cornea can lead to severe visual loss 
secondary to excessive astigmatism. Various techniques can be used to treat 
astigmatism. In the early stages, mild to moderate astigmatism can be corrected 
with spectacles and contact lenses. If marginal degeneration progresses to thin-
ning of the peripheral cornea and results in severe astigmatism and contact lens 
intolerance, alternative methods are necessary. 
Several surgical procedures have been used to treat astigmatism (eg, crescen-
tic lamellar keratoplasty and excision of ectatic stroma), but the ideal treatment 
has not been found.1,2 Laser in situ keratomileusis (LASIK) is acceptable for the 
correction of mild to moderate astigmatism3 but is not appropriate in cases 
with high irregular astigmatism such as marginal degeneration, keratoconus 
and astigmatism that occurs after penetrating keratoplasty (PKP). These patients 
could benefit from phakic toric intraocular lenses (IOLs)4 such as the Artisan 
phakic IOL, which is shown to correct high myopia with a stable and fairly 
predictable refractive outcome.5,6 Artisan toric phakic IOLs are available with 
a cylindrical power up to 7.0 diopters (D) and are appropriate for treatment of 
high astigmatism.7
CASE REPORT
A 51-year-old man with peripheral marginal corneal degeneration was referred 
to us in 1996 with a best corrected visual acuity (BCVA) of 20/100. An examina-
tion in 1991 revealed a BCVA of 20/20 in both eyes with a refraction of –6.00 
–5.00 X 87 in the right eye and –8.50 –5.00 X 115 in the left eye. Ocular history 
included a peripheral laser coagulation treatment in the left eye in 1988 for an 
asymptomatic peripheral retinal hole. The patient’s high astigmatism resulted 
from bilateral marginal corneal degeneration present in the inferior cornea with 
some vascularization, consistent with the diagnosis of Terrien marginal degen-
eration. The medical history was unremarkable, and the patient did not have a 
collagen or vascular disease or an atopic constitution. Because of the patient’s 
low visual acuity with spectacle correction at the time of presentation, the use 
of contact lenses to correct myopia and astigmatism was advised. With contact 
lenses, the visual acuity was 20/20 in the right eye and 20/30 in the left eye. Four 
years later, the patient experienced a further decrease in visual acuity despite 
contact lens correction to 20/50 in both eyes. He was unable to wear contact 
lenses for more then 2 hours a day. 
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Because of contact lens intolerance and inadequate visual acuity with spec-
tacles, an alternative method to correct the high myopia and astigmatism was 
considered. Laser in situ keratomileusis was not a treatment option because of 
the high astigmatism and extreme thinning of the cornea from marginal degen-
eration. Implantation of the Artisan phakic IOL was discussed with the patient 
because of our long experience with this IOL and our 1-year experience with 
the Artisan toric phakic IOL. 
The preoperative BCVA was 20/40 with –4.50 –10.75 X 81 in the right eye and 
20/50 with –3.00 –13.00 X 115 in the left eye. Keratometry was 41.00/51.00D 
X 95 and 40.25/52.50 X 100, respectively. The endothelial cell count was 2244 
cells/mm2 in the right eye and 1756 cells/mm2 in the left eye with a Topcon 2000 
specular microscope. Both eyes had a 3.20 mm pupil in daylight that expanded 
to less than 5.50 mm in dark conditions. A-scan ultrasound showed axial lengths 
of 26.62 mm in the right eye and 26.40 mm in the left eye with anterior chamber 
depths of 4.02 mm and 3.91 mm, respectively. Based on the refractive data and 
limited by the 7.00 D maximum cylinder of the toric IOL, the appropriate toric 
IOL power was calculated with the Van der Heijde formula to be –5.50 –7.00 
X 90 in the right eye with implantation in axis 171 and –4.00 –7.00 X 90 in the 
left eye, with implantation in axis 25. The optical zone of these lenses was 5.0 
mm. 
After the patient was counseled and informed consent was obtained, toric IOL 
implantation was performed uneventfully in the right eye and 3 weeks later in 
the left eye. Before surgery and retrobulbar anaesthesia, the desired axis location 
was marked on the sclera with a surgical marker guided by the reflected im-
ages of the Javal keratometer on the cornea. Myotic drops (pilocarpin 2%) were 
administered to prepare the iris for IOL fixation. A limbal beveled incision of 5.5 
mm was made at 12 o’clock, and 2 more paracenteses were made at 10 o’clock 
and 2 o’clock. The anterior chamber was opened and sodium hyaluronate 1.0% 
(Healon®) was introduced to maintain depth and to protect the endothelium. 
After implantation, the IOL was fixated to the midperipheral iris stroma with an 
enclavation needle after it was positioned in the desired axis. At the end of the 
procedure, a slit iridotomy was performed at 12 o’clock to prevent angle-closure 
glaucoma and the Healon was manually irrigated. The incision was closed with 
a 10-0 nylon running suture. 
Five days postoperatively, the uncorrected visual acuity (UCVA) in the right 
eye was 20/40 and the BCVA, 20/25 with +1.25 –3.25 X 102. Further ocular 
examination was unremarkable and the iris-claw IOL was well centered and 
stable, so surgery was performed in the left eye. Five days after surgery in the left 
eye, the UCVA was 20/40 and the BCVA was 20/25 with –3.25-1.25 X 73. At 75 
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days in the right eye and 55 days in the left eye, the refraction remained stable 
with a UCVA of 20/40 and a BCVA of 20/25 in both eyes. After 6 months, the 
subjective refraction was –1.75 –0.75 X 15 in the right eye and –2.50 –0.75 X 
139 in the left eye. At 1.5 years, the subjective refraction remained fairly stable 
at –1.00 – 0.50 X 70 in the right eye and –3.00 – 0 .75 X 125 in the left eye; 
the BCVA of 20/20 in both eyes (Table 1). The keratometry changed marginally 
from the preoperative readings (Table 1). The endothelial cell count was 2694 
cells/mm2 in the right eye and 1654 cells/mm2 in the left eye. 
DISCUSSION
Implantation of a toric IOL is an alternative treatment for the correction of high 
astigmatism. The result we achieved in this case was excellent. Based on the 
toric IOL’s maximal correction of 7.00 D cylindrical power, the residual cylin-
der achieved in the subjective refraction was much lower than expected. The 
preoperative subjective refractive cylinder of –10.75 X 81 in the right eye and 
– 13.00 X 115 in the left eye changed after toric IOL implantation to –0.50 X 70 
and –0.75 X 125, respectively, with almost no change in corneal astigmatism, 
according to keratometry readings. Correction of the cylinders along with cor-
rection of the residual myopia led to a BCVA of 20/20 in both eyes. 
Annular lamellar keratoplasty (LKP) and corneal wedge excision have been 
performed in marginal corneal degeneration cases to control corneal astigma-
tism. Reports of annular LKP are restricted to a few cases; no large series have 
been reported.2,8-10 Along with other authors, we found that this procedure is 
not an optimal treatment. The time required for visual rehabilitation with LKP is 
longer than with toric IOL implantation. Reports of corneal wedge excision show 
Table 1. Preoperative and postoperative visual acuity, refraction, and keratometry in 
both eyes
Right Eye Left Eye
BCVA Subjective 
refraction
Keratometry BCVA Subjective 
refraction
Keratometry
Preoperative 20/40 -4.50-10.75
X 81
41.00/51.00
X 95
20/50 -3.00-13.00
X 115
40.25/52.50
X 100
5 days postoperative 20/25 +1.25-3.25
X 102
20/25 -3.25-1.25
X 73
18 months 
postoperative
20/20 -1.00-0.50
X 70
40.25/52.00
X 90
20/20 -3.00-0.75
X 125
39.75/52.5
X 95
BCVA, best corrected visual acuity
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a poor long-term reduction in astigmatism.1,11,12 Laser in situ keratomileusis has 
proved to be an effective treatment in eyes with less than 2.0 D of astigmatism,3 
but it cannot adequately correct high astigmatism. In our patient with a thin 
cornea and high astigmatism, LASIK was not an option. Intraocular refractive 
surgery was probably the only suitable choice. 
Lens extraction with IOL implantation is another option to correct high 
astigmatism and myopia. There are several case reports and studies of toric IOL 
implantation after lens extraction.13-19 Toric IOL implantation after lensectomy 
results in the loss of accommodation, whereas with the Artisan toric IOL, ac-
commodation is preserved. Rotational instability is a problem with toric IOLs 
in the capsular bag,19,20 but rotation of the iris-claw IOL is less likely because 
of its firm fixation to the midperipheral iris stroma. The off-axis position of an 
iris-claw lens is caused by incorrect placement of the IOL in the axis during 
surgery. A greater incidence of postoperative retinal detachment is expected 
with IOL implantation after lensectomy.21,22 We consider the phakic toric IOL a 
more favorable option to correct high astigmatism and myopia in a patient with 
a clear lens. 
Another phakic IOL option is posterior chamber (PC) IOLs. The potential for 
long-term effects such as cataractogenesis and pigment dispersion with phakic 
PC IOLs is a serious concern,23-25 as is endothelial cell loss with phakic iris-claw 
IOLs.26 Gimbel and Ziémba27 report on a case with moderate astigmatism of 
–2.25 in which a toric posterior phakic IOL was used. We chose the Artisan toric 
anterior chamber IOL because it was the only available toric phakic IOL at the 
time surgery was planned.
Limitations to the Artisan IOL are a cylindrical power up to only 7.00 D and 
an optical zone of 5.00 mm. In high myopia, a small optical zone may produce 
halo effects and glare in dim illumination conditions. Careful patient selection 
excluding those with a pupil diameter of more than 5.00 mm under scotopic 
conditions might prevent these side effects. The incidence of astigmatism greater 
than 7.00 D is low. As this case report illustrates, full correction of astigmatism is 
not necessary to achieve an excellent BCVA in a patient with marginal corneal 
degeneration. Possible explanations of this are that the correcting cylinder of the 
IOL is closer to the nodal point of the eye or that full correction of astigmatism 
is not necessary because of the extreme irregularity. 
The toric Artisan IOL cannot be implanted through a small incision. This can 
result in induced astigmatism, adding a level of unpredictability to the final 
result. The induction of astigmatism was negligible compared with the high 
astigmatism already present in this patient, however, and a change of only 
0.5 D in corneal astigmatism with an axis shift of 5 degrees was seen after the 
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procedure. With anterior chamber IOL implantation, there is a possible risk for 
damage to the endothelium but the endothelial cell loss is probably the result 
of the surgical procedure.26,28,29 Extensive follow-up and accurate methods to 
evaluate mean endothelial cell count are necessary to determine the long-term 
effect of iris-claw IOLs on endothelial cell loss. In this patient, endothelial cell 
counts with the Topcon 2000 specular microscope revealed a small decrease in 
the left eye and a small increase in the right eye. This may reflect the inaccuracy 
of counting methods. 
To our knowledge, there is only one report of the implantation of an Artisan 
toric phakic IOL to correct high astigmatism.4 This high astigmatism occurred 
after PKP. We believe our patient is the first in whom high astigmatism from 
marginal corneal degeneration was corrected with the Artisan toric phakic IOL. 
Marginal corneal degeneration is usually a contraindication for corneal refrac-
tive surgery.30,31 This patient’s visual improvement might not have been achieved 
through more common methods of refractive surgery.
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ABSTRACT
Purpose: To evaluate the correction of astigmatism and spherical ametropia in patients with kerato-
conus through implantation of an Artisan toric phakic intraocular lens (PIOL) (Ophtec, Groningen, 
The Netherlands).
Methods: Artisan toric PIOLs were implanted uneventfully in both eyes of three patients with kera-
toconus with clear central corneas and contact lens intolerance.
Results: Best spectacle-corrected subjective visual acuity after lens implantation was unchanged in 
one eye and improved in five eyes. Spherical equivalent refraction was significantly reduced in all 
eyes (P = 0.03). The safety index was 1.44. 
Conclusions: The implantation of an Artisan toric PIOL may be an alternative for treating astigma-
tism and myopia in contact lens intolerant patients with keratoconus with clear central corneas. 
Especially in patients with associated myopia, this procedure is worth considering before planning 
a penetrating keratoplasty.
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INTRODUCTION
Keratoconus is a non-inflammatory condition characterized by ectasia and thin-
ning of the cornea, inducing myopia and astigmatism. The disease usually starts 
around puberty and progresses slowly and may stabilize at a later age. In the 
early stages, spectacles and contact lenses are the usual treatment of choice. 
If a patient becomes contact lens intolerant, treatment consists of penetrating 
keratoplasty (PK) or lamellar keratoplasty (LK). Although good visual results usu-
ally are achieved with PK in patients with keratoconus,1 visual recovery after the 
operation is long.2 Frequent postoperative follow-up and use of corticosteroids 
for a prolonged time are necessary, and high astigmatism is a major postopera-
tive complication.
In view of this, other treatment modalities could be preferred in an attempt 
to delay or avoid PK in select patients with contact lens intolerance and clear 
corneas. The implantation of a toric phakic toric intraocular lens might be a 
surgical alternative, especially as high myopia and an anterior chamber depth 
>3.0 mm often are associated with keratoconus.3 The Artisan toric phakic in-
traocular lens (PIOL) (Ophtec, Groningen, The Netherlands) has been shown 
to correct high ametropia and astigmatism with a stable and fairly predictable 
refractive outcome.4 Artisan toric PIOLs are available with a cylindrical power 
of up to 7.0 diopters (D) and a spherical power ranging between –3.0 and -23.5 
D for myopia and +1 and +12 D for hyperopia. Therefore, these lenses can be 
used to correct high astigmatism and ametropia present in keratoconus. This 
article presents three contact lens intolerant patients with keratoconus with clear 
central corneas who were treated with the Artisan toric PIOL in both eyes.
METHODS
Artisan toric PIOLs were implanted between May 2002 and April 2003 in six 
eyes of three patients with keratoconus. All patients had a clear central cornea, 
were contact lens intolerant in at least one eye, and requested refractive surgery. 
After informed consent was given, patients underwent implantation of an Artisan 
toric PIOL. The Artisan toric PIOL is an iris-fixated anterior chamber implant 
of Perspex CQ-UV polymethylmethacrylate with ultraviolet filtration. Its overall 
diameter is 8.5 mm and the optical zone diameter is 5.0 mm. As some surgeons 
prefer to insert the lens through a temporal incision and to allow optimal im-
plantation to the correct axis, two models are available. In Model A the axis runs 
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through the claws 0º and in Model B the axis is perpendicular to the line that 
runs through the claws (90º). 
Pre- and postoperative examination of all patients included slitlamp biomicros-
copy, determination of best spectacle corrected visual acuity (BSCVA), manifest 
refraction, tonometry, keratometry (autokeratometer), measurement of mesopic 
pupil diameter (Colvard pupillometer), endothelial cell count (non-contact 
specular microscopy, Topcon SP-2000 P, Tokyo, Japan), A-scan biometry (mea-
surement of the anterior chamber depth) and indirect ophthalmoscopy. Exclu-
sion criteria were uveitis, previous corneal or intraocular surgery, and systemic 
disease. The normally used exclusion criterion in refractive surgery of endothelial 
cell count < 2000 cells/mm2 was not an absolute exclusion criterion in our study 
with pathologic corneas. Four days before surgery, patients were asked to apply 
indometacine 0.1% four times daily in both eyes. Surgery was performed under 
general anaesthesia by one surgeon (C.B.). Lenses were implanted in both eyes 
of one patient simultaneously, with a change of gloves and use of separate sets 
of surgical instruments for the second eyes. The surgical technique followed 
standard protocol as described in the toric PIOL European Multicenter Study.4 
A 5.5 mm corneoscleral incision was made superiorly and two paracenteses 
were made at 10 and 2 o’clock. After instillation of a cohesive viscoelastic fluid 
(Healon GV; Pharmacia & Upjohn, Kalamazoo, Mich), the Artisan toric PIOL 
was implanted and enclavated onto the iris. The enclavation sites on the iris 
were marked before surgery with an argon laser. An iridotomy was performed at 
12 o’clock to prevent angle-closure glaucoma. The incision was closed with a 
10-0 nylon running suture. On discharge patients were prescribed predmycine 
(Allergan, Antwerpen, Belgium) eyedrops four times daily and a combination 
of dexamethasone/neomycine/polymyxine ointment to be applied at night for 
2 weeks. The appropriate power of the toric PIOL was calculated using the Van 
der Heijde formula.5 
Follow-up took place 2 days, 2 weeks, 6 weeks and 6 months after surgery. At 
follow-up, patients were asked to report subjective complaints, such as monocu-
lar diplopia, halos or glare. Patients were asked to rate their overall satisfaction 
with their vision after implantation on a scale from 1 to 5 (with 1 being very poor 
and 5 being excellent). To analyze safety index (mean postoperative BSCVA / 
mean preoperative BSCVA) and efficacy index (mean postoperative uncorrected 
visual acuity / mean preoperative BSCVA), Snellen visual acuity was converted 
into logarithm of the minimum angle of resolution notation to calculate the mean 
and then transformed back into Snellen visual acuity. Vector analysis was used to 
analyze surgical-induced refractive correction.6,7 For this purpose, preoperative 
and 6-months BSCVA refraction results were used. To analyze surigical-induced 
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corneal astigmatism (ie, incisional-induced astigmatism), vector analysis of pre- 
and postoperative keratometric values was used.6,7 Student paired t test (P < 
0.05) was used to analyze the change in spherical equivalent refraction after 
implantation. 
RESULTS
Implantation of the Artisan toric PIOL was performed uneventfully in all six 
eyes. Preoperative patient characteristics are shown in Table 1. Preoperatively, 
intraocular pressure was normal in all eyes (range: 9 to 16 mmHg). No patient 
had evidence of cataract or had undergone prior ocular surgery. Funduscopy re-
vealed myopic atrophy in the third patient. Contact lens intolerance was present 
in all patients. Contact lens wear had to be discontinued in the third patient due 
to the development of corneal neovascularization. All patients had keratoconus 
and a transparant central cornea. Probably due to the high refractive error and 
corneal irregularities, there was a low repeatibility between different preopera-
tive keratometric and objective refraction measurements in the left eye of the 
last patient, making appropriate power calculations of the toric PIOL difficult. 
Moreover, the lens power required by the third patient was not available. She 
was therefore given the strongest available lens. Follow-up ranged from 6 months 
to 1 year. Postoperative BSCVA was stable from 6 weeks onward and improved 
in five eyes and remained unchanged in one eye. Preoperative and 6-months 
follow-up refractive data are presented in Table 2. The safety index was 1.44 
and the efficacy index was 1.24. Preoperative spherical equivalent refraction 
was –13.88 D (range: –4.00 to –29.00 D). Mean spherical equivalent refraction 
Table 1. Characteristics of study patients with keratoconus who underwent implantation of 
an Artisan toric phakic intraocular lens
Patient/
Sex/
Age
Eye ACD (mm) Endothelial
cell count
(cells/mm2)
Axial length
(mm)
Mesopic
pupil (mm)
1/M/27 R 3.56 1625 23.64 4
L 3.79 2384 24.06 4
2/M/26 R 3.91 3100 25.36 5
L 3.45 2900 24.04 5
3/F/44 R 3.45 2300 30.11 4.75
L 3.56 1800 29.94 4.75
ACD, Anterior Chamber Depth
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postoperatively was -0.29 D (range: +1.00 to –2.00 D). Reduction in spherical 
equivalent refraction was significant (P = 0.03). Postoperatively, four of the six 
eyes were within ± 1.00 D of emmetropia. The average magnitude of refractive 
astigmatism was -3.75 D (range: –2.00 to –6.00 D) preoperatively and –1.33 D 
(range: 0 to –2.50 D) postoperatively. Incisional-induced corneal astigmatism 
and surgical-induced refractive correction are presented in Table 3. Based on the 
change in keratometry pre- and postoperatively the average incisional-induced 
cylinder was 1.14 D (range: 0.28 to 3.00 D).
None of the patients experienced pigment cell deposits on the crystalline lens 
or posterior synaechiae. Two patients reported mild glare (starburst or acuity 
Table 2. Preoperative and 6- month postoperative refractive data of patients with 
keratoconus who underwent implantation of an Artisan toric phakic intraocular lens
Preoperative Postoperative (6 months)
Patient/
Eye
PTIOL
power
Axis BSCVA SR keratometry BSCVA SR keratometry ECC
1/R -12 – 5.5
x 0
15 20/50 -11 – 6
x 15
52.87/58.37 
x 111
20/30 0 – 2.5
x 45
52.87/57.37
x 105
3500
1/L -3.5 – 5
x 0
135 20/30 -3 – 4.5
x 135
46.25/50.75 
x 47
20/30 -1 – 2
x 105
46.00/50.25
x 46
2558
2/R -4 – 2
x 0
45 20/25 -3 – 2
x 63
41.25/42.87 
x 120
20/20 plan 41.37/43.00
x 115
3200
2/L -4 – 3
x 90
28 20/50 -3.5 – 3
x 118
41.50/44.37 
x 49
20/30 1 – 1.50
x 164
41.25/44.50
x 44
2800
3/R -21 – 2
x 90
155 20/40 -24.5 – 3
x 65
48.75/51.00 
x 121
20/25 1 45.75/47.25
x 129
2500
3/L -21 – 2
x 90
175 20/60 -27 – 4
x 85
47.00/51.25 
x 30
20/40 1.25 – 2
x 153
45.75/47.00
x 31
2100
PTIOL, phakic toric intraocular lens; BSCVA, best spectacle corrected visual acuity; SR, subjective 
refraction; ECC, endothelial cell count
Table 3. Surgical-induced refractive correction and incisional-induced corneal 
astigmatism
Patient/Eye Surgical-induced refractive
correction
Incisional-induced corneal
astigmatism
1/R -10.14 – 5.22 x 3 1.44 x 41
1/L -1.30 – 3.90 x 148 0.52 x 145
2/R -3.00 – 2.00 x 63 0.28 x 74
2/L -3.55 – 3.40 x 104 0.65 x 19
3/R -25.50 – 3.00 x 65 0.91 x 17
3/L -26.44 – 5.61 x 78 3.00 x 120
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distortion noted at night but not interfering with function). No patient reported 
monocular diplopia. All patients were satisfied with the result. Mean subjec-
tive response for satisfaction was 4.17 using the previously described scale. All 
patients tolerate spectacle correction of the remaining refractive error. 
DISCUSSION
Many patients with keratoconus can be succesfully fitted with modern contact 
lenses, which can reduce the number of patients requiring surgery. However, 
some patients cannot be corrected with contact lenses succesfully. Patients 
with globus cones, which may involve a large part of the cornea and may have 
a inferotemporally thinning in the periphery of the cornea, have trouble with 
contact lens fitting, and in these patients, a corneal graft may be more diffi-
cult to perform and frequently results in a high postoperative astigmatism. For 
these patients, the implantation of a toric PIOL can be an alternative to reduce 
spherical equivalent error and astigmatism. In our small study, visual acuity 
improved in almost all eyes compared to preoperative measures, and thereby at 
least postponed the need for PK. Because keratoconus is a progressive disorder, 
refraction is not expected to remain stable after the implantation of a toric PIOL. 
However, a PK in the future is unlikely to be negatively affected by the prior im-
plantation of a PIOL. Furthermore, toric IOLs could be exchanged if necessary. 
Currently, patients with keratoconus and contact lens intolerance are primarily 
treated with PK or LK.8-10 However, slow visual rehabilitation after keratoplasty 
is a disadvantage. Further surgical options such as laser in situ keratomileusis 
remain limited as keratoconus is considered a contraindication because of poor 
refractive stability and the risk of progressive keratectasis.11,12
In an effort to postpone or prevent PK and to shorten visual rehabilitation, 
various other surgical options have been investigated. Colin et al.13 reported 
the results of INTACS inserts for keratoconus in 10 patients, and the Ferrara 
intrastromal corneal rings were used in a study on 26 patients by Siganos et al..14 
In both studies the spherical equivalent error and astigmatism were significantly 
reduced. However, the amount of possible reduction of myopia and astigma-
tism is probably less with INTACS or Ferrara intrastromal rings than with toric 
PIOLs. Especially in higher ametropia and astigmatism such as > –10 D myopia 
or > 2 D astigmatism, toric PIOLs might be a more suitable option. The large 
reduction of myopic error in our last patient would not have been possible with 
INTACS or Ferrara intrastromal corneal ring segments. Progression of the disease 
is not suspected to slow down after toric PIOL implantation. Although corneal 
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ring segments may reshape or reinforce the abnormal cornea, there is also no 
evidence that they can stop disease progression. Besides, the predictability of 
corneal implants in keratoconus is not yet high and a relative high residual re-
fractive error might remain. Epikeratoplasty and LK have also been investigated 
as alternatives to PK for patients with keratoconus; owever, PK was found to be 
statistically superior with respect to visual outcome.15,16 
Limitations of the Artisan toric PIOL are a cylindrical power of 7 D, a myopic 
power of 23.5 D and an optical zone of 5.0 mm. In high myopia, the small 
5.0 mm optical zone may produce halo effects and glare in dim illumination 
conditions. Two of our patients reported glare after the operation; however, this 
complaint did not interfere with function. The reduction in spherical error in all 
six eyes was higher (87.4%) than the reduction in astigmatic error (64.5%), sug-
gesting a high predictability for spherical errors, but a moderate predictability for 
astigmatic errors. This was partly caused by the limitation of maximum available 
spherocylindrical correction and may have also been caused by difficulty in 
measuring the astigmatism. 
The Artisan toric PIOL cannot yet be implanted through an incision smaller 
than 5.5 mm. This can also result in induced astigmatism, adding a level of 
unpredictability to the final result. Dick et al.4 reported a incisional-induced 
astigmatism of 0.53 D after implantation of toric PIOLs for correcting ametropia 
with astigmatism in nondiseased eyes. The contribution of the incisional-in-
duced astigmatism to the level of unpredictability in our small study seems to 
be relatively low in five eyes (average 0.76 D). Only the left eye of the third 
patient had a large cylinder. This may be due to a low repeatibility of preop-
erative keratometry and refractive measures. Furthermore, the biomechanics of 
keratoconic corneas are not the same as those of normal corneas. Although 
keratometry results can also change due to progression of the keratoconus, it 
is difficult to analyze only the incisional-induced astigmatism. Progression of 
keratoconus leading to refraction change is a concern after implantation. Ideally, 
toric PIOL implantation should not be performed until keratometry and subjec-
tive refraction are stabilized. This implies that toric PIOL implantation should 
not be performed in recently diagnosed keratoconus or in younger patients with 
a progressive keratoconus. However, it is possible that there is no stabilization 
at any time.17 A longer period of poor vision can have significant implication for 
young adults. After discussing the risk of an inadequate correction due to possible 
progression with the patient we believe that toric PIOL implantation is permitted 
if keratometry is not changed significantly over the past 6 months. Preoperative 
BCSVA should be at least 20/60, otherwise a PK is expected to have a superior 
visual outcome. Furthermore, patients are only good candidates for toric PIOL 
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implantation if subjective refraction is possible. This is typically complicated by 
the reduced repeatability of subjective refraction in patients with keratoconus 
compared to nondiseased eyes, as was certainly a problem in the left eye of 
the third patient.18 An aveage subjective refraction, which was well tolerated 
by this patient was used for lens calculation. Moreover, there is a possible risk 
of damage to the endothelium, with anterior chamber IOL implantation. In our 
patients, however, we did not observe endothelial cell loss at 6 weeks postop-
eratively. Endothelial cell count in the right eye of the first patient was incredibly 
high after implantation compared to preoperative measurement. Inaccuracy of 
the present counting methods for pathologic corneas might also underlie the 
inconsistency in endothelial cell count among pre- and postoperative periods. 
Endothelial cell count might be misleading in patients with keratoconus because 
of an uneven distribution of endothelial cells. Contact lens wear for a prolonged 
time is related with higher pleomorphism and polymegatism of endothelial cells 
in patients with keratoconus.19 With anterior chamber IOL implantation, there is 
a risk of damage to the endothelium. This remains a cause for concern. Studies 
on toric PIOL implantation in nondiseased eyes use endothelial cell count of 
<2000/mm2 as an exclusion criteria.4 We believe that in keratoconus eyes a 
lower cell density is also permitted if a PK is considered as the alternative to 
restore visual acuity. If PK becomes necessary after toric PIOL implantation, it 
is always possible to remove the lens at surgery. Implantation of a new Artisan 
toric lens after transplantation adjusted to postoperative refractive data is also an 
option.20 A disadvantage of a possible earlier corneal decompensation after toric 
PIOL implantation would be a less favorable indication for transplantation (ie, 
bullous keratopathy instead of keratoconus).1 
Our short-term results in this small series of patients are encouraging. Visual 
rehabilitation was rapid in all patients. No serious complications occurred. The 
implantation of a toric PIOL can be an alternative for correcting astigmatism 
and myopia in contact lens intolerant patients with keratoconus and clear 
central corneas. Long-term results and additional patients are needed to draw 
strong conclusions regarding the predictability for astigmatic correction and the 
influence of this procedure on the outcome of possible PK. In the meantime, 
especially in patients with associated myopia, this procedure can be worth 
considering before planning PK.
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ABSTRACT 
Purpose: To evaluate postoperative astigmatism with regard to incisionally induced astigmatism and 
deviation in axial alignment with the use of preoperative limbal marking with the Javal keratometer 
in eyes implanted with the Artisan toric phakic intraocular lens (IOL).
Design: Prospective nonrandomized trial. 
Participants: Fifty-four eyes of 33 patients with myopia (mean –9.67 D) and astigmatism (mean –3.44 
D). 
Intervention: The enclavation site was marked on the limbus using the Javal Keratometer. The Artisan 
toric phakic IOL was then implanted according to the axis marked on the limbus. Follow-up was a 
minimum of 6 months.
Main outcome measures: Safety index, efficacy index, predictability and vector analysis of total 
refractive correction were determined. The effect of axis misalignment and incisionally induced 
astigmatism on the final results were evaluated.
Results: At 6 months postoperative the safety index was 1.29 ± 0.29 and the efficacy index was 1.04 
± 0.35. Mean spherical equivalent subjective refraction reduced from –11.39 ± 4.86 preoperatively 
to –0.38 ± 0.57 D at 6 months. Mean preoperative cylinder was 2.94 ± 1.47 D at an axis of 90.9°. 
At 6 months the mean cylinder was 0.28 ± 0.54 D at an axis of 174.3°. Vector analysis of total 
surgically induced astigmatism revealed a mean cylindric change of 3.21 ± 1.71 D. Average axis 
misalignment was 0.37 ± 5.34°. The mean incisionally induced astigmatism was 0.75 ± 0.61 D at 
178.5 ± 26.2°.
Conclusions: Implantation of the myopic toric IOL leads to safe, efficacious and predictable results. 
The level of unpredictability caused by axis IOL misalignment has a minor effect on the residual 
refractive error. The procedure of axis alignment with the Javal keratometer appears to be an accurate 
method of marking the eye for toric IOL implantation. Incisionally induced astigmatism can result in 
an overcorrection of the cylinder. A systematic undercorrection of –0.50 D for attempted cylindric 
outcome could result in an achieved correction closer to emmetropia.
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INTRODUCTION
Achieving emmetropia or other desired refractions is challenging when spheri-
cal ametropia is combined with astigmatism. Keratorefractive procedures with 
excimer laser have shown to be accurate for the treatment of mild to moderate 
myopia combined with astigmatism.1 Among higher refractive errors, however, 
such procedures can lead to complications related to small optical treatment 
zones, preparation of the flap and to the irreversible weakening of the cornea.2,3 
Over the last few years, studies on diverse phakic intraocular lenses (IOLs) have 
demonstrated satisfactory results in the correction of high ametropia.4-6 
The Artisan toric phakic (TP)IOL can be used for the combination of myopia 
and astigmatism. It is an iris-fixated anterior chamber implant of Perspex CQ-
UV polymethylmethacrylate with ultraviolet filtration. Its overall diameter is 8.5 
mm with an optical zone diameter of 5.0 mm. The myopic toric Artisan IOL is 
available in half diopter (D) increments with a cylindrical power up to 7.5 D and 
a spherical power from –3.0 to –23.5 D. Two models of TPIOLs are available to 
allow lens insertion through a temporal incision and to allow optimal implanta-
tion on the correct axis. In Model A, the axis runs through the claws at 0º and 
in Model B, at 90º. 
Several studies published recently on the outcome of the TPIOL have dem-
onstrated good results.7-10 The Artisan lens has also shown to be rotationally 
stable.8,11 A drawback of the lens, however, is that it requires an incision of 5.2 
to 5.5 mm. This incision can induce corneal astigmatism. 
Precise enclavation of the lens is paramount. Especially in higher degrees of 
astigmatism, minimal misalignment greatly reduces the corrective value of the 
lens, as approximately one third of the cylindric correction is lost if the IOL 
is rotated 10 degrees off axis.12 Some surgeons mark the enclavation sites on 
the iris with the Argon or YAG laser.7 Although this procedure appears to be 
accurate, laser burns can cause inflammatory reactions, iris bleeding or endo-
thelial cell loss.13,14 As laser burns have to be placed at least one week prior to 
lens implantation, they also create logistical efforts. Other surgeons use a digital 
image system, in which the axis is projected on the iris. This image can be used 
during surgery to find the correct lens position. At our center, the intended posi-
tion of enclavation is marked on the corneal limbus using the Javal keratometer, 
directly prior to anaesthesia. 
In this single center prospective study, we evaluate the safety, efficacy and 
predictability of the toric Artisan myopia phakic IOL. We further assess the 
influence of accurate axis lens placement using corneal markings with the Javal 
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keratometer and study the effect of astigmatism induced by the incision on the 
total surgically induced refractive correction of myopic astigmatism. 
PATIENTS AND METHODS
Fifty-four consecutive eyes of 33 TPIOL patients were enrolled in this prospective 
study. Lens implantations were performed by one surgeon (GL) between 2000 
and January 2004. Inclusion criteria consisted of the following: 1. General good 
health. 2. A minimum of 18 years of age. 3. Stable refraction for a minimum of 
one year 4. Astigmatism greater than 1.5 D combined with myopia 5. Absence 
of ocular pathology 6. Endothelial cell count greater than 2000 cells/mm2 7. 
Anterior chamber depth greater than 3.0 mm (including corneal thickness) 8. 
Mesopic pupil size equal to or less than 5.0 mm. Informed consent in accor-
dance with the Helsinki Declaration was obtained for each patient. 
Prior to preoperative examination, patients were requested to discontinue 
contact lens wear for a minimum of 14 days to avoid the possibility of contact 
lens induced corneal warpage. The examination included best spectacle cor-
rected visual acuity (BSCVA) in Snellen notation, slitlamp biomicroscopy, endo-
thelial cell count (Topcon SP-2000-P), keratometry (autokeratometer, Topcon KR 
7000P), A-scan immersion biometry, applanation tonometry, measurement of 
mesopic pupil diameter (Colvard pupillometer), and indirect ophthalmoscopy. 
Furthermore, objective refraction was measured with cyclopentolate hydrochlo-
rate 1.0% eyedrops to exclude any accomodative error in subjective refraction. 
If large differences were found between the two refractive errors, subjective 
refraction was measured again. The power of the IOL, including the intended 
axis of enclavation, was calculated according to the Van der Heijde formula.15
Intended axes were marked preoperatively onto the corneal limbus with a 
surgical marker guided by the reflected images of the Javal keratometer. Myotic 
drops (pilocarpin 4%) were administered to prepare the iris for lens fixation. 
The intervention was performed under general or retrobulbar anaesthesia. A 
corneoscleral bevelled incision of 5.5 mm was made at the steep meridian and 
paracenteses were placed 8 mm apart at either side. The anterior chamber was 
opened and filled with viscoelastic fluid (Healon®) to maintain its depth and to 
protect the endothelium. After introduction of the lens into the anterior cham-
ber with the holding forceps (Ophtec REF D02-70), it was positioned onto the 
desired axis and then fixed onto the midperipheral iris stroma with a disposable 
enclavation needle. A slit iridotomy was performed at 12 o’clock to prevent 
angle-closure glaucoma, whereafter the viscoelastic material was manually ir-
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rigated. The incision was closed with a 10-0 nylon running suture. If both eyes 
were to be operated, interventions were separated by a minimum of two weeks. 
Postoperative treatment included ketorolac and dexamethasone 0.1% eyedrops 
four times a day for 4 weeks.
Follow-up examinations were scheduled at 1 day, 1 week, 1 month, 2 months, 
6 months and 1 year after surgery and on a yearly basis thereafter. Postoperative 
examinations included slitlamp biomicroscopy, endothelial cell count (from 6 
months postoperative onwards), keratometry, applanation tonometry, subjective 
and objective refraction, uncorrected visual acuity (UCVA) and BSCVA. Within 
the first 6 postoperative weeks, sutures were dissected or removed if they created 
undesirable corneal astigmatism. After 6 weeks, sutures were removed if they 
caused discomfort or had loosened. At 1 month follow-up, the Javal keratometer 
was used to determine the postoperative IOL axis alignment. Axis misalignment 
was defined as the difference between intended and achieved axis. The postop-
erative IOL position was measured without knowledge of the intended axis of 
implantation by one of the investigators (MB). Furthermore, patients were asked 
if they experienced halo or glare. 
All data were collected prospectively from patient charts during follow-up 
examinations.
Statistics
To analyse BSCVA, UCVA, safety index (mean postoperative BSCVA / mean 
preoperative BSCVA) and efficacy index (mean postoperative UCVA / mean pre-
operative BSCVA), Snellen visual acuity was first converted into logarithm of the 
minimum angle of resolution (logMAR) notation to calculate the mean and then 
transformed back into Snellen visual acuity. Change in cylindrical refraction was 
calculated with vector analysis.12 
Cylindrical refractions were transformed into double-angle vectors and rect-
angular coordinates, as described by Holladay.12 The double-angle vector plots 
chart the cylinders horizontally (parallel, x-coordinates) and vertically (orthogo-
nal, y-coordinates). After calculation, the horizontal and vertical components 
were transformed back to cylinders. 
Total surgically induced refractive change in astigmatism was calculated with 
the use of vector analysis using cylindrical subjective refraction results.12 
Incisionally induced astigmatism was defined as the vector of the change that 
occurred based on preoperative and postoperative keratometry values. In this 
analysis, eyes in which additional operations were performed after implantation 
were excluded to prevent possible bias (n = 3). Furthermore the one eye with 
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a Model B lens implantation was also excluded, as it was the only eye with an 
incision on the flat axis. 
Comparison of data between preoperative and postoperative periods were 
performed with Student t-test for paired data using a level of significance of p = 
0.05. A likelihood test was performed to evaluate the stability of refractive results 
during follow-up.
RESULTS
Patient population
All 54 eyes of the 33 patients were followed-up for a minimum of 6 months. 
At one year, follow-up data was available for 45 eyes of 27 patients and at 
two years, 20 eyes of 14 patients. Mean follow-up was 17.1 ± 11.4 months. 
Twenty-three of the 33 patients were female (69.7%). Mean age was 39.5 ± 2.0 
years (range: 19 - 57 years). Average axial length was 27.34 ± 0.27 mm (range: 
23.72 - 32.54 mm) and average anterior chamber depth was 3.66 ± 0.31 mm 
(range: 3.18 - 4.32 mm). Mesopic pupil diameter averaged 4.7 ± 0.9 mm (range: 
3.0 –7.0 mm). Surgery was performed with the use of retrobulbar anaesthesia 
with the exception of 13 eyes of 7 patients where surgery was performed under 
general anaesthesia. Model A was implanted in 53 eyes and Model B in 1 eye.
Table 1. Preoperative and postoperative refractive results
Preoperative Postoperative
(54 eyes, 33 
patients)
6 months
(54 eyes, 33 
patients)
12 months
(45 eyes, 27 
patients)
24 months
(20 eyes, 14 
patients)
SE (mean) ± SD (D), (range) -11.39 ± 4.86,
(–2.13 to -25.63)
-0.38 ± 0.57,
(-2.25 to +0.75)
-0.44 ± 0.62,
(-2.75 to +0.50)
-0.44 ± 0.51,
(-2.13 to 0.00)
Mean vectorial astigmatism 
(D) x axis
2.94 ± 1.47 x 90.9° 0.28 ± 0.54 x 
174.3°
0.23 ± 0.54 x 
173.9°
0.26 ± 0,43 x 
175.4°
Mean UCVA ± SD 0.72 ± 0.28 0.70 ± 0.28 0.75 ± 0.26
Mean BSCVA ± SD 0.71 ± 0.23 0.88 ± 0.23 0.85 ± 0.25 0.94 ± 0.25
± 1.00 D of emmetropia (%) - 88.9 90.7 95.0
± 0.50 D of emmetropia (%) - 66.7 65.1 70.0
Loss ≥ 2 lines BSCVA - 0 1 (2.2%) 0
Gain ≥ 1 line BSCVA - 40 (74.1%) 33 (73.3%) 14 (70.0%)
SE, spherical equivalent refraction; UCVA, uncorrected visual acuity; BSCVA, best spectacle 
corrected visual acuity
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Visual acuity and refraction
Preoperative refractive measurements are presented in Table 1, along with the 
postoperative spherical equivalent (SE) of subjective refraction, UCVA, BSCVA 
and percentages of eyes within ± 1.00 D or ± 0.50 D of emmetropia at 6 months, 
1 year and 2 years. The deviation of the achieved SE correction from attempted 
SE correction at 6 months is presented in Figure 1. Average BSCVA improved 
significantly after implantation with 0.71 ± 0.23 preoperatively to 0.88 ± 0.23 
at 6 months (p < 0.001). A gain of one or more BSCVA lines was seen in 74.1% 
of the eyes at 6 months. The safety index after 6 months and 1 year was 1.29 
and 1.26, respectively. The efficacy index was 1.04 at 6 months and 1.02 at one 
year.
Surgically and incisionally induced astigmatism
The mean preoperative astigmatism using vector analysis was –2.94 ± 1.47 D 
for the horizontal component (x) and –0.09 ± 1.52 D for the vertical component 
(y), equivalent to a cylinder of 2.94 ± 1.50 D at an axis of 90.9°. A double-angle 
minus cylinder plot of preoperative subjective cylinder is presented in Figure 2. 
At 6 months, the total surgically induced refractive change was 3.21 ± 1.71 D 
at an axis of 0.3°. Based on the amount of cylindric correction of the implanted 
IOL, average attempted cylindric outcome was –0.14 D at 180º. Mean achieved 
postoperative astigmatism at 6 months was + 0.28 ± 0.57 D for x and -0.06 ± 
0.51 D for y, translating to a cylinder of +0.28 ± 0.54 D at a mean axis of 174.3° 
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Figure 1. Attempted spherical equivalent versus achieved subjective spherical equivalent at 
6 months postoperative.
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(Figure 3). There was no significant difference in postoperative astigmatism dur-
ing all the follow-up periods (likelihood ratio test, p = 0.47). 
From 2 months postoperative, keratometric data remained stable (Figure 4). 
Suture removal at any time after 2 months did not significantly influence kerato-
metric data. Average incisionally induced astigmatism calculated after 2 months 
was + 0.75 ± 0.61 D at a mean axis of 178.5°. Considering this incisionally 
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Figure 2. Double-angle plot of minus cylinder of subjective preoperative refraction.
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Figure 3. Double-angle plot of minus cylinder of subjective refraction 6 months 
postoperatively.
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induced astigmatism, mean expected cylindric outcome changed from –0.14 D 
at 180° to + 0.61 D at an axis of 178.1°.
Axis misalignment
The mean difference between the achieved and the intended axis alignment of 
the lens was 0.37 ± 5.34° (range -13 to +14°). The mean absolute deviation was 
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Figure 4. Mean absolute incisionally induced astigmatism in diopters at different follow-up 
periods.
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Figure 5. Postoperative deviation in attempted axis of enclavation per eye.
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4.15 ± 3.34°. Axis misalignment is presented in Figure 5. The position of an IOL 
with a cylindric correction of –7.0 D had to be changed in one eye due to a 
residual cylinder of –1.75 D at 130º in combination with an axis misalignment 
of 8°. After changing the IOL position, the residual cylinder decreased to -0.50 
D at 65°. An axis misalignment of more than 10º was seen in two eyes only. 
The correcting cylinders of these toric IOLs were –2.00 and –3.00 D. In the first 
of these two eyes, no subjective residual astigmatism was seen, despite an axis 
deviation of 14º. In the second eye, a deviation of -13º from the target axis was 
found, resulting in a residual subjective cylinder of –1.00 D. 
The average (absolute) spectacle cylindric error as a result of axis misalign-
ment was calculated to be 0.16 ± 0.12 D. The attempted cylindric correction, 
-0.14 D at 180º, changed marginally to –0.15 D at 180º, when the known axis 
deviation for each lens was accounted for.
Endothelial cell loss
Mean preoperative endothelial cell count was 2724 ± 388 cells/mm2 (range: 
1577 - 3463). Mean postoperative endothelial cell count was not significantly 
different from mean preoperative endothelial cell count with 2779 ± 458 cells/
mm2 (range: 1658 - 3784) at 6 months, 2783 ± 475 cells/mm2 (range: 1658 
- 3591) at 1 year and 2717 ± 356 cells/mm2 (range: 2249 - 3344) at 2 years 
(Paired t-test, p > 0.45). 
Complications
Intervention was uneventful in all patients. One patient developed a wound 
leak after suture removal at one week, requiring resuturing of the incision. One 
patient, with a preoperative asymptomatic retinal break treated with Argon 
laser, developed a retinal detachment 10 days after surgery. At 1 year follow-up, 
BSCVA in this eye was 0.40, compared to 0.50 preoperatively. 
The mean preoperative intraocular pressure (IOP) was 15.3 ± 3.4 mmHg. 
Seven eyes developed a temporary IOP rise above 21 mmHg within the first 
month of surgery (range: 22-30 mmHg), although it normalized in all eyes 
after discontinuing topical corticosteroids. The mean postoperative IOP over 
all follow-up periods (15.7 ± 3.4 mmHg) did not differ significantly from the 
preoperative values (p > 0.25). 
One eye in the study experienced a significant loss of lines after developing 
cataract one year postoperatively. Visual acuity decreased from 0.4 preoperative 
to 0.2 postoperative. To our knowledge, surgery had been uneventful. 
No pigment dispersion or pupillary block occurred in any eyes during the 
follow-up period. Seven of the 33 patients noted having more difficulty with 
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haloes or glare postoperatively. Only one of the patients with such a complaint 
had a mesopic pupil size greater than 5 mm. All patients were satisfied with the 
outcome of surgery. No patient considered removal of the lens.
DISCUSSION
The safety, efficacy and predictability of phakic toric Artisan lens implantation 
for the correction of myopia and astigmatism in this study were high. The toric 
Artisan lens was investigated before in a large European Study. The effect of axis 
misalignment and incisionally induced astigmatism on the final outcome were 
not analyzed in that study by Dick et al.. In our study we demonstrated that the 
intended astigmatism correction was a slight undercorrection of 0.14 D. The 
final result of the astigmatism correction was, however, an overcorrection of 
0.28 D. We analyzed the effect of incisionally induced astigmatism and axis 
misalignment on the refractive outcome. We found that we introduced an against 
the rule astigmatism of 0.75 D by making the incision of 5.5 mm at the steep 
axis. This induced astigmatism is also known to result after cataract surgery.16,17 
Taking into account the incisionally induced astigmatism, the expected cylinder 
outcome was a 0.61 D overcorrection. Instead of this amount we observed a 
smaller overcorrection of 0.28 D. Besides incisionally induced astigmatism, axis 
misalignment can also create unpredictability to the final result. Proper surgical 
alignment of the IOL is a prerequisite for the success of TPIOL implantation. Due 
to the firm fixation of the Artisan lens to the midperipheral iris stroma, rotation 
of the lens has not been observed. Hence, axial misplacement of an iris-claw 
lens is caused by incorrect alignment of the lens during the surgical procedure. 
We found an absolute axis deviation of 4.15 ± 3.34º, which is comparable with 
the deviation found in the study by Tehrani et al..8 Although most surgeons use 
preoperative laser iridotomies to mark the axis, our center uses limbal marking 
with the use of the Javal keratometer. This method does not incur the risk of in-
traocular inflammation and can also prove to be practical for the surgeon, as the 
marking can take place directly preoperative, avoiding an extra patient visit. One 
disadvantage of this method, however, is that the marking can fade or disappear 
during preoperative preparation of the eye. We encountered this problem in one 
eye, resulting in a deviation of -14º from the intended axis. Another lens required 
realignment after developing a subjective postoperative cylinder of –1.75 D. The 
effect of the misalignment on the final cylindric outcome is however small. The 
mean attempted cylindric outcome of –0.14 D at 180º, changed marginally to 
–0.15 D at 180º, when the known axis error for each lens was accounted for. 
122
C
ha
pt
er
 7
Both incisionally induced astigmatism and axis misalignment could not explain 
the discrepancy between expected and achieved cylindric corrections. Several 
other factors could have influenced the achieved correction. Firstly, fixed factors 
such as the lens only being available in increments of half diopters and a calibra-
tion error of ± 0.3 D of the lens itself can decrease precision. Secondly, our data 
are based on subjective refraction results. Our clinical impression is that patients 
tend to experience less astigmatism than objectively observed, subsequently the 
subjective cylindric correction is lower. 
Refractive results in this study were, however, predictable and efficacious 
and resemble those achieved with LASIK in lower degrees of myopia and 
astigmatism.1 Nearly ninety percent of the eyes in our study were within 1.00 
D of emmetropia from 6 months onwards. These data compare favorably with 
LASIK results for moderate to high myopia and astigmatism, where studies report 
between 41% to 76% of eyes being within 1.00 D of emmetropia.1,18-22 LASIK 
correction among higher refractive errors, however, tends to result in lower 
predictability.23,24 Furthermore, the large amount of stromal tissue ablated during 
a LASIK procedure to correct these higher degrees of myopia and astigmatism 
predisposes eyes to corneal ectasia and associated visual problems.25 
Another option for the correction of high myopia with astigmatism is clear lens 
extraction with toric IOL implantation. Studies have shown that implantation of 
a toric IOL after clear lens extraction carries a higher risk of retinal detachment 
and further results in the loss of accommodation in young patients.26 Moreover, 
rotational stability may be a problem with toric IOLs in the capsular bag.27 
Compared to LASIK or clear lens extraction, the correction of moderate to high 
myopia combined with astigmatism appears to be safer and more predictable 
with phakic IOL implantation, where the degree of correction does less physi-
cally affect the eye. Among phakic IOL options are posterior chamber (PC) IOLs, 
which require a smaller incision (3.2 mm) for lens implantation compared with 
the 5.5 mm for the toric Artisan lens.28-30 To our best knowledge, only one case 
report has been published on the result of a toric PCIOL for the correction of 
myopia combined with astigmatism.31 The potential for cataractogenesis and 
pigment dispersion with these IOLs is a crucial long-term concern.32,33 In our 
study, however, one patient also developed a cataract. Although myopia is a 
known risk factor for cataract development at an earlier age, it is unclear if 
intraocular surgery accelerated this process. 
In our study, seventy percent or more of the cases exhibited a gain of one 
or more lines of BSCVA. Such improvements in visual acuity have also been 
reported in other studies34,35 and have been attributed to the increase in the size 
of the retinal image compared to spectacle correction.36
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Successful correction of myopia and astigmatism with a TPIOL depends on 
several variables. In this study, we not only report the accuracy of the refractive 
results, but also the refractive contribution of variables such as the deviation 
between intended and achieved axis of implantation and the contribution of 
incisionally induced astigmatism. We believe that understanding these extra 
parameters allows greater insight into increasing the predictability of TPIOL 
implantation. 
In conclusion toric myopic Artisan lens implantation leads to highly predict-
able, effective and safe results. Marking the enclavation site for TPIOL implanta-
tion with the use of the Javal keratometer appears to be a safe and reliable 
method. Predictability could be further increased by accounting for incisionally 
induced astigmatism. A systematic undercorrection of –0.50 D for attempted 
cylindric outcome is advised when using a corneoscleral incision of 5.5 mm.
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ABSTRACT 
Purpose: To evaluate the Artisan toric phakic intraocular lens for the correction of hyperopia and 
astigmatism and mixed astigmatism.
Setting: Department of Ophthalmology, Erasmus MC Rotterdam, The Netherlands and Department 
of Ophthalmology, Sint Truiden, Belgium.
Methods: Prospective study on 50 eyes of 30 patients with hyperopia and astigmatism (n = 47) or 
mixed astigmatism (n = 3). Artisan toric phakic intraocular lenses were implanted between April 
1999 and June 2004. We analyzed uncorrected visual acuity, best-corrected visual acuity, refraction, 
astigmatism, safety and predictability. Change in astigmatism was analyzed with vector analysis. 
Results: Mean preoperative Spherical Equivalent was +4.23 ± 2.26 D in the hyperopic group and 
–1.21 ± 0.50 D in the mixed astigmatism group. Mean follow-up was 11.6 months (range: 6.0 
- 37.0). A gain of one or more lines BSCVA was seen in 36%. Safety index and efficacy index after 6 
months were 1.06 and 0.82, respectively. The mean postoperative astigmatism at 6 months was 0.24 
D at an axis of 150º. At 6 months about three-quarters (76%) of the eyes had an uncorrected visual 
acuity of 20/40 or better. Two eyes lost 2 or more lines BSCVA. In 2 eyes the lens position had to be 
changed because of a large axis misalignment. No serious complications developed in any of the 
treated eyes during follow-up.
Conclusions: Artisan toric phakic intraocular lenses can correct moderate to high hyperopia com-
bined with astigmatism with good refractive results. In this study, there were no serious complica-
tions. However, the predictability of the refractive results appears to be lower as compared to the 
correction of myopia and astigmatism with toric Artisan lenses. 
Artisan toric phakic lens for hyperopia and astigmatism 129
INTRODUCTION
Refractive surgery options to treat moderate to high hyperopia and hyperopic 
astigmatism are limited. Predictability and safety with either Laser in situ ker-
atomileusis (LASIK) or Photorefractive keratectomy (PRK) is lower compared 
to the treatment of moderate myopia with or without astigmatism.1,2 Reported 
complications are regression, corneal ectasia, epithelial ingrowth, irregular 
astigmatism and low predictability, especially in eyes with higher hyperopia or 
hyperopia combined with astigmatism.3-6 Clear lens extraction with implanta-
tion of a toric intraocular lens has the disadvantage of accommodation loss in 
a younger age group. Phakic intraocular lenses can be an alternative for the 
correction of hyperopia and hyperopic astigmatism. Over the last few years, 
studies on diverse phakic IOLs have demonstrated satisfactory results to correct 
high ametropia.7-10 Several studies have recently been published on the Arti-
san toric phakic intraocular lens (TPIOL) for the correction of ametropia with 
astigmatism.11-13 The Artisan toric lens is an iris-fixated anterior chamber implant 
of Perspex CQ-UV polymethylmethacrylate with ultraviolet filtration. Its overall 
diameter is 8.5 mm and the optical zone diameter is 5.0 mm. Two models of the 
Artisan lens are available. In Model A the axis runs through the claws at 0º and in 
Model B the axis is perpendicular to the line that runs through the claws at 90º. 
In eyes with a preoperative cylinder axis between 0 and 45 degrees or between 
135 and 180 degrees Model A is recommended. In eyes with a preoperative 
cylinder axis between 45 and 135 degrees Model B is recommended. 
Studies on the toric Artisan lens mainly report the results of the correction 
of myopia with astigmatism. Differences between hyperopia and myopia that 
are important for refractive surgery are iris configuration, a shallower anterior 
chamber depth and limited improvement of best spherical corrected visual 
acuity postoperatively. The third is due to a smaller image size with corrected 
refraction closer to the eye’s nodal point in hyperopic patients. In our opinion 
these differences justify a study evaluating solely the results of TPIOLs correcting 
hyperopia and astigmatism. The hyperopic toric Artisan lenses are available in 
half diopter increments with a cylindrical power up to 7.5 Diopters (D) and a 
spherical power from +2.0 to +12.0 D. In this paper we report the results of 
TPIOL implantation in 50 eyes of 30 patients with hyperopia and astigmatism or 
mixed astigmatism.
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PATIENTS AND METHODS
We enrolled 50 consecutive eyes of 30 patients in this prospective study. 
Between April 1999 and June 2004 consecutive implantation of the TPIOL’s 
was performed by two surgeons (GL and CB) in two separate clinics (Erasmus 
MC Rotterdam, The Netherlands and Sint Truiden, Belgium). Inclusion criteria 
consisted of general good health, 18 years of age or more, stable refraction for 
at least one year, astigmatism greater than or equal to 1.5 D combined with 
hyperopia, absence of ocular pathology, endothelial cell count more than 2000 
cells/mm2, anterior chamber depth more than 3.0 mm (including corneal thick-
ness), no convex iris configuration and mesopic pupil size equal or less than 
5.0 mm. Informed consent in accordance with the Helsinki Declaration was 
obtained for each patient. 
Preoperative examination included slit lamp biomicroscopy, endothelial cell 
count (non contact specular microscopy, Topcon SP-2000-P), keratometry (Top-
con KR-7000-P), A-scan biometry (Alcon), applanation tonometry, measurement 
of mesopic pupil diameter (Colvard pupillometer), indirect ophthalmoscopy and 
subjective and objective refraction. Objective refraction with cyclopentolate hy-
drochlorate 1.0% eye drops was measured to exclude any accommodative error 
in subjective refraction. If large differences were found, subjective refraction 
was performed again. Best spectacle corrected visual acuity (BSCVA) was also 
noted (Snellen). All patients were requested to discontinue contact lens wear at 
least 14 days before preoperative examination. 
The power of the Artisan lens and the intended axis of enclavation was cal-
culated based on keratometric readings, anterior chamber depth and subjective 
refraction error, according to the Van der Heijde formula.14 Prior to surgery the 
desired axis location was either marked on the limbus with a surgical marker 
guided by the reflected images of the Javal keratometer on the cornea (GL) or the 
enclavation sites on the iris were marked with an argon laser at least one week 
before surgery (CB). Myotic drops (pilocarpin 4%) were administered to prepare 
the iris for lens fixation. Intervention was performed under general anaesthesia 
(all cases in Sint Truiden and some cases in Erasmus MC) or retrobulbar anaes-
thesia (Erasmus MC). A corneoscleral bevelled incision of 5.5 mm was made at 
the steepest axis for Model A and at the flattest axis for Model B and paracenteses 
were placed at either side, 8 mm apart from each other. The anterior chamber 
was opened and introduced with viscoelastic fluid (Healon®/Healon GV®) to 
maintain its depth and to protect the endothelial cell layer. After introduction of 
the lens into the anterior chamber with the holding forceps, it was positioned 
onto the desired axis and then fixed onto the midperipheral iris stroma with a 
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disposable enclavation needle. A slit iridotomy was performed at 12 o’clock 
to prevent angle-closure glaucoma, whereafter the viscoelastic material was 
manually irrigated. The incision was closed with a 10-0 nylon running suture. 
Postoperative treatment included dexamethasone 0.1% or predmycine® eye 
drops and ketorolac eye drops four times a day for 4 weeks. 
Follow-up examinations were scheduled at 1 day, 1 week, 1 month, 2 months, 
6 months and 1 year after surgery and on a yearly basis thereafter. Examinations 
included slit lamp biomicroscopy, endothelial cell count, keratometry, applana-
tion tonometry, subjective and manifest refraction, UCVA and BSCVA. Within 
the first two postoperative months, sutures were removed depending on residual 
refractive astigmatism and change in topographic astigmatism. Furthermore, pa-
tients were asked about subjective complaints of halos and glare. All data were 
collected prospectively from patient charts during the follow-up examination.
Statistics
Refractive outcomes at 6 months and 1 year were analyzed. To analyse BSCVA, 
UCVA, safety index (mean postoperative BSCVA / mean preoperative BSCVA) and 
efficacy index (mean postoperative UCVA / mean preoperative BSCVA) Snellen 
visual acuity was first converted into logarithm of the minimum angle of resolu-
tion notation (logMAR) to calculate the mean and subsequently transformed 
back into Snellen visual acuity. Change in cylindrical refraction was calculated 
with vector analysis as described by Holladay et al.,15 using subjective refraction 
results. To compare preoperative and postoperative astigmatism, the astigma-
tism vector computations were analyzed using Mixed Model ANOVA statistics 
(SAS software). The model was corrected for a possible inclusion of two eyes 
of one individual patient. The vector change in keratometric cylinder between 
preoperative and 6 months postoperative values was considered the astigmatism 
induced by the incision. For the analysis of incisionally induced astigmatism, 
eyes that underwent a second surgical intervention within 6 months after im-
plantation were excluded (n = 2). Continuous variables were described with 
mean, standard deviation and range. Comparison of continuous data between 
preoperative and postoperative periods was performed with Student t-test for 
paired data. A level of significance of p = 0.05 was used.
RESULTS
Fifty eyes of 30 patients were included in this study. Preoperatively, all patients had 
clear lenses and no retinal pathology was noted. A certain degree of amblyopia 
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 8 was observed in 21 eyes, but none of the eyes had a BSCVA of less than 20/60. 
Mean amplitude of the anterior chamber depth was 3.2 ± 0.2 mm (range: 3.0-
3.8) and mean axial length was 21.6 ± 1.0 mm (range: 19.5-23.7). Mean intra 
ocular pressure (IOP) was 15.5 ± 3.4 mmHg. Mesopic pupil diameter averaged 
4.4 ± 0.9 mm (range: 3-6). Ten patients were male and 20 patients were female. 
Mean age (primary eye in bilateral subjects) was 37.0 years (range: 19.0–65.8). 
Mean preoperative hyperopic refraction was +5.71 ± 2.39 D and mean absolute 
refractive astigmatism was –3.48 ± 1.77 D. Mean preoperative endothelial cell 
count was 3001 ± 362 (range: 2100-3721). Follow-up ranged from 6 months 
to 3 years with an average of 11.6 months. All patients attended follow-up at 6 
months. At one year, complete follow-up data were available for 17 eyes.
Preoperative refractive data are presented in Table 1 along with endothelial 
cell count and postoperative visual acuity and refractive results. Postoperative 
data are given at 6 months, otherwise this will be mentioned in the text. A gain 
of one or more lines in BSCVA occurred in 18 eyes (36%). About three-quarters 
(76%) of the eyes had an uncorrected visual acuity of 20/40 or better. At one year 
14 of the 17 eyes (82.4%) had a visual acuity of 20/40 or better. Two eyes lost 2 
lines and 3 eyes lost 1 line. One of the patients with a loss of 2 lines in BSCVA 
had complains of halos and glare. We could not find an explanation for the loss 
of 2 lines in BSCVA in the second eye. According to vector analysis adjusted for 
two eyes per patient the mean preoperative astigmatism was 2.36 ± 2.26 D at 
Table 1. Preoperative and postoperative endothelial cell count and refractive results
Preoperative 6 Months follow-up
 (n = 50)
12 Months follow-up
(n = 17)
ECC ± SD, (range) 3001 ± 362
(2100-3721)
2976 ± 350
(2059-3610)
3000 ± 177
(2700-3300) 
SE (mean) ± SD, (range) 3.97 ± 2.54
(-1.75- + 8.88)
-0.125 ± 1.22
(-0.25 to 3.0)
0.21 ± 1.02
(-1.50 to 2.50)
Mean UCVA ± SD - 0.55 ± 0.27 0.59 ± 0.31
Mean BSCVA ± SD 0.68 ± 0.16 0.72 ± 0.14 0.76 ± 0.11
± 1.00 D of emmetropia (%) - 78.0% 82.4%
± 0.50 D of emmetropia (%) - 48.0% 47.1%
UCVA ≥ 20/40 76.0% 82.4%
Loss ≥ 2 lines BSCVA (%) 4.0% 0%
Gain ≥ 1 line BSCVA (%) 36.0% 52.9%
Safety index 1.06 1.12
Efficacy index 0.82 0.87
ECC, endothelial cell count; n = number of eyes; SE, spherical equivalent; UCVA, uncorrected 
visual acuity; BSCVA, best spectacle corrected visual acuity
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an axis of 92.6º. A double-angle minus cylinder power plot of preoperative data 
is presented in Figure 1. Six months after implantation the astigmatism averaged 
0.24 ± 0.85 D at an axis of 150º and one year after implantation the astigmatism 
averaged 0.20 ± 0.83 D at an axis of 173º. In the double angle minus cylinder 
power plot for postoperative data at 6 months presented in Figure 2, a tendency 
towards a clearly lower but more against the rule astigmatism is seen. The aver-
age Spherical Equivalent (SE) of the subjective refraction at 6 month follow-up 
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Figure 1. Double angle minus cylinder plot of preoperative refractive cylinders.
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Figure 2. Double-angle minus cylinder plot of postoperative refractive cylinders at 6 
months.
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was –0.125 ± 1.22 D, range -0.25 to 3.00 D and at one year 0.21 ± 1.02 D, 
range -1.50 to 2.50 D. Six months after surgery 78.0% of the eyes were within 
± 1.00 D of emmetropia and 48.0% of the eyes were within ± 0.50 D of em-
metropia. The deviation of the achieved SE correction from the attempted SE 
correction is presented in Figure 3. The safety index after 6 months and 1 year 
was 1.06 and 1.12 respectively. The efficacy index was 0.82 at 6 months and 
0.86 at 1 year. The mean incisionally induced corneal astigmatism was 0.61 ± 
0.61 D at a mean axis of 177º. 
Intervention was uneventful in all patients. No eyes lost more than two lines in 
BSCVA at last follow-up. In 3 eyes of 3 patients there was a slight decentration of 
the TPIOL. However, this did not affect visual acuity. In 2 eyes of 2 patients it was 
necessary to reposition the lens because of a deviation from the intended axis. 
In one eye with an implanted cylinder of 3.0 D a deviation of approximately 27º 
from the intended axis existed, resulting in a residual astigmatism of –2.00 D at 
an axis of 155º. After the lens position was changed to the correct axis, a residual 
astigmatism of only -0.50 D at an axis of 163º was left. In the second eye with 
an implanted cylinder of 7.0 D axis misalignment of approximately 11º resulted 
in a residual astigmatism of –1.75 D at an axis of 115º. A residual astigmatism of 
–0.50 D at 40º was left after the lens position was changed. 
Iris pigment depositions on the TPIOL were observed in 4 eyes of 3 patients. 
Two of these patients also reported glare and halo symptoms. Complaints of halo 
and glare were reported in a total of 4 patients. These 4 patients also comprised 
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Figure 3. Spread of achieved spherical equivalent refraction at 6 months against intended 
refraction. D = Diopters.
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one of the eyes with a loss of 2 lines in BSCVA. No patients reported complaints 
of binocular diplopia after implantation. IOP after implantation was not sig-
nificantly different from preoperative IOP. In two eyes a temporary elevation 
of IOP over 21 mmHg was observed in the first month after operation. A good 
reaction to topical IOP lowering medication was seen. The mean postoperative 
endothelial cell count (2976 ± 350 at 6 months and 3000 ± 177 at 1 year) was 
not significantly different from mean preoperative cell count. No cataract forma-
tion was found during follow-up. No posterior synaechiae or fibrin membrane 
formation was observed in any eye. None of the eyes developed other serious 
sight-threatening complications such as retinal detachment, or endophthalmitis 
during follow-up.
DISCUSSION
Refractive surgery encompasses attention to both spherical and cylindrical 
components of refraction. Especially the treatment of hyperopia combined with 
astigmatism is challenging. This study demonstrates that in selected patients it is 
possible to correct moderate to high hyperopia combined with astigmatism by 
Artisan TPIOL implantation with relatively good refractive results and few com-
plications. Results, however, compare less favourable to myopic toric Artisan 
implantations. 
Artisan TPIOL implantation is a recent alternative to correct ametropia and 
astigmatism. A few studies report on the results of these TPIOLs.11-13,16 We have 
reviewed and summarized the published data for toric Artisan lenses in hyper-
opic patients. In the European Multicenter Study by Dick et al.11 22 hyperopic 
eyes are included. Preoperative SE refraction was +3.25 D. Average magnitude 
of refractive astigmatism was 3.70 D (no vector analysis). Mean postoperative 
endothelial cell count, efficacy index and safety index are given together with 
the myopic group. All eyes were within ± 1.00 D of the intended refraction. 
Tehrani and colleagues13 reported their results in 9 eyes with hyperopia and 
astigmatism. Mean age in the hyperopic group was somewhat higher with 40 
years compared to the myopic group (35 years). Mean preoperative SE refraction 
was +3.8 D and mean preoperative astigmatism according to vector analysis 
was 2.9 D. The study reports mainly on the stability of the toric Artisan lens, 
which was shown to be good. Refractive results are not separately analyzed 
for the hyperopic group. The last study by Guell et al.12 included 27 eyes with 
high myopia or hyperopia and astigmatism. Mean SE refraction was –11.78 D 
(range: +6.00 to –19.50). The number of hyperopic eyes included is not given 
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and data are not analyzed separately for myopic or hyperopic eyes. In contrast 
to the aforementioned studies the present study reports refractive results after 
toric Artisan lens implantation including a larger group with solely hyperopia 
and astigmatism (average SE refraction +4.23D) or mixed astigmatism (average 
SE refraction –1.21D). Hyperopic eyes do not resemble myopic eyes and in our 
opinion a separate analysis of refractive results is more appropriate. Hyperopic 
eyes tend to be smaller with smaller anterior segments and a higher frequency 
of convex irises is seen. Less hyperopic eyes will meet the inclusion criteria 
for anterior chamber iris-fixated lens implantation compared to myopic eyes. 
The potential of endothelial cell loss might be higher in hyperopic eyes, be-
cause a greater cell loss is reported in eyes with shallower anterior chambers 
and thicker IOLs.8,17 In this study we did not observe endothelial cell loss, 
however, follow-up was only 6 months for all eyes and 1 year for 17 eyes. 
Longer follow-up is required to assess a potential risk of endothelial cell loss.17 
The serious complication of posterior synaechiae after TPIOL implantation is 
reported mainly in hyperopic eyes.8 None of the eyes in this study encountered 
this problem, probably because of the exclusion of convex irises and anterior 
chamber depth smaller than 3.00 mm. Since hyperopia becomes an increasing 
problem with advancing age, patients treated for hyperopia might on average 
be older than myopic patients. However, patients in our study group were not 
older than patients implanted with the myopic toric Artisan lens. To uncover 
any latent hyperopia, cycloplegic refraction in hyperopic patients is important. 
Hyperopia is more frequently associated with strabismus and amblyopia than 
myopia. The percentage of eyes with a postoperative UCVA of 20/40 or better is 
highly affected by the number of amblyopic eyes included. This could account 
for the lower percentage of UCVA of 20/40 or better found in this study (21 
amblyopic eyes) compared to the European multicenter study.11 In hyperopic 
and possibly amblyopic eyes the evaluation of efficacy using the UCVA pa-
rameter is not very meaningful and the efficacy index might be of more value. 
Correction of the refractive error with TPIOLs in highly anisometropic patients 
could exacerbate strabismus or change disparity in retinal image size resulting 
in diplopic symptoms.18 Although two patients with the high range astigmatism 
encountered some trouble in the first few weeks, none encountered permanent 
problems. In our clinic we test patients with high anisometropia corrected with 
spectacles by the Awaya aniseiconia test to prevent problems. This is done both 
with spectacles and with contact lens correction. Tolerance to postoperative 
induced anisophoria might be predicted by this test. Lens implantation was 
discouraged in patients who did not tolerate full contact lens correction of their 
ametropia. In comparison to preoperative visual acuity with glasses in hyperopic 
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eyes no gain in corrected visual acuity is expected after TPIOL implantation. This 
is in contrast to myopic eyes where an increase in the size of the retinal image 
after correction with TPIOL attributes to a gain in visual acuity. This discrepancy 
can underlie the relatively low safety index found in this study compared to the 
safety index in myopic patients. In terms of percentages of eyes within ± 1.00 
or ± 0.50 D of emmetropia, predictability in this study was lower compared to 
the correction of myopic astigmatism with Artisan lenses as shown in Table 2. 
The position of an IOL in a hyperopic eye is more critical than in a myopic eye, 
since the effect of a miscalculation is inversely related to the length of an eye. 
Calculation of the dioptric power of the lens with the Van der Heijde formula14 
using anterior chamber depth as a variable might be less accurate in hyperopic 
eyes. 
Accurate axis alignment of the TPIOL is essential for the success, especially in 
higher astigmatism. Approximately one third of the correction is lost if the lens 
is rotated 10 degrees off axis. Rotation of the Artisan lens is not likely, because of 
the firm fixation to the midperipheral iris stroma. Off axis position of an iris-claw 
lens is most likely caused by incorrect placement of the lens in the axis during 
surgery. Lens position had to be changed in two eyes of two different patients in 
our study. The technique to change the lens position is relatively simple. The iris 
is pushed back through the slits of the haptic and the lens is refixated to the iris at 
a different part. After the lens position in two patients was changed, astigmatism 
reduced to –0.50 D in both eyes compared to –2.00 D and –1.75 D before.
Alternative surgical options for the correction of hyperopia with astigmatism 
have their limits. Large treatment zones are necessary to correct astigmatism 
and hyperopia with LASIK or PRK. Hyperopic PRK appears to be relatively safe 
and effective for corrections up to + 4.00 D.3,19 In higher corrections reduced 
predictability and possible loss of best spectacle corrected visual acuity are 
reported.20 After treatment of hyperopic astigmatism with PRK a higher percent-
age of eyes (15.8%) is reported to lose two or more lines BSCVA.5 In this study 
we observed that only 4% of the eyes lost two or more lines at six months. 
Table 2. Predictability of achieved spherical equivalents after implantation of toric phakic 
intraocular lenses
Study Preoperative SE 6 months, refraction within 1 year, refraction within
± 0.50 D ± 1.00 D ± 0.50 D ± 1.00 D
Dick et al. 11 -8.90D 40/48 (83.3%) 48/48 (100%)
Guell et al.12 -11.78D 17/27 (63%) 26/27 (96.2%)
This study +3.97D 24/50 (48%) 39/50 (78%) 8/17 (47.1%) 14/17 (82.4%)
SE, spherical equivalent
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The higher risk of haze or scar formation with PRK in larger hyperopia might 
underlie this difference. Significant regression has been reported in LASIK for 
hyperopia, being strongly associated with the magnitude of hyperopia.20 In com-
parison to hyperopic PRK and LASIK, hyperopic TPIOL implantation is expected 
to achieve an earlier and more stable refraction. It is difficult to compare the 
results of our study with the results of studies on the treatment of hyperopia and 
astigmatism with either LASIK or PRK, mainly because of a large variation in 
the range of preoperative hyperopia. LASIK has been shown to be very effective 
and predictable in lower hyperopia up to 3 D.1 However, above approximately 
4-5 D, efficacy and stability falls off markedly.21,22 Spherical ametropia and the 
amount of cylinder was rather high in this study with only 9 eyes having either a 
SE below 3 D or a cylinder lower than 4 D. Many patients included in this study 
were referred to us from other centres to evaluate the possibilities for Artisan 
lens implantation, because LASIK or PRK was not an option. Posterior toric IOL 
implantation after clear lens extraction is another option for the correction of 
high astigmatism and hyperopia. Clear lens extraction, however, will result in 
permanent and complete loss of accommodation in relatively young patients. 
Furthermore, a greater incidence of intraoperative complications and postopera-
tive retinal detachment is reported and rotational stability might be a problem 
with toric IOLs in the capsular bag.23 Other phakic IOL options are posterior 
chamber (PC)IOLs.9,10,24 The advantage of a phakic PCIOL lens in hyperopic 
patients might be a greater distance between the IOL and the endothelial layer. 
However, other risks are reported in these PCIOLs such as cataractogenesis 
and pigment dispersion.9,25-28 In hyperopic eyes there might be a significantly 
higher risk of developing a pupil block glaucoma.24 Besides, until now phakic 
toric PCIOLs for the correction of both hyperopia and astigmatism in a single 
procedure have not been commercially available.
The Artisan hyperopic TPIOL might be a valuable alternative to correct com-
bined hyperopia and astigmatism in carefully selected patients with clear lenses 
and an anterior chamber depth of at least 3.00 mm and no convex irises. More 
patients should be studied to assess whether the used formula for lens calculation 
have to be adjusted for hyperopic eyes, since the refractive outcome appears to 
be less accurate as compared to the implantation with the myopic toric Artisan 
lens. Furthermore, a larger follow-up is needed to evaluate the long-term effect 
of TPIOL on endothelial cell loss.
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WAYS TO IMPROVE VISUAL OUTCOME IN CORNEAL TRANSPLANTATION, 
CORNEAL PATHOLOGY AND ASTIGMATISM
The normally transparent cornea can lose its ability to refract light regularly from 
various conditions. Among these conditions are corneal opacities and corneal 
diseases leading to a distortion of the corneal contour. Vision might be restored 
by a corneal transplantation. Corneal transplantation is widely practised and 
can be very successful. The high success rate of corneal transplantation has been 
attributed to the avascularity of the cornea and the immune privileged site of the 
cornea. The leading cause, however, of corneal graft failure is graft rejection. 
The incidence of graft rejection and failure is increased in high-risk patients hav-
ing corneal vascularisation or a history of previous graft rejection. For a patient 
to benefit from corneal transplantation the graft must be optically clear with 
minimal aberrations. Consequently, reducing corneal graft failure and reducing 
postoperative astigmatism can improve the outcome of a corneal transplantation. 
The aim of studies described in this thesis was to improve the (visual) outcome of 
corneal transplantations. The ultimate life span of each corneal graft is limited, 
even if an immune reaction has never occurred. In an attempt to postpone a 
corneal graft we investigated the toric Artisan lens as an alternative to correct 
high astigmatism associated with keratoconus and marginal degeneration. The 
toric Artisan lens was also investigated in eyes without corneal pathology. 
Chapter 1 is a short introduction to this thesis, with a review of the literature 
on the immunologic mechanisms associated with corneal transplantation in the 
first part and a review of published studies on refractive surgery in the second 
part.
The objective of the study described in Chapter 2 was to assess the contribu-
tion of coincidental HLA matches between donors and recipients to rejection 
free graft survival. All donor corneas were randomly allocated. Retrospective 
HLA-A, HLA-B and HLA-DR typing on corneal derived DNA samples from 
recipients and donors was performed on cases with and cases without graft 
rejection. Coincidental HLA matches were observed. This finding could be 
explained by the abundance of certain HLA alleles in a rather homogeneous 
gene pool from which both donors and recipients are derived. The conclusion of 
this study was that coincidental HLA-A and HLA-DR matches were associated 
with a prolonged rejection free survival time in the total group and in the high-
risk group, respectively. This result supports the beneficial effect of prospective 
HLA-A and HLA-DR typing upon corneal graft survival. 
Chapter 3 deals also with the role of HLA matching on corneal graft rejection. 
The study population described in this study consisted of high-risk patients who 
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received a matched corneal transplant. Allocation of donor corneas was based 
on the acceptation of a minimum of 2 HLA-A and HLA-B antigen matches based 
on broad typing. Retrospective analysis of HLA antigens on the more selective 
split typing level was also performed. The influence on immunologic graft failure 
for an increasing number of matched HLA-A and HLA-B antigens based on split 
typing was analysed. Rejection was the cause of one third of all graft failures. 
Having fewer HLA-A and HLA-B antigen split mismatches (0 or 1 mismatch) 
was in a multivariate analysis associated with a longer immune failure free graft 
survival and with a better overall graft survival. 
In Chapter 4 we describe the results of a study comparing two suture materials 
used for penetrating keratoplasty in patients with Fuchs’ endothelial dystrophy. 
A group of transplants sutured with Nylon filament was compared to a group 
of transplants sutured with Mersilene filament. Complications related to suture 
material and astigmatism control were investigated. Nylon is commonly used in 
penetrating keratoplasty, however, it may loosen and weaken over time, due to 
biodegradation. Biodegradation is not seen in Mersilene sutures. Although trans-
plant survival did not differ between groups, astigmatism and risk of developing 
certain complications appeared to be higher in the Mersilene group. Transplants 
sutured with Mersilene had a significantly higher risk of surgical intervention 
to correct astigmatism or wound dehiscence. Longer follow-up after which all 
Nylon sutures are removed is needed to draw strong conclusions because the 
long lasting tensile strength of Mersilene may lead to fewer complications and 
less wound dehiscence with subsequent astigmatism in long-term follow-up. 
Chapter 5 and Chapter 6 report on the results of phakic toric Artisan lens 
implantation in patients with keratoconus and marginal degeneration. This pro-
cedure was investigated as an alternative for keratoplasty. All patients included 
in these studies were contact lens intolerant and had a clear central cornea. 
After IOL implantation patients were highly satisfied with the refractive results. 
Spectacles to correct the residual refractive error were well-tolerated by all 
patients. A penetrating keratoplasty for the correction of astigmatism associated 
with keratoconus and marginal degeneration could be delayed or even avoided 
in these patients. Especially for patients with associated myopia, toric Artisan 
lens implantation could be beneficial even in case the full corneal astigmatism 
cannot be treated.
Chapter 7 and Chapter 8 deal with the safety, efficacy and predictability of 
phakic toric Artisan lens implantations in patients with astigmatism and myopia 
or hyperopia. Proper surgical axis alignment of the toric IOL is crucial to the 
success of this treatment. In Chapter 7 the method of marking the enclavation 
site using the Javal keratometer was evaluated. With the use of Javal keratometer 
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marking, axis misalignment of the IOL appeared to be a minor disturbing factor 
for predictability in the myopic population. Insicionally induced astigmatism, 
however, contributed to an overcorrection of the achieved cylinder. A systematic 
undercorrection of –0.50 Diopters for attempted cylindrical outcome is advised 
to achieve a refractive result closer to emmetropia. Although refractive results 
were rather good in terms of efficacy and safety, the predictability for eyes with 
astigmatism and hyperopia appeared to be lower in comparison with eyes with 
astigmatism and myopia.
The clinical relevance of studies described in this thesis is multifold. Our data 
from the studies described in chapter 2 and 3, together with those of others 
suggest that all corneal transplant patients, high-risk and low-risk, could benefit 
from various degrees of HLA-matching. As a consequence of the results of these 
positive matching studies an increase in demand for matched corneal grafts is to 
be expected. In my opinion HLA matching is one way to improve efficiently graft 
survival. Several points should be considered when attempting to match donor 
and recipient. It is both more laborious and more expensive. The HLA system 
is polymorphic and the probability of finding a complete match is low. The 
chance of a good match on the more selective split antigen level is even lower 
than on the broad antigen level. Subsequently, allocation based on (split) HLA 
matching will have consequences for the time that a patient will have to wait for 
a transplant. Time spent on the waiting list is associated with a reduced quality 
of life and possibly with social costs of blindness. One should be aware of the 
fact that the benefit of HLA matching shown in chapter 2 and 3 regards only 
patient groups. The individual patient may not benefit from HLA matching. If the 
lifespan of a transplant is expanded by a good match, younger high-risk patients 
are expected to benefit the most. In future research the potential economic ef-
fects and increased waiting time associated with the transplantation of donor 
corneas with various numbers of HLA mismatches should be weight against the 
possible benefits. 
Also without immune rejection the functional outcome of a corneal transplant 
could be reduced by high astigmatism. High astigmatism after transplantation 
is still a major complication that remains to be solved. It appears that Mersilene 
sutures will not solve this problem. In eyes with endothelial disorders, astigma-
tism after transplantation might be better controlled with new or rediscovered 
techniques such as posterior lamellar keratoplasty and mushroom shaped 
keratoplasty. In future research these techniques should be compared with con-
ventional penetrating keratoplasty. Points of interest are endothelial cell count 
(related to transplant survival) and visual outcome (related to astigmatism). 
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The phakic toric IOL can correct astigmatism and ametropia associated with 
corneal pathology but is never a treatment of the underlying disorder in contrast 
to penetrating keratoplasty. Progression of the disease can negatively influence 
refractive outcome after IOL implantation. The purpose of phakic toric IOL 
implantation is to postpone keratoplasty. Taking into account the results of our 
studies, we consider the phakic toric Artisan lens a suitable option to correct 
high myopia and astigmatism in select patients with keratoconus and marginal 
degeneration. As is shown by our case report, it might not be necessary to cor-
rect the full refractive cylinder. If the power of the cylinder of the IOL is calcu-
lated with the currently used formula based on Plano attempted refraction, an 
overcorrection of the cylinder might be the result. To enhance predictability, the 
results of toric phakic IOL implantation should be investigated in more patients 
with keratoconus and marginal degeneration. 
Refractive surgery represents a new and fast evolving field. Current refractive 
surgery techniques include intraocular procedures and methods that alter the 
cornea. To discuss the possibilities with a patient, an accurate analysis of refrac-
tive results and complications of different treatment techniques is required. The 
best treatment option depends on several variables and differs for each individual 
patient. A possible long-term complication after phakic Artisan lens implanta-
tion is endothelial cell loss, which might be more pronounced in hyperopic 
eyes. Longer follow-up than provided by our studies is required to assess the 
potential risk of endothelial cell loss.
Proper patient selection for each refractive surgery procedure is crucial to 
achieve efficient and safe results. The results of our studies on the Artisan lens 
could be used to inform patients. Furthermore, the analysis of different variables 
contributing to the final refractive result could increase the predictability of toric 
phakic IOL implantation.
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SAMENVATTING IN HET NEDERLANDS
MOGELIJKHEDEN OM HET (VISUELE) RESULTAAT TE VERBETEREN BIJ 
CORNEATRANSPLANTATIES, CORNEAPATHOLOGIE EN ASTIGMATISME
Het gezonde hoornvlies (cornea) is een heldere structuur en draagt door zijn 
specifieke vorm bij aan de breking van licht. Diverse aandoeningen kunnen de 
helderheid of de vorm van het hoornvlies verstoren, hetgeen kan leiden tot een 
verminderd gezichtsvermogen. Om het gezichtsvermogen te herstellen kan een 
hoornvliestransplantatie nodig zijn. Hoornvliestransplantaties behoren wereld-
wijd tot de meest frequent uitgevoerde transplantaties en worden gekenmerkt 
door een relatief hoog succespercentage. In tegenstelling tot andere orgaan-
transplantaten, kunnen hoornvliestransplantaten overleven zonder gebruik van 
systemische medicatie. Dit fenomeen wordt onder meer toegeschreven aan 
de avasculariteit van het hoornvlies en de speciale positie van het hoornvlies 
ten opzichte van het afweersysteem. Desondanks is een afstotingsreactie de 
belangrijkste oorzaak voor het troebel worden van het transplantaat. Risico-
factoren hiervoor zijn vaatingroei en afstoting van een eerder transplantaat. 
Astigmatisme is naast falen van het transplantaat een belangrijke postoperatieve 
complicatie, die tot een slecht visueel resultaat kan leiden ondanks een helder 
transplantaat. Door cilindrisch geslepen brillenglazen kan regulair astigmatisme 
gecorrigeerd worden. Behalve een zeer belangrijke postoperatieve complicatie 
kan het astigmatisme ook de indicatie voor een hoornvliestransplantatie zijn, 
zoals bijvoorbeeld bij keratoconus en marginale degeneratie. Het succes van 
een hoornvliestransplantatie kan worden verbeterd door falen te voorkomen en 
astigmatisme na de operatie te reduceren. Echter, zelfs als er geen afstoting is 
geweest, is de overleving op de lange duur beperkt. In dit proefschrift worden 
onderzoeken beschreven naar factoren die het risico van afstoting verlagen en 
het optreden van postoperatief astigmatisme reduceren. Ook is gekeken naar de 
toepasbaarheid van de torische Artisan lens als alternatief voor een hoornvlies-
transplantatie bij een subpopulatie van relatief jonge patiënten. Deze patiënten 
hadden vanwege astigmatisme bij een keratoconus of marginale degeneratie 
een indicatie voor een hoornvliestransplantatie. Tenslotte onderzochten wij de 
veiligheid en effectiviteit van torische Artisan lenzen in ogen zonder hoorn-
vliespathologie.
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Hoofdstuk 1 is een korte introductie met een overzicht van de literatuur over 
transplantaat afstotingen in het eerste deel en een overzicht van refractiechirur-
gische behandelingen in het tweede deel. 
In Hoofdstuk 2 wordt een studie beschreven waarin retrospectief gekeken is of 
toevallig aanwezige overeenkomsten in hoornvliesweefsel van donor en ontvan-
ger resulteren in een kleinere kans op afstoting. De weefselantigenen van donor 
en patiënt waren niet bekend ten tijde van transplantatie. Tijdens de operatie 
werd van zowel patiënt als donor hoornvliesweefsel bewaard. Achteraf werd uit 
dit weefsel DNA geïsoleerd. Uit het DNA werden met moleculair biologische 
technieken de HLA-A, HLA-B en HLA-DR weefseltyperingen bepaald. Patiënten 
met 1 of 2 HLA-A overeenkomsten met de donor hadden een significant langere 
overleving van het transplantaat zonder afstotingsreactie dan patiënten zonder 
HLA-A overeenkomsten. Bij patiënten met vooraf een verhoogd risico op falen 
van het transplantaat, resulteerden overeenkomsten in HLA-DR in een langer af-
stotingsvrij interval van het transplantaat. De conclusies van deze studie zijn dat 
toevallig aanwezige overeenkomsten in weefseltypen tussen donor en ontvanger 
bijdragen aan een langer afstotingsvrij interval en dat er een positief effect op de 
transplantaatoverleving te verwachten is indien de donor geselecteerd wordt op 
basis van overeenkomsten in HLA-A en HLA-DR. 
Hoofdstuk 3 gaat eveneens over de rol van overeenkomsten in weefselantige-
nen bij hoornvliestransplantaties. De studiepopulatie bestond uit patiënten met 
een verhoogd risico op falen van het transplantaat. Alle patiënten kregen een 
donorhoornvlies met tenminste twee overeenkomsten in HLA-A en HLA-B op 
basis van een zogenaamde ‘broad’ typering. In retrospectie werd gekeken naar 
het effect op afstoting van overeenkomsten in HLA-A en HLA-B op basis van 
een verfijndere indeling, de zogenaamde ‘split’ typering. Alleen afstotingen die 
leidden tot een falen van het transplantaat werden geanalyseerd. Afstoting was 
een belangrijke oorzaak voor het falen, namelijk bij 1/3 van alle transplantaten 
die faalden was een afstoting hiervoor de reden. Het bleek dat transplantaten 
die een betere overeenkomst hadden op basis van de ‘split’ typering een be-
duidend lager risico hadden op falen door een afstoting. Bovendien was de 
algehele overlevingsduur van het transplantaat langer voor de transplantaten 
met een hogere mate van overeenkomst. De conclusie van deze studie is dat het 
toewijzen van donorhoornvliezen op basis van geen of slechts één afwijking bij 
split typering van HLA-A en HLA-B kan bijdragen aan een betere transplantaat 
overleving.
In Hoofdstuk 4 worden twee hechtmaterialen voor hoornvliestransplantaties 
met elkaar vergeleken voor wat betreft de bijwerkingen van het materiaal en 
het induceren van postoperatief astigmatisme. Nylon is het meest gebruikte 
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hechtmateriaal. Het nadeel van Nylon is dat het na verloop van tijd trekkracht 
verliest en uiteindelijk oplost. Een mogelijk voordeel van het veel minder ge-
bruikte Mersileen is dat het de trekkracht behoudt omdat het niet degradeert. De 
studiepopulatie bestond uit patiënten die een hoornvliestransplantatie kregen 
vanwege Fuchse dystrofie en was onderverdeeld in een Nylon groep en een 
Mersileen groep. Er was geen verschil in transplantaat overlevingsduur tussen de 
groepen. Het astigmatisme was gedurende de eerste twee jaar na transplantatie 
duidelijk lager in de Nylon groep. In de Mersileen groep was de kans op bepaalde 
bijwerkingen (het optreden van een infiltraat, littekenvorming langs de hechting 
en het insnijden van de hechting) groter. Bovendien was in de Mersileen groep 
eerder een aanvullende operatie nodig om het transplantaat in niveau te krijgen 
of om astigmatisme te corrigeren. Het lijkt echter of bijwerkingen door loslating 
van de hechtingen na twee jaar vaker voorkomen bij de Nylongroep. Daar deze 
bijwerkingen ernstig kunnen zijn en zelfs tot blindheid of verlies van het oog 
kunnen leiden, bestaat er wellicht op de lange termijn een voordeel voor de 
transplantaten ingehecht met Mersileen. 
In Hoofdstuk 5 en 6 worden patiënten beschreven met een zeer hoog astig-
matisme als gevolg van keratoconus en marginale degeneratie. Bij deze groep 
patiënten is gewoonlijk een hoornvliestransplantatie geïndiceerd indien zij 
ondanks correctie met bril of contactlenzen niet meer goed kunnen zien. Wij 
onderzochten de toepasbaarheid van de torische Artisan lens als alternatief voor 
een hoornvliestransplantatie. Dit type lens wordt in de voorste oogkamer aan 
de iris vastgeklemd en bevat zowel een sferische als een cilindrische correctie. 
De resultaten van implantatie van de lens in 8 ogen met hoornvliespathologie 
toonden aan dat de best mogelijk gezichtsscherpte verbeterde en dat een trans-
plantatie uitgesteld dan wel voorkomen kon worden. Alle patiënten verdroegen 
de bril voor correctie van het resterende astigmatisme goed en waren zeer 
tevreden over het resultaat van de behandeling.
Indien de torische Artisan lens gebruikt wordt in ogen zonder hoornvliespa-
thologie met het doel zowel de sferische als de cilindrische afwijking te 
verminderen, is er sprake van refractiechirurgie. Veelal wordt de Artisan lens 
gebruikt indien de refractieafwijking zodanig is dat een persoon niet voor een 
laserbehandeling in aanmerking komt. Om de Artisan lens in het oog te plaatsen 
is een operatie nodig, waarbij er een opening van 5,5 mm wordt gemaakt. In 
Hoofdstuk 7 en 8 onderzochten wij de veiligheid, effectiviteit en voorspelbaar-
heid van Artisan lens implantaties in ogen zonder andere bekende afwijkingen. 
Tevens werd nagegaan wat de invloed was van de plaats van de lens in het oog 
en de opening van 5,5 mm op het uiteindelijke resultaat. In Hoofdstuk 7 zijn 
patiënten beschreven die vooraf bijziend waren en in Hoofdstuk 8 patiënten 
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die vooraf verziend waren. Bij beide groepen bleek de veiligheid hoog. De ef-
fectiviteit, veiligheid en voorspelbaarheid van de behandeling waren goed. De 
voorspelbaarheid van de resultaten voor de groep van bijziende patiënten was 
beter dan voor de groep van verziende patiënten. Wij berekenden dat de 5,5 
mm opening bijdraagt aan een kleine overcorrectie van de cilinder.
Het belang van de studies beschreven in dit proefschrift is meervoudig. De 
bevindingen in hoofdstuk 2 en 3 tezamen met resultaten van andere recente 
studies, suggereren dat hoornvliestransplantatiepatiënten gebaat kunnen zijn bij 
een bepaalde mate van overeenkomst in HLA antigenen. Deze bevindingen kun-
nen aanleiding geven tot het vaker aanvragen van een zogenaamd gematched 
donorhoornvlies. Aan de allocatie van donorhoornvliezen op basis van HLA 
overeenkomsten met de patiënt zijn echter ook nadelen verbonden. Behalve dat 
een dergelijk allocatie systeem duurder kan zijn en logistieke problemen met 
zich meebrengt, kan een patiënt hierbij langer op een donorhoornvlies moeten 
wachten. Een langere wachttijd is geassocieerd met een verminderde kwaliteit 
van leven en mogelijk ook met extra kosten ten gevolge van een langere periode 
van slechtziendheid. Voor de individuele patiënt hoeft het geen voordeel te 
zijn een donortransplantaat met HLA overeenkomsten toegewezen te krijgen. 
Zo is een oudere patiënt met een laag risico op afstoting van het transplantaat 
meer gebaat bij een snelle transplantatie dan bij een hogere lange termijn 
overlevingskans van het transplantaat. In toekomstig onderzoek zullen van een 
allocatie systeem gebaseerd op HLA overeenkomsten de economische effecten 
en de implicaties voor de wachttijd moeten worden onderzocht. 
Een helder transplantaat kan ook zonder dat het een afstoting heeft doorge-
maakt door een hoog astigmatisme een slecht functioneel resultaat geven. Om 
een betere gezichtsscherpte te bereiken na transplantatie wordt een zo laag 
mogelijk astigmatisme nagestreefd. Hoog astigmatisme is echter nog steeds een 
belangrijk probleem na transplantatie. Mersileen hechtingen lijken op de korte 
termijn geen oplossing voor dit probleem te zijn. Nieuwe (posterieure lamellaire 
transplantaten) en herontdekte (paddestoelvormige transplantaten) technieken 
kunnen misschien het astigmatisme adequater reduceren. 
De resultaten van de studies in hoofdstuk 5 en 6 tonen aan dat de implantatie 
van een torische lens in het oog bij een selecte patiëntengroep een hoornvlies-
transplantatie kan uitstellen, hetgeen met name voor jonge patiënten gunstig 
kan zijn omdat de overleving van een hoornvliestransplantaat uiteindelijk 
gelimiteerd is. Het plaatsen van de lens in het oog is echter geen behandeling 
voor de onderliggende aandoening en voorkomt progressie van de aandoening 
niet. Om de voorspelbaarheid van de correctie met de Artisan lens in patiënten 
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met keratoconus en marginale degeneratie te verbeteren, zullen de gegevens 
van meer patiënten die deze procedure hebben ondergaan moeten worden 
geanalyseerd. Eventueel kan dan de gebruikelijke formule voor het berekenen 
van de lenssterkte worden aangepast.
De refractiechirurgie is een jong en een snel ontwikkelend vakgebied bin-
nen de oogheelkunde. Refractiechirurgische behandelingen kunnen in twee 
groepen worden ingedeeld: een groep waarbij het hoornvlies wordt veranderd 
en een groep waarbij er een operatie in het oog plaatsvindt. Individueel zal 
moeten worden afgewogen welke behandeling het beste is. Goede analyse van 
alle mogelijke refractiechirurgische behandelingen is essentieel om kandidaten 
voor refractiechirurgie goed te kunnen informeren en adviseren. Wij denken dat 
de laatste twee studies hier zeker een bijdrage aan leveren. 
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voor hun bijdrage aan de artikelen.
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Ruchi Saxena. Jou ben ik niet alleen als medeauteur van één van de artikelen 
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proefschrift jouw stempel gedrukt. Ik denk dat ze er een stuk leesbaarder door 
zijn geworden. Voor Engelse correcties van enkele andere artikelen ben ik 
Annelies van Rij zeer erkentelijk.
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wereld. Nicole, ik ben zeer vereerd dat je vandaag naast me wilt staan. 
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naast me wilt staan.
Wim en Welmoed Buwalda, dank ik voor hun interesse en alle oppasactivitei-
ten.
Floris, Rogier en Annelot. Dank voor alle belangstelling naar mijn voor jullie 
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Joeri, exact één jaar na jouw verdediging sta ik voor de commissie. Jouw sugges-
ties, steun en hulp zijn heel belangrijk geweest voor de totstandkoming van dit 
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